ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: Executive Summary


Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons

Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine

WRITING COMMITTEE MEMBERS

Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Cynthia D. Adams, RN, PhD, FAHA; Elliott M. Antman, MD, FACC, FAHA; Charles R. Bridges, ScD, MD, FACC, FAHA*; Robert M. Califf, MD, MACC; Donald E. Casey, Jr, MD, MPH, MBA, FACP†; William E. Chavey II, MD, MS‡; Francis M. Fesmire, MD, FACEP§; Judith S. Hochman, MD, FACC, FAHA; Thomas N. Levin, MD, FACC, FSCAI¶; A. Michael Lincoff, MD, FACC; Eric D. Peterson, MD, MPH, FACC, FAHA; Pierre Theroux, MD, FACC, FAHA; Nanette Kass Wenger, MD, FACC, FAHA; R. Scott Wright, MD, FACC, FAHA

ACC/AHA TASK FORCE MEMBERS

Sidney C. Smith, Jr, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Vice-Chair; Cynthia D. Adams, RN, PhD, FAHA; Jeffrey L. Anderson, MD, FACC, FAHA; Elliott M. Antman, MD, FACC, FAHA; Jonathan L. Halperin, MD, FACC, FAHA; Sharon A. Hunt, MD, FACC, FAHA; Harlan M. Krumholz, MD, FACC, FAHA; Frederick G. Kushner, MD, FACC, FAHA; Bruce W. Lytle, MD, FACC, FAHA; Rick Nishimura, MD, FACC, FAHA; Joseph P. Ornato, MD, FACC, FAHA; Richard L. Page, MD, FACC, FAHA; Barbara Riegel, DNSC, RN, FAHA

*Society of Thoracic Surgeons Representative.
†American College of Physicians Representative.
‡American Academy of Family Physicians Representative.
§American College of Emergency Physicians Representative.
¶Immediate Past Chair.
#Former Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees in February 2007 and by the American Heart Association Science Advisory and Coordinating Committee in February 2007.


This article has been copublished in the August 14, 2007, issue of the Journal of the American College of Cardiology.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). To purchase Circulation reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation or the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the “Permission Request Form” appears on the right side of the page.

(Circulation. 2007;116:803–877.)

© 2007 by the American College of Cardiology Foundation and the American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.107.185752
TABLE OF CONTENTS

I. Introduction ..................................... 806
   A. Organization of Committee and Evidence Review . 806
   B. Changes Since Publication of These Guidelines in 2002 . 806
      1. Purpose of These Guidelines .................. 808
   C. Recommendations for Management of Patients With UA/NSTEMI . 808
      1. Identification of Patients at Risk of UA/NSTEMI . 808
      2. Initial Evaluation and Management ............. 808
         a. Clinical Assessment ...................... 808
         b. Early Risk Stratification .................. 809
         c. Immediate Management .................... 809
      3. Early Hospital Care .......................... 810
         a. Anti-Ischemic and Analgesic Therapy ......... 810
         b. Antiplatelet/Anticoagulant Therapy in Patients with Whom Diagnosis of UA/NSTEMI Is Likely or Definite .. 811
         c. Initial Conservative Versus Initial Invasive Strategies ........... 813
         d. Risk Stratification Before Discharge .......... 813
      4. Revascularization With PCI and CABG in Patients With UA/NSTEMI . 814
         a. Percutaneous Coronary Intervention ........... 814
         b. CABG .................................. 814
      5. Late Hospital Care, Hospital Discharge, and Post-Hospital Discharge Care ................. 815
         a. Medical Regimen and Use of Medications ...... 815
         b. Long-Term Medical Therapy and Secondary Prevention ................ 815
         c. Postdischarge Follow-Up .................... 818
         d. Cardiac Rehabilitation ..................... 819
      6. Special Groups ............................... 819
         a. Women .................................. 819
         b. Diabetes Mellitus ......................... 819
         c. Post-CABG Patients ....................... 819
         d. Older Adults ............................ 819
         e. Chronic Kidney Disease .................... 820
         f. Cocaine and Methamphetamine Users ......... 820
         g. Variant (Prinzmetal’s) Angina ............... 820
         h. Cardiovascular “Syndrome X” ............... 820
II. Overview of the Acute Coronary Syndromes ................ 820
   A. Definition of Terms ............................ 820
   B. Pathogenesis of UA/NSTEMI ..................... 821
   C. Presentations of UA and NSTEMI ................. 821
   D. Prevention of UA/NSTEMI ....................... 821
   E. Onset of UA/NSTEMI ........................... 821
      1. Recognition of Symptoms by Patient ........... 821
      2. Silent and Unrecognized Events ............... 821
III. Initial Evaluation and Management......................... 822
   A. Clinical Assessment ........................... 822
   I. Patient Transportation and ED or Outpatient Facility Evaluation .................. 822
   B. Early Risk Stratification ....................... 823
      1. Estimation of the Level of Risk ............... 823
      2. History .................................. 823
      3. Tools to Estimate Risk at Presentation .......... 824
      4. Electrocardiogram .......................... 824
      5. Physical Examination ......................... 824
   C. Immediate Management ......................... 826
      1. Chest Pain Units ............................ 826
      2. Rationale for the Conservative Strategy ........ 845
         a. Anti-Ischemic and Analgesic Therapy ......... 829
         b. Antiplatelet/Anticoagulant Therapy in Patients with Whom Diagnosis of UA/NSTEMI Is Likely or Definite .. 830
         c. Initial Conservative Versus Initial Invasive Strategies ........... 813
         d. Risk Stratification Before Discharge .......... 813
      4. Comparison of Invasive and Conservative Strategies .................. 846
         a. Subgroups ............................... 848
   D. Prevention of UA/NSTEMI ....................... 821
      1. Estimation of the Level of Risk ............... 823
      2. History .................................. 823
      3. Tools to Estimate Risk at Presentation .......... 824
      4. Electrocardiogram .......................... 824
      5. Physical Examination ......................... 824
   E. Onset of UA/NSTEMI ........................... 821
      1. Recognition of Symptoms by Patient ........... 821
      2. Silent and Unrecognized Events ............... 821
   IV. Early Hospital Care ............................ 826
Preamble

It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies as they are introduced and tested in the detection, management, or prevention of disease states. Rigorous and expert analysis of the available data documenting absolute and relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and favorably affect the overall cost of care by focusing resources on the most effective strategies.

The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980. The American College of Cardiology (ACC)/AHA Task Force on Practice Guidelines, whose charge is to develop, update, or revise practice guidelines for important cardiovascular diseases and procedures, directs this effort. Writing committees are charged with the task of performing an assessment of the evidence and acting as an independent group of authors to develop, update, or revise written recommendations for clinical practice.

Experts in the subject under consideration have been selected from both organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other medical practitioner and specialty groups when appropriate. Writing committees are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities and issues of patient preference that might influence the choice of particular tests or therapies are considered as well as frequency of follow-up and cost-effectiveness. When available, information from studies on cost will be considered; however, review of data on efficacy and clinical outcomes will constitute the primary basis for preparing recommendations in these guidelines.

The ACC/AHA Task Force on Practice Guidelines makes every effort to avoid any actual, potential, or perceived conflict of interest that may arise as a result of an industry relationship or personal interest of the Writing Committee. Specifically, all members of the Writing Committee, as well as peer reviewers of the document, were asked to provide disclosure statements of all such relationships that may be perceived as real or potential conflicts of interest. Writing Committee members are also strongly encouraged to declare a previous relationship with industry that might be perceived as relevant to guideline development. If a Writing Committee member develops a new relationship with industry during their tenure, they are required to notify guideline staff in writing.
I. Introduction

A. Organization of Committee and Evidence Review

The ACC/AHA Task Force on Practice Guidelines was formed to make recommendations regarding the diagnosis and treatment of patients with known or suspected cardiovascular disease. Coronary artery disease (CAD) is the leading cause of death in the United States. Unstable angina (UA) and the closely related condition of non–ST-segment elevation myocardial infarction (NSTEMI) are very common manifestations of this disease.

The committee members reviewed and compiled published reports through a series of computerized literature searches of the English-language literature since 2002 and a final manual search of selected articles. Details of the specific searches conducted for particular sections are provided when appropriate. Detailed evidence tables were developed whenever necessary with the specific criteria outlined in the individual sections. The recommendations made were based primarily on these published data. The weight of the evidence was ranked highest (A) to lowest (C). The final recommendations for indications for a diagnostic procedure, a particular therapy, or an intervention in patients with UA/NSTEMI summarize both clinical evidence and expert opinion.

Classification of Recommendations

The schema for classification of recommendations and level of evidence is summarized in Table 1, which also illustrates how the grading system provides an estimate of the size of the treatment effect and an estimate of the certainty of the treatment effect.

The Writing Committee consisted of acknowledged experts in general internal medicine representing the American College of Physicians, family medicine from the American Academy of Family Physicians, emergency medicine from the American College of Emergency Physicians, thoracic surgery from the Society of Thoracic Surgeons, interventional cardiology from the Society for Cardiovascular Angiography and Interventions (SCAI), and general and critical care cardiology, as well as individuals with recognized expertise in more specialized areas, including noninvasive testing, preventive cardiology, coronary intervention, and cardiovascular surgery. Both the academic and private practice sectors were represented. This document was reviewed by 2 outside reviewers nominated by each of the ACC and AHA.

B. Changes Since Publication of These Guidelines in 2002

The writing committee considered evidence published since 2002 and drafted revised recommendations to incorporate results from major clinical trials. The text has been reorganized and rewritten to reflect these developments. Greater participation of the Writing Committee member will be reviewed. These statements are reviewed by the parent task force, reported orally to all members of the Writing Committee at each meeting, and updated and reviewed by the Writing Committee as changes occur. Please refer to the methodology manual for ACC/AHA Guideline Writing Committees for further description of the relationships with industry policy, available on ACC and AHA World Wide Web sites (http://www.acc.org/clinical/manual/manual_introltr.htm and http://circ.ahajournals.org/manual/). Please see Appendix 1 for author relationships with industry and Appendix 2 for peer reviewer relationships with industry that are pertinent to these guidelines.

These practice guidelines are intended to assist health care providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management and prevention of specific diseases or conditions. Clinical decision making should consider the quality and availability of expertise in the area where care is provided. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. These guideline recommendations reflect a consensus of expert opinion after a thorough review of the available, current scientific evidence and are intended to improve patient care.

Patient adherence to prescribed and agreed upon medical regimens and lifestyles is an important aspect of treatment. Prescribed courses of treatment in accordance with these recommendations will only be effective if they are followed. Since lack of patient understanding and adherence may adversely affect treatment outcomes, physicians and other health care providers should make every effort to engage the patient in active participation with prescribed medical regimens and lifestyles.

If these guidelines are used as the basis for regulatory/payer decisions, the ultimate goal is quality of care and serving the patient’s best interests. The ultimate judgment regarding care of a particular patient must be made by the health care provider and the patient in light of all of the circumstances presented by that patient. There are circumstances in which deviations from these guidelines are appropriate.

The guidelines will be reviewed annually by the ACC/AHA Task Force on Practice Guidelines and will be considered current unless they are updated, revised, orunsetted and withdrawn from distribution. The executive summary and recommendations are published in the August 14, 2007, issue of the Journal of the American College of Cardiology and the August 14, 2007, issue of Circulation. The full-text guidelines are e-published in the same issue of the journals noted above, as well as posted on the ACC (www.acc.org) and AHA (www.americanheart.org) World Wide Web sites. Copies of the full text and the executive summary are available from both organizations.

Sidney C. Smith, Jr., MD, FACC, FAHA  
Chair, ACC/AHA Task Force on Practice Guidelines
emphasis is placed on earlier access to medical evaluation of the acute coronary syndrome (ACS) patient, including avoidance of delays inherent in patient self-medication, as well as facilitated emergency department (ED) diagnosis and triage. New imaging tests (cardiac magnetic resonance imaging and coronary computed tomographic [CT] angiography) have emerged as diagnostic options in selected patients. Troponins have become the dominant cardiac biomarker of necrosis, have redefined NSTEMI, and have changed its demographics and prognosis. B-type natriuretic peptide (BNP) now may be added to the list of biomarkers that are potentially useful in risk assessment. Clinical trials data continue to build support for an initial invasive strategy for higher-risk UA/NSTEMI patients (as assessed by troponin positivity or a formal risk score); in contrast, such a strategy is not of benefit and may be harmful in low-risk women, in whom an initially conservative strategy is recommended. Two new anticoagulants, fondaparinux and bivalirudin, have undergone favorable testing in clinical trials and are recommended as alternatives to unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHS) for specific or more general applications. Support for thienopyridine use (primarily with clopidogrel) continues to grow, including higher loading-dose options, earlier (upstream) administration, and longer administration (especially after drug-eluting stent placement). The question of how best to integrate thienopyridine use with parenteral glycoprotein (GP) IIb/IIIa antagonists to provide optimal antiplatelet therapy early in the course of UA/NSTEMI therapy, including cardiac catheterization, is an evolving subject and continues to present a challenge. These guidelines incorporate changes based on recent updates for percutaneous coronary intervention (PCI) and for secondary prevention as they impact patients with UA/NSTEMI.

### Table 1. Applying Classification of Recommendations and Level of Evidence†

<table>
<thead>
<tr>
<th>CLASS</th>
<th>SIZE OF TREATMENT EFFECT</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Benefit &gt;&gt; Risk</td>
<td>Procedure/Treatment SHOULD be performed/administered</td>
</tr>
<tr>
<td>IIa</td>
<td>Benefit &gt;&gt; Risk</td>
<td>Additional studies with focused objectives needed; IT IS REASONABLE to perform procedure/administer treatment</td>
</tr>
<tr>
<td>IIb</td>
<td>Risk</td>
<td>Procedure/Treatment MAY BE CONSIDERED</td>
</tr>
<tr>
<td>IIc</td>
<td>Risk</td>
<td>Recommendation of procedure or treatment is useful/effective</td>
</tr>
<tr>
<td>III</td>
<td>Risk ≥ Benefit</td>
<td>Procedure/Treatment should not be performed/administered since it is NOT helpful and may be harmful</td>
</tr>
</tbody>
</table>

†Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will increase readers' comprehension of the guidelines and will allow queries at the individual recommendation level.
2. Initial Evaluation and Management

A. CLINICAL ASSESSMENT

CLASS I

1. Patients with symptoms that may represent ACS (Table 2) should not be evaluated solely over the telephone but should be referred to a facility that allows evaluation by a physician and the recording of a 12-lead ECG and biomarker determination (e.g., an ED or other acute care facility). (Level of Evidence: C)

2. Patients with symptoms of ACS (chest discomfort with or without radiation to the arm[s], back, neck, jaw, or epigastrium; shortness of breath; weakness; diaphoresis; nausea; lightheadedness) should be instructed to call 9-1-1 and should be transported to the hospital by ambulance rather than by friends or relatives. (Level of Evidence: B)

3. Health care providers should actively address the following issues regarding ACS with patients with or at risk for CHD and their families or other responsible caregivers:
   a. The patient’s heart attack risk; (Level of Evidence: C)
   b. How to recognize symptoms of ACS; (Level of Evidence: C)
   c. The advisability of calling 9-1-1 if symptoms are unimproved or worsening after 5 min, despite feelings of uncertainty about the symptoms and fear of potential embarrassment; (Level of Evidence: C)
   d. A plan for appropriate recognition and response to a potential acute cardiac event, including the phone number to access emergency medical services (EMS), generally 9-1-1 (4). (Level of Evidence: C)

4. Prehospital EMS providers should administer 162 to 325 mg of aspirin (ASA; chewed) to chest pain patients suspected of having ACS unless contraindicated or already taken by the patient. Although some trials have used enteric-coated ASA for initial dosing, more rapid buccal absorption occurs with non–enteric-coated formulations. (Level of Evidence: C)

5. Health care providers should instruct patients with suspected ACS for whom nitroglycerin (NTG) has been prescribed previously to take not more than 1 dose of NTG sublingually in response to chest discomfort/pain. If chest discomfort/pain is unimproved or is worsening 5 min after 1 NTG dose has been taken, it is recommended that the patient or family member/friend/caregiver call 9-1-1 immediately to access EMS before taking additional NTG. In patients with chronic stable angina, if symptoms are significantly improved by 1 dose of NTG, it is appropriate to instruct the patient or family member/friend/caregiver to repeat NTG every 5 min for a maximum of 3 doses and call 9-1-1 if symptoms have not resolved completely. (Level of Evidence: C)

6. Patients with a suspected ACS with chest discomfort or other ischemic symptoms at rest for greater than 20 min, hemodynamic instability, or recent syncope or presyncope should be referred immediately to an ED. Other patients with a suspected ACS who are experiencing less severe symptoms and who have none of the above high-risk features, including those who respond to an NTG dose, may be seen initially in an ED or an outpatient facility able to provide an acute evaluation. (Level of Evidence: C)

CLASS IIa

1. It is reasonable for health care providers and 9-1-1 dispatchers to advise patients without a history of ASA allergy who have symptoms of ACS to chew ASA (162 to 325 mg) while awaiting arrival of prehospital EMS providers. Although some trials have used enteric-
coated ASA for initial dosing, more rapid buccal absorption occurs with non-enteric-coated formulations. *(Level of Evidence: B)*

2. It is reasonable for health care providers and 9-1-1 dispatchers to advise patients who tolerate NG to repeat NG every 5 min for a maximum of 3 doses while awaiting ambulance arrival. *(Level of Evidence: C)*

3. It is reasonable that all prehospital EMS providers perform and evaluate 12-lead electrocardiograms (ECGs) in the field (if available) on chest pain patients suspected of ACS to assist in triage decisions. Electrocardiographs with validated computer-generated interpretation algorithms are recommended for this purpose. *(Level of Evidence: B)*

4. If the 12-lead ECG shows evidence of acute injury or ischemia, it is reasonable that prehospital ACLS providers relay the ECG to a predetermined medical control facility and/or receiving hospital. *(Level of Evidence: B)*

B. EARLY RISK STRATIFICATION

**CLASS I**

1. A rapid clinical determination of the likelihood risk of obstructive CAD (i.e., high, intermediate, or low) should be made in all patients with chest discomfort or other symptoms suggestive of an ACS and considered in patient management. *(Level of Evidence: C)*

2. Patients who present with chest discomfort or other ischemic symptoms should undergo early risk stratification for the risk of cardiovascular events (e.g., death or reinfarction) that focuses on history, including anginal symptoms, physical findings, ECG findings, and biomarkers of cardiac injury and results should be considered in patient management. *(Level of Evidence: C)*

3. A 12-lead ECG should be performed and shown to an experienced emergency physician as soon as possible after ED arrival, with a goal of within 10 min of ED arrival for all patients with chest discomfort (or anginal equivalent) or other symptoms suggestive of ACS. *(Level of Evidence: B)*

4. If the initial ECG is not diagnostic but the patient remains symptomatic and there is high clinical suspicion for ACS, serial ECGs, initially at 15- to 30-min intervals, should be performed to detect the potential for development of ST-segment elevation or depression. *(Level of Evidence: B)*

5. Cardiac biomarkers should be measured in all patients who present with chest discomfort consistent with ACS. *(Level of Evidence: B)*

6. A cardiac-specific troponin is the preferred marker, and if available, it should be measured in all patients who present with chest discomfort consistent with ACS. *(Level of Evidence: B)*

7. Patients with negative cardiac biomarkers within 6 h of the onset of symptoms consistent with ACS should have biomarkers remeasured in the time frame of 8 to 12 h after symptom onset. *(Level of Evidence: C)*

**CLASS IIb**

1. Use of risk-stratification models, such as the Thrombolysis In Myocardial Infarction (TIMI) or Global Registry of Acute Coronary Events (GRACE) risk score or the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) risk model, can be useful to assist in decision making with regard to treatment options in patients with suspected ACS. *(Level of Evidence: B)*

2. It is reasonable to remeasure positive biomarkers at 6- to 8-h intervals 2 to 3 times or until levels have peaked, as an index of infarct size and dynamics of necrosis. *(Level of Evidence: B)*

3. It is reasonable to obtain supplemental ECG leads V5 through V9 in patients whose initial ECG is nondiagnostic to rule out MI due to left circumflex occlusion. *(Level of Evidence: B)*

4. Continuous 12-lead ECG monitoring is a reasonable alternative to serial 12-lead recordings in patients whose initial ECG is nondiagnostic. *(Level of Evidence: B)*

**CLASS IIIb**

1. For patients who present within 6 h of the onset of symptoms consistent with ACS, assessment of an early marker of cardiac injury (e.g., myoglobin) in conjunction with a late marker (e.g., troponin) may be considered. *(Level of Evidence: B)*

2. For patients who present within 6 h of symptoms suggestive of ACS, a 2-h delta CK-MB mass in conjunction with 2-h delta troponin may be considered. *(Level of Evidence: B)*

3. For patients who present within 6 h of symptoms suggestive of ACS, myoglobin in conjunction with CK-MB mass or troponin when measured at baseline and 90 min may be considered. *(Level of Evidence: B)*

4. Measurement of BNP or NT-pro-BNP may be considered to supplement assessment of global risk in patients with suspected ACS. *(Level of Evidence: B)*

C. IMMEDIATE MANAGEMENT

**CLASS I**

1. The history, physical examination, 12-lead ECG, and initial cardiac biomarker tests should be integrated to assign patients with chest pain into 1 of 4 categories: a noncardiac diagnosis, chronic stable angina, possible ACS, and definite ACS. *(Level of Evidence: C)*

2. Patients with probable or possible ACS but whose initial 12-lead ECG and cardiac biomarker levels are normal should be observed in a facility with cardiac monitoring (e.g., chest pain unit or hospital telemetry ward), and repeat ECG (or continuous 12-lead ECG monitoring) and repeat cardiac biomarker measurement(s) should be obtained at predetermined, specified time intervals (see Section III.B). *(Level of Evidence: B)*

3. In patients with suspected ACS in whom ischemic heart disease is present or suspected, if the follow-up 12-lead ECG and cardiac biomarkers measurements are normal, a stress test (exercise or pharmacological) to provoke ischemia should be performed in the ED, in a chest pain unit, or on an inpatient basis in a timely fashion (within 72 h) as an alternative to inpatient admission. Low-risk patients with a negative diagnostic test can be managed as outpatients. *(Level of Evidence: C)*

4. In low-risk patients who are referred for outpatient stress testing (see above), precautionary appropriate pharmacotherapy (e.g., ASA,
sublingual NTG, and/or beta blockers) should be given while awaiting results of the stress test. (Level of Evidence: C)

5. Patients with definite ACS and ongoing ischemic symptoms, positive cardiac biomarkers, new ST-segment deviations, deep T-wave inversions, hemodynamic abnormalities, or a positive stress test should be admitted to the hospital for further management. Admission to the critical care unit is recommended for those with active, ongoing ischemia/injury and hemodynamic or electrical instability. Otherwise, a telemetry step-down unit is reasonable. (Level of Evidence: C)

6. Patients with possible ACS and negative cardiac biomarkers who are unable to exercise or who have an abnormal resting ECG should undergo a pharmacological stress test. (Level of Evidence: B)

7. Patients with definite ACS and ST-segment elevation in leads V1 to V6 due to left circumflex should be evaluated for immediate reperfusion therapy. (Level of Evidence: A)

8. Patients discharged from the ED or chest pain unit should be given specific instructions for activity, medications, additional testing, and follow-up with a personal physician. (Level of Evidence: C)

CLASS IIa
In patients with suspected ACS with a low or intermediate probability of CAD, in whom the follow-up 12-lead ECG and cardiac biomarker measurements are normal, performance of a noninvasive coronary imaging test (i.e., coronary CT angiography) is reasonable as an alternative to stress testing. (Level of Evidence: B)

3. Early Hospital Care

A. ANTI-ISCHEMIC AND ANALGESIC THERAPY

CLASS I

1. Bed/chair rest with continuous ECG monitoring is recommended for all UA/NSTEMI patients during the early hospital phase. (Level of Evidence: C)

2. Supplemental oxygen should be administered to patients with UA/NSTEMI with an arterial saturation less than 90%, respiratory distress, or other high-risk features for hypoxemia. (Pulse oximetry is useful for continuous measurement of SaO2.) (Level of Evidence: C)

3. Patients with UA/NSTEMI with ongoing ischemic discomfort should receive sublingual NTG (0.4 mg) every 5 min for a total of 3 doses, after which assessment should be made about the need for intravenous NTG, if not contraindicated. (Level of Evidence: C)

4. Intravenous NTG is indicated in the first 48 h after UA/NSTEMI for treatment of persistent ischemia, heart failure (HF), or hypertension. The decision to administer intravenous NTG and the dose used should not preclude therapy with other proven mortality-reducing interventions such as beta blockers or angiotensin-converting enzyme (ACE) inhibitors. (Level of Evidence: B)

5. Oral beta-blocker therapy should be initiated within the first 24 h for patients who do not have 1 or more of the following: 1) signs of HF, 2) evidence of a low-output state, 3) increased risk* for cardiogenic shock, or 4) other relative contraindications to beta blockade (PR interval greater than 0.24 s, second or third degree heart block, active asthma, or reactive airway disease). (Level of Evidence: B)

6. In UA/NSTEMI patients with continuing or frequently recurring ischemia and in whom beta blockers are contraindicated, a nondihydropyridine calcium channel blocker (e.g., verapamil or diltiazem) should be given as initial therapy in the absence of clinically significant left ventricular (LV) dysfunction or other contraindications. (Level of Evidence: B)

7. An ACE inhibitor should be administered orally within the first 24 h to UA/NSTEMI patients with pulmonary congestion or LV ejection fraction (LVEF) less than or equal to 0.40, in the absence of hypotension (systolic blood pressure less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to that class of medications. (Level of Evidence: A)

8. An angiotensin receptor blocker should be administered to UA/NSTEMI patients who are intolerant of ACE inhibitors and have either clinical or radiological signs of HF or LVEF less than or equal to 0.40. (Level of Evidence: A)

9. Because of the increased risks of mortality, reinfarction, hypertension, HF, and myocardial rupture associated with their use, nonsteroidal anti-inflammatory drugs (NSAIDs), except for ASA, whether nonselective or cyclooxygenase (COX)-2-selective agents, should be discontinued at the time a patient presents with UA/NSTEMI. (Level of Evidence: C)

CLASS IIb

1. It is reasonable to administer supplemental oxygen to all patients with UA/NSTEMI during the first 6 h after presentation. (Level of Evidence: C)

2. In the absence of contradictions to its use, it is reasonable to administer morphine sulfate intravenously to UA/NSTEMI patients if there is uncontrolled ischemic chest discomfort despite NTG, provided that additional therapy is used to manage the underlying ischemia. (Level of Evidence: B)

3. It is reasonable to administer intravenous (IV) beta blockers at the time of presentation for hypertension to UA/NSTEMI patients who do not have 1 or more of the following: 1) signs of HF, 2) evidence of a low-output state, 3) increased risk* for cardiogenic shock, or 4) other relative contraindications to beta blockade (PR interval greater than 0.24 s, second or third degree heart block, active asthma, or reactive airway disease). (Level of Evidence: B)

4. Oral long-acting nondihydropyridine calcium antagonists are reasonable for use in UA/NSTEMI patients for recurrent ischemia in the absence of contraindications after beta blockers and nitrates have been fully used. (Level of Evidence: C)

5. An ACE inhibitor administered orally within the first 24 h of UA/NSTEMI can be useful in patients without pulmonary congestion or LVEF less than or equal to 0.40 in the absence of hypotension (systolic blood pressure less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to that class of medications. (Level of Evidence: B)

6. Intra-aortic balloon pump counterpulsation is reasonable in UA/NSTEMI patients with severe ischemia that is continuing or recurs frequently despite intensive medical therapy, for hemodynamic instability in patients before or after coronary angiography, and for mechanical complications of MI. (Level of Evidence: C)

CLASS IIIb

1. The use of extended-release forms of nondihydropyridine calcium antagonists instead of a beta blocker may be considered in patients with UA/NSTEMI. (Level of Evidence: B)
2. Immediate-release dihydropyridine calcium antagonists in the presence of adequate beta blockade may be considered in patients with UA/NSTEMI with ongoing ischemic symptoms or hypertension. *(Level of Evidence: B)*

**CLASS III**

1. Nitrates should not be administered to UA/NSTEMI patients with systolic blood pressure less than 90 mm Hg or greater than or equal to 30 mm Hg below baseline, severe bradycardia (less than 50 beats per min), tachycardia (more than 100 beats per min) in the absence of symptomatic HF, or right ventricular infarction. *(Level of Evidence: C)*

2. Nitroglycerin or other nitrates should not be administered to patients with UA/NSTEMI who had received a phosphodiesterase inhibitor for erectile dysfunction within 24 h of sildenafil or 48 h of tadalafl use. The suitable time for the administration of nitrates after vardenafil has not been determined. *(Level of Evidence: C)*

3. Immediate-release dihydropyridine calcium antagonists should not be administered to patients with UA/NSTEMI in the absence of a beta blocker. *(Level of Evidence: A)*

4. An intravenous ACE inhibitor should not be given to patients within the first 24 h of UA/NSTEMI because of the increased risk of hypotension. *(A possible exception may be patients with refractory hypertension.)* *(Level of Evidence: B)*

5. It may be harmful to administer IV beta blockers to UA/NSTEMI patients who have contraindications to beta blockade, signs of HF or low-output state, or other risk factors for cardiogenic shock. *(Level of Evidence: A)*

6. Nonsteroidal anti-inflammatory drugs (except for ASA), whether nonselective or COX-2–selective agents, should not be administered during hospitalization for UA/NSTEMI because of the increased risks of mortality, reinfarction, hypertension, HF, and myocardial rupture associated with their use. *(Level of Evidence: C)*

**B. ANTIPLATELET/ANTICOAGULANT THERAPY IN PATIENTS FOR WHOM DIAGNOSIS OF UA/NSTEMI IS LIKELY OR DEFINITE**

Recommendations are written as the reader follows through the algorithm for Antiplatelet/Anticoagulant Therapy and Triage for Angiography (Figs. 6, 7, and 8). Letters after recommendations refer to the specific box in the algorithm. See Table 6 for dosing recommendations.

**I. ANTIPLATELET THERAPY**

**CLASS I**

1. Aspirin should be administered to UA/NSTEMI patients as soon as possible after hospital presentation and continued indefinitely in patients not known to be intolerant of that medication. *(Level of Evidence: A)* *(Figs. 6 and 7; Box A)*

2. Clopidogrel (loading dose followed by daily maintenance dose) should be administered to UA/NSTEMI patients who are unable to take ASA because of hypersensitivity or major gastrointestinal intolerance. *(Level of Evidence: A)* *(Figs. 6 and 7; Box A)*

3. In UA/NSTEMI patients with a history of gastrointestinal bleeding, when ASA and clopidogrel are administered alone or in combination, drugs to minimize the risk of recurrent gastrointestinal bleeding (e.g., proton-pump inhibitors) should be prescribed concomitantly. *(Level of Evidence: B)*

4. For UA/NSTEMI patients in whom an initial invasive strategy is selected, antiplatelet therapy in addition to aspirin should be initiated before diagnostic angiography (upstream) with either clopidogrel (loading dose followed by daily maintenance dose) or an IV GP IIb/IIIa inhibitor. *(Level of Evidence: A)* Abciximab as the choice for upstream GP IIb/IIIa therapy is indicated only if there is no appreciable delay to angiography and PCI is likely to be performed; otherwise, IV eptifibatide or tirofiban is the preferred choice of GP IIb/IIIa inhibitor. *(Level of Evidence: B)*

5. For UA/NSTEMI patients in whom an initial conservative strategy is selected (see Section IV.C), clopidogrel (loading dose followed by daily maintenance dose) should be added to ASA and anticoagulant therapy as soon as possible after admission and administered for at least 1 month *(Level of Evidence: A)* and ideally up to 1 year. *(Level of Evidence: B)* *(Fig. 7; Box C2)*

6. For UA/NSTEMI patients in whom an initial conservative strategy is selected, if recurrent symptoms/ischemia, HF, or serious arrhythmias subsequently appear, then diagnostic angiography should be performed *(Level of Evidence: A)* *(Fig. 7; Box D)*. Either an IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban; *(Level of Evidence: A)* or clopidogrel (loading dose followed by daily maintenance dose; *(Level of Evidence: A)* should be added to ASA and anticoagulant therapy before diagnostic angiography (upstream). *(Level of Evidence: C)*

**CLASS IIa**

1. For UA/NSTEMI patients in whom an initial conservative strategy is selected and who have recurrent ischemic discomfort with clopidogrel, ASA, and anticoagulant therapy, it is reasonable to add a GP IIb/IIIa antagonist before diagnostic angiography. *(Level of Evidence: C)*

2. For UA/NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to initiate antiplatelet therapy with both clopidogrel (loading dose followed by daily maintenance dose) and an IV GP IIb/IIIa inhibitor *(Level of Evidence: B)*. Abciximab as the choice for upstream GP IIb/IIIa therapy is indicated only if there is no appreciable delay to angiography and PCI is likely to be performed; otherwise, IV eptifibatide or tirofiban is the preferred choice of GP IIb/IIIa inhibitor. *(Level of Evidence: B)*

3. For UA/NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to omit upstream administration of an IV GP IIb/IIIa antagonist before diagnostic angiography if bivalirudin is selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 h earlier than planned catheterization or PCI. *(Level of Evidence: B)*

**CLASS IIb**

For UA/NSTEMI patients in whom an initial conservative (i.e., noninvasive) strategy is selected, it may be reasonable to add eptifibatide or...
tirofiban to anticoagulant and oral antiplatelet therapy. *(Level of Evidence: B)* *(Fig. 7; Box C2)*

**CLASS III**

Abciximab should not be administered to patients in whom PCI is not planned. *(Level of Evidence: A)*

II. **ANTICOAGULANT THERAPY**

Recommendations are written as the reader follows through the algorithm for Antiplatelet/Anticoagulant Therapy and Triage for Angiography *(Figs. 6, 7, and 8)*. Letters after recommendations refer to the specific box in the algorithm. See Table 6 for dosing recommendations.

**CLASS I**

Anticoagulant therapy should be added to antiplatelet therapy in UA/NSTEMI patients as soon as possible after presentation.

a. For patients in whom an invasive strategy is selected, regimens with established efficacy at a Level of Evidence: A include enoxaparin and UFH *(Fig. 6; Box B1)*, and those with established efficacy at a Level of Evidence: B include bivalirudin and fondaparinux *(Fig. 7; Box B1)*.

b. For patients in whom a conservative strategy is selected, regimens using either enoxaparin* or UFH *(Level of Evidence: A)* or fondaparinux *(Level of Evidence: B)* have established efficacy. *(Fig. 8; Box C1)*

c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. *(Level of Evidence: B)* *(Fig. 7; Box C1)*

**CLASS IIa**

For UA/NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin* or fondaparinux is preferable to UFH as anticoagulant therapy, unless coronary artery bypass graft surgery (CABG) is planned within 24 h. *(Level of Evidence: B)*

III. **ADDITIONAL MANAGEMENT CONSIDERATIONS FOR ANTIPLATELET AND ANTICOAGULANT THERAPY**

Recommendations are written as the reader follows through the algorithm for Antiplatelet/Anticoagulant Therapy and Triage for Angiography *(Figs. 6, 7, and 8)*. Letters after recommendations refer to the specific box in the algorithm. See Table 6 for dosing recommendations.

**CLASS I**

1. For UA/NSTEMI patients in whom an initial conservative strategy is selected and no subsequent features appear that would necessitate diagnostic angiography (recurrent symptoms/ischemia, HF, or serious arrhythmias), a stress test should be performed. *(Level of Evidence: B)* *(Fig. 7; Box O)*

   a. If, after stress testing, the patient is classified as not at low risk, diagnostic angiography should be performed. *(Level of Evidence: A)* *(Fig. 7; Box E1)*

   b. If, after stress testing, the patient is classified as being at low risk *(Fig. 7; Box E2)*, the instructions noted below should be followed in preparation for discharge *(Fig. 7; Box K)* *(Level of Evidence: A)*:

   1. Continue ASA indefinitely. *(Level of Evidence: A)*

   2. Continue clopidogrel for at least 1 month *(Level of Evidence: A)* and ideally up to 1 year. *(Level of Evidence: B)*

   3. Discontinue IV GP IIb/IIIa inhibitor if started previously. *(Level of Evidence: A)*

   4. Continue UFH for 48 h or administer enoxaparin or fondaparinux for the duration of hospitalization, up to 8 d, and then discontinue anticoagulant therapy. *(Level of Evidence: A)*

2. For UA/NSTEMI patients in whom CABG is selected as a postangiography management strategy, the instructions noted below should be followed *(Fig. 8; Box G)*.

   a. Continue ASA. *(Level of Evidence: A)*

   b. Discontinue clopidogrel 5 to 7 d before elective CABG. *(Level of Evidence: B)*

   c. Discontinue IV GP IIb/IIIa inhibitor (eptifibatide or tirofiban) 4 h before CABG. *(Level of Evidence: B)*

   d. Anticoagulant therapy should be managed as follows:

      1. Continue UFH. *(Level of Evidence: B)*

      2. Discontinue enoxaparin* 12 to 24 h before CABG and dose with UFH per institutional practice. *(Level of Evidence: B)*

      3. Discontinue fondaparinux 24 h before CABG and dose with UFH per institutional practice. *(Level of Evidence: B)*

      4. Discontinue bivalirudin 3 h before CABG and dose with UFH per institutional practice. *(Level of Evidence: B)*

3. For UA/NSTEMI patients in whom PCI has been selected as a postangiography management strategy, the instructions noted below should be followed *(Fig. 8 C; Box H)*.

   a. Continue ASA. *(Level of Evidence: A)*

   b. Administer a loading dose of clopidogrel† if not started before diagnostic angiography. *(Level of Evidence: A)*

   c. Administer an IV GP IIb/IIIa inhibitor (abciximab, eptifibatide, or tirofiban) if not started before diagnostic angiography for troponin-positive and other high-risk patients. *(Level of Evidence: A)*

   d. Continue anticoagulant therapy after PCI for uncomplicated cases. *(Level of Evidence: B)*

4. For UA/NSTEMI patients in whom medical therapy is selected as a postangiography management strategy and in whom no significant obstructive CAD on angiography was found, antiplatelet and anticoagulant therapy should be administered at the discretion of the clinician. *(Level of Evidence: C)* For patients in whom evidence of coronary atherosclerosis is present (e.g., luminal irregularities or intravascular ultrasound–demonstrated lesions), albeit without flow-limiting stenoses, long-term treatment with ASA and other secondary prevention measures should be prescribed. *(Fig. 8; Box I)* *(Level of Evidence: C)*

5. For UA/NSTEMI patients in whom medical therapy is selected as a postangiography management strategy and in whom CAD was found on angiography, the following approach is recommended *(Fig. 8; Box J)*.

   a. Continue ASA. *(Level of Evidence: A)*

   b. Administer a loading dose of clopidogrel† if not given before diagnostic angiography. *(Level of Evidence: A)*

†Some uncertainty exists about optimum dosing of clopidogrel. Randomized trials establishing its efficacy and providing data on bleeding risks used a loading dose of 300 mg orally followed by a daily oral maintenance dose of 75 mg. Higher oral loading doses such as 600 or 900 mg of clopidogrel more rapidly inhibit platelet aggregation and achieve a higher absolute level of inhibition of platelet aggregation, but the additive clinical efficacy and the safety of higher oral loading doses have not been rigorously established.

*Limited data are available for the use of other LMWHs (e.g., dalteparin; see Tables 6 and 7) in UA/NSTEMI.
c. Discontinue IV GP IIb/IIIa inhibitor if started previously. (Level of Evidence: B)
d. Anticoagulant therapy should be managed as follows:
   1. Continue IV UFH for at least 48 h or until discharge if given before diagnostic angiography. (Level of Evidence: A)
   2. Continue enoxaparin for duration of hospitalization, up to 8 d, if given before diagnostic angiography. (Level of Evidence: A)
   3. Continue fondaparinux for duration of hospitalization, up to 8 d, if given before diagnostic angiography. (Level of Evidence: B)
   4. Either discontinue bivalirudin or continue at a dose of 0.25 mg per kg per h for up to 72 h at the physician’s discretion, if given before diagnostic angiography. (Level of Evidence: B)

6. For UA/NSTEMI patients in whom a conservative strategy is selected and who do not undergo angiography or stress testing, the instructions noted below should be followed (Fig. 7; Box K):
   a. Continue ASA indefinitely. (Level of Evidence: A)
   b. Continue clopidogrel for at least 1 month (Level of Evidence: A) and ideally up to 1 year. (Level of Evidence: B)
   c. Discontinue IV GP IIb/IIIa inhibitor it started previously. (Level of Evidence: A)
   d. Continue UFH for 48 h or administer enoxaparin or fondaparinux for the duration of hospitalization, up to 8 d, and then discontinue anticoagulant therapy. (Level of Evidence: B)

7. For UA/NSTEMI patients in whom an initial conservative strategy is selected and in whom no subsequent features appear that would necessitate diagnostic angiography (recurrent symptoms/isch-emia, HF, or serious arrhythmias), LVEF should be measured. (Level of Evidence: B) (Fig. 7; Box L)

CLASS IIa
1. For UA/NSTEMI patients in whom PCI is selected as a postangiography management strategy, it is reasonable to omit administration of an IV GP IIb/IIIa antagonist if bivalirudin was selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 h earlier. (Level of Evidence: B) (Fig. 8)
2. If LVEF is less than or equal to 0.40, it is reasonable to perform diagnostic angiography. (Level of Evidence: B) (Fig. 7; Box M)
3. If LVEF is greater than 0.40, it is reasonable to perform a stress test. (Level of Evidence: B) (Fig. 7; Box N)

CLASS IIb
For UA/NSTEMI patients in whom PCI is selected as a postangiography management strategy, it may be reasonable to omit an IV GP IIb/IIIa inhibitor if not started before diagnostic angiography for troponin-negative patients without other clinical or angiographic high-risk features. (Level of Evidence: C)

CLASS III
Intravenous fibrinolytic therapy is not indicated in patients without acute ST-segment elevation, a true posterior MI, or a presumed new left bundle-branch block. (Level of Evidence: A)

C. INITIAL CONSERVATIVE VERSUS INITIAL INVASIVE STRATEGIES

CLASS I
1. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is indicated in UA/NSTEMI patients who have refractory angina or hemodynamic or electrical instability (without serious comorbidities or contraindications to such procedures). (Level of Evidence: B)

2. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is indicated in initially stabilized UA/NSTEMI patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events (see Table 5 and Sections III.B and IV.C.5). (Level of Evidence: A)

CLASS IIb
1. In initially stabilized patients, an initially conservative (i.e., a selectively invasive) strategy may be considered as a treatment strategy for UA/NSTEMI patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events (see Table 5 and Sections III.B and IV.C.5) including those who are troponin positive. (Level of Evidence: B) The decision to implement an initial conservative (vs. initial invasive) strategy in these patients may be made by considering physician and patient preference. (Level of Evidence: C)

2. An invasive strategy may be reasonable in patients with chronic renal insufficiency. (Level of Evidence: C)

CLASS III
1. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is not recommended in patients with extensive comorbidities (e.g., liver or pulmonary failure, cancer), in whom the risks of revascularization and comorbid conditions are likely to outweigh the benefits of revascularization. (Level of Evidence: C)

2. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) is not recommended in patients with acute chest pain and a low likelihood of ACS. (Level of Evidence: C)

3. An early invasive strategy (i.e., diagnostic angiography with intent to perform revascularization) should not be performed in patients who will not consent to revascularization regardless of the findings. (Level of Evidence: C)

D. RISK STRATIFICATION BEFORE DISCHARGE

CLASS I
1. Noninvasive stress testing is recommended in low-risk patients (Table 3) who have been free of ischemia at rest or with low-level activity and of HF for a minimum of 12 to 24 h. (Level of Evidence: C)

2. Noninvasive stress testing is recommended in patients at intermediate risk (Table 3) who have been free of ischemia at rest or with low-level activity and of HF for a minimum of 12 to 24 h. (Level of Evidence: C)

3. Choice of stress test is based on the resting ECG, ability to perform exercise, local expertise, and technologies available. Treadmill exercise is useful in patients able to exercise in whom the ECG is free of baseline ST-segment abnormalities, bundle-branch block, LV hypertrophy, intraventricular conduction defect, paced rhythm, pre-excitation, and digoxin effect. (Level of Evidence: C)

4. An imaging modality should be added in patients with resting ST-segment depression (greater than or equal to 0.10 mV), LV hypertrophy, bundle-branch block, intraventricular conduction defect, preexcitation, or digoxin who are able to exercise. In patients undergoing a low-level exercise test, an imaging modality can add sensitivity. (Level of Evidence: B)

5. Pharmacological stress testing with imaging is recommended when physical limitations (e.g., arthritis, amputation, severe peripheral vascular disease, severe chronic obstructive pulmonary disease, or
6. Prompt angiography without noninvasive risk stratification should be performed for failure of stabilization with intensive medical treatment. (Level of Evidence: B)

7. A noninvasive test (echocardiogram or radionuclide angiogram) is recommended to evaluate LV function in patients with definite ACS who are not scheduled for coronary angiography and left ventriculography. (Level of Evidence: B)

4. Revascularization With PCI and CABG in Patients With UA/NSTEMI

A. PERCUTANEOUS CORONARY INTERVENTION

CLASS I
1. An early invasive PCI strategy is indicated for patients with UA/NSTEMI who have no serious comorbidity and who have coronary lesions amenable to PCI and any of the high-risk features listed in Section IV.5. (See Section 3.C for specific recommendations and their Level of Evidence.)

2. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)

3. Percutaneous coronary intervention (or CABG) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

4. An intravenous platelet GP IIb/IIIa inhibitor is generally recommended in UA/NSTEMI patients undergoing PCI. (Level of Evidence: A) See Section IV.B.3. and Figures 6, 7, and 8 for details on timing and dosing recommendations (see Table 6).

CLASS IIa
1. Percutaneous coronary intervention is reasonable for focal saphenous vein graft (SVG) lesions or multiple stenoses in UA/NSTEMI patients who are undergoing medical therapy and who are poor candidates for reoperative surgery. (Level of Evidence: C)

2. Percutaneous coronary intervention (or CABG) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)

3. Percutaneous coronary intervention (or CABG) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)

4. Use of PCI is reasonable in patients with UA/NSTEMI with significant left main CAD (greater than 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG or who require emergent intervention at angiography for hemodynamic instability. (Level of Evidence: B)

CLASS IIb
1. In the absence of high-risk features associated with UA/NSTEMI, PCI may be considered in patients with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. (Level of Evidence: B)

2. Percutaneous coronary intervention may be considered for UA/NSTEMI patients who are undergoing medical therapy who have 2- or 3-vessel disease, significant proximal left anterior descending CAD, and treated diabetes or abnormal LV function, with anatomy suitable for catheter-based therapy. (Level of Evidence: B)

CLASS III
1. Percutaneous coronary intervention (or CABG) is not recommended for patients with 1- or 2-vessel CAD without significant proximal left anterior descending CAD with no current symptoms or symptoms that are unlikely to be due to myocardial ischemia and who have no ischemia on noninvasive testing. (Level of Evidence: C)

2. In the absence of high-risk features associated with UA/NSTEMI, PCI is not recommended for patients with UA/NSTEMI who have single-vessel or multivessel CAD and any trial of medical therapy, or who have 1 or more of the following:
   a. Only a small area of myocardium at risk. (Level of Evidence: C)
   b. All lesions or the culprit lesion to be dilated with morphology that conveys a low likelihood of success. (Level of Evidence: C)
   c. A high risk of procedure-related morbidity or mortality. (Level of Evidence: C)
   d. Insignificant disease (less than 50% coronary stenosis). (Level of Evidence: C)
   e. Significant left main CAD and candidacy for CABG. (Level of Evidence: B)

3. A PCI strategy in stable patients with persistently occluded infarct-related coronary arteries after NSTEMI is not indicated. (Level of Evidence: B)

B. CABG

CLASS I
1. Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients with significant left main CAD (greater than 50% stenosis). (Level of Evidence: A)

2. Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients with 3-vessel disease; the survival benefit is greater in patients with abnormal LV function (LVEF less than 0.50). (Level of Evidence: A)

3. Coronary artery bypass graft surgery is recommended for UA/NSTEMI patients with 2-vessel disease with significant proximal left anterior descending CAD and either abnormal LV function (LVEF less than 0.50) or ischemia on noninvasive testing. (Level of Evidence: A)

4. Coronary artery bypass graft surgery is recommended for UA/NSTEMI in patients in whom percutaneous revascularization is not optimal or possible and who have ongoing ischemia not responsive to maximal nonsurgical therapy. (Level of Evidence: B)

5. Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a large area of viable myocardium and high-risk criteria on noninvasive testing. (Level of Evidence: B)

6. Coronary artery bypass graft surgery (or PCI) is recommended for UA/NSTEMI patients with multivessel coronary disease with suitable coronary anatomy, with normal LV function, and without diabetes mellitus. (Level of Evidence: A)

CLASS IIa
1. For patients with UA/NSTEMI and multivessel disease, CABG with use of the internal mammary arteries can be beneficial over PCI in patients being treated for diabetes. (Level of Evidence: B)
2. It is reasonable to perform CABG with the internal mammary artery for UA/NSTEMI patients with multivessel disease and treated diabetes mellitus. (Level of Evidence: B)

3. Repeat CABG is reasonable for UA/NSTEMI patients with multiple SVG stenoses, especially when there is significant stenosis of a graft that supplies the left anterior descending coronary artery (LAD). (Level of Evidence: C)

4. Coronary artery bypass graft surgery (or PCI) is reasonable for UA/NSTEMI patients with 1- or 2-vessel CAD with or without significant proximal left anterior descending CAD but with a moderate area of viable myocardium and ischemia on noninvasive testing. (Level of Evidence: B)

5. Coronary artery bypass graft surgery (or PCI) can be beneficial compared with medical therapy for UA/NSTEMI patients with 1-vessel disease with significant proximal left anterior descending CAD. (Level of Evidence: B)

6. Coronary artery bypass graft surgery (or PCI) with stenting is reasonable for patients with multivessel disease and symptomatic myocardial ischemia. (Level of Evidence: B)

**CLASS IIb**

Coronary artery bypass graft surgery may be considered in patients with UA/NSTEMI who have 1- or 2-vessel disease not involving the proximal LAD with a modest area of ischemic myocardium when percutaneous revascularization is not optimal or possible. (If there is a large area of viable myocardium and high-risk criteria on noninvasive testing, this recommendation becomes a Class I recommendation.) (Level of Evidence: B)

**CLASS III**

Coronary artery bypass graft surgery (or PCI) is not recommended for patients with 1- or 2-vessel CAD without significant proximal left anterior descending CAD with no current symptoms or symptoms that are unlikely to be due to myocardial ischemia and who have no ischemia on noninvasive testing. (Level of Evidence: C)

5. Late Hospital Care, Hospital Discharge, and Post-Hospital Discharge Care

**RECOMMENDATIONS**

**CLASS I**

1. Medications required in the hospital to control ischemia should be continued after hospital discharge in patients with UA/NSTEMI who do not undergo coronary revascularization, patients with unsuccessful revascularization, and patients with recurrent symptoms after revascularization. Upward or downward titration of the doses may be required. (Level of Evidence: C)

2. All post-UA/NSTEMI patients should be given sublingual or spray NTG and instructed in its use. (Level of Evidence: C)

3. Before hospital discharge, patients with UA/NSTEMI should be informed about symptoms of worsening myocardial ischemia and MI and should be instructed in how and when to seek emergency care and assistance if such symptoms occur. (Level of Evidence: C)

4. Before hospital discharge, post-UA/NSTEMI patients and/or designated responsible caregivers should be provided with supportable, easily understood, and culturally sensitive instructions with respect to medication type, purpose, dose, frequency, and pertinent side effects. (Level of Evidence: C)

5. In post-UA/NSTEMI patients, anginal discomfort lasting more than 2 or 3 min should prompt the patient to discontinue physical activity or remove himself or herself from any stressful event. If pain does not subside immediately, the patient should be instructed to take 1 dose of NTG sublingually. If the chest discomfort/pain is unimproved or worsening 5 min after 1 NTG dose has been taken, it is recommended that the patient or a family member/friend call 9-1-1 immediately to access EMS. While activating EMS access, additional NTG (at 5-min intervals 2 times) may be taken while lying down or sitting. (Level of Evidence: C)

6. If the pattern or severity of anginal symptoms changes, which suggests worsening myocardial ischemia (e.g., pain is more frequent or severe or is precipitated by less effort or now occurs at rest), the patient should contact his or her physician without delay to assess the need for additional treatment or testing. (Level of Evidence: C)

**B. LONG-TERM MEDICAL THERAPY AND SECONDARY PREVENTION**

**I. ANTIPLATELET THERAPY**

**CLASS I**

1. For UA/NSTEMI patients treated medically without stenting, aspirin* (75 to 162 mg per day) should be prescribed indefinitely (Level of Evidence: A). Clopidogrel† (75 mg per day) should be prescribed for at least 1 month (Level of Evidence: A) and ideally for up to 1 year. (Level of Evidence: B)

2. For UA/NSTEMI patients treated with bare-metal stents, aspirin* 162 to 325 mg per day should be prescribed for at least 1 month (Level of Evidence: B), then continued indefinitely at a dose of 75 to 162 mg per day (Level of Evidence: A). Clopidogrel should be prescribed at a dose of 75 mg per day for a minimum of 1 month and ideally for up to 1 year (unless the patient is at increased risk of bleeding, then it should be given for a minimum of 2 weeks). (Level of Evidence: B)

3. For UA/NSTEMI patients treated with DES, aspirin* 162 to 325 mg per day should be prescribed for at least 3 months after sirolimus-eluting stent implantation and 6 months after paclitaxel-eluting stent implantation then continued indefinitely at a dose of 75 to 162 mg per day. (Level of Evidence: B) Clopidogrel 75 mg daily should be given for at least 12 months to all post-PCI patients receiving DES. (Level of Evidence: B)

4. Clopidogrel 75 mg daily (preferred) or ticlopidine (in the absence of contraindications) should be given to patients recovering from UA/NSTEMI when ASA is contraindicated or not tolerated because of hypersensitivity or gastrointestinal intolerance (but with gastroprotective agents such as proton-pump inhibitors). (Level of Evidence: A)

**CLASS IIa**

For UA/NSTEMI patients in whom the physician is concerned about the risk of bleeding, a lower initial aspirin dose after PCI of 75 to 162 mg per day is reasonable. (Level of Evidence: C)

---

*For ASA-allergic patients, use clopidogrel alone (indefinitely), or try aspirin desensitization.
†For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily.
II. BETA BLOCKERS

CLASS I
1. Beta blockers are indicated for all patients recovering from UA/NSTEMI unless contraindicated. (For those at low risk, see Class IIa recommendation below). Treatment should begin within a few days of the event, if not initiated acutely, and should be continued indefinitely. (Level of Evidence: B)

2. Patients recovering from UA/NSTEMI with moderate or severe LV failure should receive beta-blocker therapy with a gradual titration scheme. (Level of Evidence: B)

CLASS IIa
It is reasonable to prescribe beta blockers to low-risk patients (i.e., normal LV function, revascularized, no high-risk features) recovering from UA/NSTEMI in the absence of absolute contraindications. (Level of Evidence: B)

III. INHIBITION OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

CLASS I
1. Angiotensin-converting enzyme inhibitors should be given and continued indefinitely for patients recovering from UA/NSTEMI with HF, LV dysfunction (ejection fraction less than 0.40), hypertension, or diabetes mellitus unless contraindicated. (Level of Evidence: A)

2. An angiotensin receptor blocker should be prescribed at discharge to those UA/NSTEMI patients who are intolerant of an ACE inhibitor and who have either clinical or radiological signs of HF and LVEF less than 0.40. (Level of Evidence: A)

3. Long-term aldosterone receptor blockade should be prescribed for UA/NSTEMI patients without significant renal dysfunction (estimated creatinine clearance should be greater than 30 ml per min) or hyperkalemia (potassium should be less than or equal to 5 mEq per liter) who are already receiving therapeutic doses of an ACE inhibitor, have an LVEF less than or equal to 0.40, and have either symptomatic HF or diabetes mellitus. (Level of Evidence: A)

CLASS IIa
1. Angiotensin-converting enzyme inhibitors are reasonable for patients recovering from UA/NSTEMI in the absence of LV dysfunction, hypertension, or diabetes mellitus unless contraindicated. (Level of Evidence: A)

2. Angiotensin-converting enzyme inhibitors are reasonable for patients with HF and LVEF greater than 0.40. (Level of Evidence: A)

3. In UA/NSTEMI patients who do not tolerate ACE inhibitors, an angiotensin receptor blocker can be useful as an alternative to ACE inhibitors in long-term management provided there are either clinical or radiological signs of HF and LVEF less than 0.40. (Level of Evidence: B)

CLASS IIb
The combination of an ACE inhibitor and an angiotensin receptor blocker may be considered in the long-term management of patients recovering from UA/NSTEMI with persistent symptomatic HF and LVEF less than 0.40 despite conventional therapy including an ACE inhibitor or angiotensin receptor blocker alone. (Level of Evidence: B)

IV. NITROGLYCERIN

CLASS I
Nitroglycerin to treat ischemic symptoms is recommended. (Level of Evidence: C)

V. CALCIUM CHANNEL BLOCKERS

CLASS I
1. Calcium channel blockers§ are recommended for ischemic symptoms when beta blockers are not successful. (Level of Evidence: B)

2. Calcium channel blockers§ are recommended for ischemic symptoms when beta blockers are contraindicated or cause unacceptable side effects. (Level of Evidence: C)

VI. WARFARIN THERAPY

CLASS I
Use of warfarin in conjunction with ASA and/or clopidogrel is associated with an increased risk of bleeding and should be monitored closely. (Level of Evidence: A)

CLASS IIb
Warfarin either without (international normalized ratio 2.5 to 3.5) or with low-dose ASA (75 to 81 mg per d; international normalized ratio 2.0 to 2.5) may be reasonable for patients at high CAD risk and low bleeding risk who do not require or are intolerant of clopidogrel. (Level of Evidence: B)

VII. LIPID MANAGEMENT

CLASS I
1. The following lipid recommendations are beneficial:
   a. Lipid management should include assessment of a fasting lipid profile for all patients, within 24 h of hospitalization. (Level of Evidence: C)
   b. Hydroxymethyl glutaryl-coenzyme A reductase inhibitors (statins), in the absence of contraindications, regardless of baseline LDL-C and diet modification, should be given to post-UA/NSTEMI patients, including postrevascularization patients. (Level of Evidence: A)
   c. For hospitalized patients, lipid-lowering medications should be initiated before discharge. (Level of Evidence: A)
   d. For UA/NSTEMI patients with elevated LDL-C (greater than or equal to 100 mg per dL), cholesterol-lowering therapy should be initiated or intensified to achieve an LDL-C of less than 100 mg per dL. (Level of Evidence: A) Further titration to less than 70 mg per dL is reasonable. (Class IIa, Level of Evidence: A)
   e. Therapeutic options to reduce non–HDL-C are recommended.

CLASS IIb
The safety of this combination has not been proven in patients also on aldosterone antagonist and is not recommended.

§Short-acting dihydropyridine calcium channel antagonists should be avoided.
[Non–HDL-C = total cholesterol minus HDL-C.

*Continue ASA indefinitely and warfarin longer term as indicated for specific conditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary emboli.
†An international normalized ratio of 2.0 to 2.5 is preferable while given with ASA and clopidogrel, especially in older patients and those with other risk factors for bleeding.
‡The safety of this combination has not been shown to be effective.
§Short-acting dihydropyridine calcium channel antagonists should be avoided.
including more intense LDL-C-lowering therapy. (Level of Evidence: B)

f. Dietary therapy for all patients should include reduced intake of saturated fats (to less than 7% of total calories), cholesterol (to less than 200 mg per dL), and trans fat (to less than 1% of energy). (Level of Evidence: B)

g. Promoting daily physical activity and weight management are recommended. (Level of Evidence: B)

2. Treatment of triglycerides and non–HDL-C is useful, including the following:

a. If triglycerides are 200 to 499 mg per dL, non–HDL-C* should be less than 130 mg per dL. (Level of Evidence: B)

b. If triglycerides are greater than or equal to 500 mg per dL†, therapeutic options to prevent pancreatitis are fibrate‡ or niacin§ before LDL-lowering therapy is recommended. It is also recommended that LDL-C be treated to goal after triglyceride-lowering therapy. Achievement of a non–HDL-C* less than 130 mg per dL (i.e., 30 mg per dL greater than LDL-C target) if possible is recommended. (Level of Evidence: C)

c. Further reduction of non–HDL-C* to less than 100 mg per dL is reasonable; if triglycerides are 200 to 499 mg per dL, non–HDL-C target is less than 130 mg per dL. (Level of Evidence: B)

d. Therapeutic options to reduce non–HDL-C* (after LDL-lowering therapy) include niacin‡ or fibrate† therapy.

e. Nicotinic acid (niacin‡) and fibric acid derivatives (fenofibrate, gemfibrozil†) can be useful as therapeutic options (after LDL-lowering therapy) for HDL-C less than 40 mg per dL. (Level of Evidence: B)

f. Nicotinic acid (niacin‡) and fibric acid derivatives (fenofibrate, gemfibrozil†) can be useful as therapeutic options (after LDL-lowering therapy) for triglycerides greater than 200 mg per dL. (Level of Evidence: B)

g. The addition of plant stanol/sterols (2 g per d) and/or viscous fiber (more than 10 g per d) is reasonable to further lower LDL-C. (Level of Evidence: A)

CLASS IIb

Encouraging consumption of omega-3 fatty acids in the form of fish§ or in capsule form (1 g per d) for risk reduction may be reasonable. For treatment of elevated triglycerides, higher doses (2 to 4 g per d) may be used for risk reduction. (Level of Evidence: B)

VIII. BLOOD PRESSURE CONTROL

CLASS I

Blood pressure control according to Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines is recommended (i.e., blood pressure less than 140/90 mm Hg or less than 130/80 mm Hg if the patient has diabetes mellitus or chronic kidney disease). (Level of Evidence: A) Additional measures recommended to treat and control blood pressure include the following:

a. Patients should initiate and/or maintain lifestyle modifications, including weight control, increased physical activity, alcohol moderation, sodium reduction, and emphasis on increased consumption of fresh fruits, vegetables, and low-fat dairy products. (Level of Evidence: B)

b. For patients with blood pressure greater than or equal to 140/90 mm Hg (or greater than or equal to 130/80 mm Hg for individuals with chronic kidney disease or diabetes mellitus), it is useful to add blood pressure medication as tolerated, treating initially with beta blockers and/or ACE inhibitors, with addition of other drugs such as thiazides as needed to achieve target blood pressure. (Level of Evidence: A)

IX. DIABETES MELLITUS

CLASS I

Diabetes management should include lifestyle and pharmacotherapy measures to achieve a near-normal hemoglobin A1c level of less than 7%. (Level of Evidence: B) Diabetes management should also include the following:

a. Vigorous modification of other risk factors (e.g., physical activity, weight management, blood pressure control, and cholesterol management) as recommended should be initiated and maintained. (Level of Evidence: B)

b. It is useful to coordinate the patient’s diabetic care with the patient’s primary care physician or endocrinologist. (Level of Evidence: C)

X. SMOKING CESSATION

CLASS I

Smoking cessation and avoidance of exposure to environmental tobacco smoke at work and home are recommended. Follow-up, referral to special programs, or pharmacotherapy (including nicotine replacement) is useful, as is adopting a stepwise strategy aimed at smoking cessation (the 5 As are: Ask, Advise, Assess, Assist, and Arrange). (Level of Evidence: B)

XI. WEIGHT MANAGEMENT

CLASS I

Weight management, as measured by body mass index and/or waist circumference, should be assessed on each visit. A body mass index of 18.5 to 24.9 kg per m² and a waist circumference (measured horizontally at the iliac crest) of less than 40 inches for men and less than 35 inches for women is recommended. (Level of Evidence: B) Additional weight management practices recommended include the following:

a. On each patient visit, it is useful to consistently encourage weight maintenance/reduction through an appropriate balance of physical activity, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg per m². (Level of Evidence: B)

b. If waist circumference is 35 inches or more in women or 40 inches or more in men, it is reasonable to recommend pharmacotherapy for weight reduction.

CLASS IIa

The following lipid management strategies can be beneficial:

a. Further reduction of LDL-C to less than 70 mg per dL is reasonable. (Level of Evidence: A)

b. If baseline LDL cholesterol is 70 to 100 mg per dL, it is reasonable to treat LDL-C to less than 70 mg per dL. (Level of Evidence: B)

c. Further reduction of non–HDL-C* to less than 100 mg per dL is reasonable; if triglycerides are 200 to 499 mg per dL, non–HDL-C target is less than 130 mg per dL. (Level of Evidence: B)

d. Therapeutic options to reduce non–HDL-C* (after LDL-lowering therapy) include niacin‡ or fibrate† therapy.

e. Nicotinic acid (niacin‡) and fibric acid derivatives (fenofibrate, gemfibrozil†) can be useful as therapeutic options (after LDL-lowering therapy) for HDL-C less than 40 mg per dL. (Level of Evidence: B)

f. Nicotinic acid (niacin‡) and fibric acid derivatives (fenofibrate, gemfibrozil†) can be useful as therapeutic options (after LDL-lowering therapy) for triglycerides greater than 200 mg per dL. (Level of Evidence: B)

g. The addition of plant stanol/sterols (2 g per d) and/or viscous fiber (more than 10 g per d) is reasonable to further lower LDL-C. (Level of Evidence: A)
or more in men, it is beneficial to initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated. 
(Level of Evidence: B)
c. The initial goal of weight loss therapy should be to reduce body weight by approximately 10% from baseline. With success, further weight loss can be attempted if indicated through further assessment. (Level of Evidence: B)

XII. PHYSICAL ACTIVITY

CLASS I
1. The patient’s risk after UA/NSTEMI should be assessed on the basis of an in-hospital determination of risk. A physical activity history or an exercise test to guide initial prescription is beneficial. (Level of Evidence: B)

2. Guided/modified by an individualized exercise prescription, patients recovering from UA/NSTEMI generally should be encouraged to achieve physical activity duration of 30 to 60 min per d, preferably 7 (but at least 5) d per week of moderate aerobic activity, such as brisk walking, supplemented by an increase in daily lifestyle activities (e.g., walking breaks at work, gardening, and household work). (Level of Evidence: B)

3. Cardiac rehabilitation/secondary prevention programs are recommended for patients with UA/NSTEMI, particularly those with multiple modifiable risk factors and/or those moderate-to high-risk patients in whom supervised exercise training is particularly warranted. (Level of Evidence: B)

CLASS IIb
The expansion of physical activity to include resistance training on 2 d per week may be reasonable. (Level of Evidence: C)

XIII. PATIENT EDUCATION

CLASS I
Beyond the detailed instructions for daily exercise, patients should be given specific instruction on activities (e.g., heavy lifting, climbing stairs, yard work, and household activities) that are permissible and those that should be avoided. Specific mention should be made regarding resumption of driving, return to work, and sexual activity. (Level of Evidence: C) Specific recommendations for physical activity follow in Section VI.E.

CLASS III
An annual influenza vaccination is recommended for patients with cardiovascular disease. (Level of Evidence: B)

XIV. INFLUENZA

CLASS III
Nonsteroidal anti-inflammatory drugs with increasing degrees of relative COX-2 selectivity should be considered for pain relief only for situations in which intolerable discomfort persists despite attempts at stepped-care therapy with acetaminophen, small doses of narcotics, nonacetylated salicylates, or nonselective NSAIDs. In all cases, the lowest effective doses should be used for the shortest possible time. (Level of Evidence: C)

CLASS IIb
Nonsteroidal anti-inflammatory drugs with increasing degrees of relative COX-2 selectivity should not be administered to UA/NSTEMI patients with chronic musculoskeletal discomfort when therapy with acetaminophen, small doses of narcotics, nonacetylated salicylates, or nonselective NSAIDs provides acceptable levels of pain relief. (Level of Evidence: C)

XVII. HORMONE THERAPY

CLASS III
1. Hormone therapy with estrogen plus progesterin, or estrogen alone, should not be given de novo to postmenopausal women after UA/NSTEMI for secondary prevention of coronary events. (Level of Evidence: A)

2. Postmenopausal women who are already taking estrogen plus progesterin, or estrogen alone, at the time of UA/NSTEMI in general should not continue hormone therapy. However, women who are more than 1 to 2 years past the initiation of hormone therapy who wish to continue such therapy for another compelling indication should weigh the risks and benefits, recognizing the greater risk of cardiovascular events and breast cancer (combination therapy) or stroke (estrogen). Hormone therapy should not be continued while patients are on bedrest in the hospital. (Level of Evidence: B)

XVIII. ANTIOXIDANT VITAMINS AND FOLIC ACID

CLASS III
1. Antioxidant vitamin supplements (e.g., vitamins E, C, or beta carotene) should not be used for secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)

2. Folic acid, with or without B6 and B12, should not be used for secondary prevention in UA/NSTEMI patients. (Level of Evidence: A)

C. POSTDISCHARGE FOLLOW-UP

RECOMMENDATIONS

CLASS I
1. Detailed discharge instructions for post-UA/NSTEMI patients should include education on medications, diet, exercise, and smoking cessation counseling (if appropriate), referral to a cardiac rehabilitation/secondary prevention program (when appropriate), and the scheduling of a timely follow-up appointment. Low-risk medically treated patients and revascularized patients should return in 2 to 6 weeks, and higher risk patients should return within 14 d. (Level of Evidence: C)

2. Patients with UA/NSTEMI managed initially with a conservative strategy who experience recurrent signs or symptoms of UA or
严重的慢性稳定型心绞痛（加拿大心血管学会第三级）患者尽管在医疗管理下仍然适合进行再血管化治疗，应进行及时冠状动脉造影。(Level of Evidence: B)

3. 对于UA/NSTEMI患者，有可耐受的稳定型心绞痛或无心绞痛，应给予长期医疗治疗以维持稳定型心绞痛。(Level of Evidence: B)

4. 应采取有效措施确保UA/NSTEMI患者与医疗团队成员之间的沟通，以达到长期的依从性，并推荐生活方式的改变。(Level of Evidence: B)

D. 心脏康复

CLASS I

心脏康复/第二次预防项目，当可用时，应为UA/NSTEMI患者推荐，特别是那些有多重可改变的风险因素和那些在未经监督或监测的运动训练中较高的风险患者，即使在UA/NSTEMI之后，有证据支持。(Level of Evidence: B)

6. 特殊人群

A. 妇女

CLASS I

1. 女性UA/NSTEMI患者应与男性UA/NSTEMI患者共同管理，同样的病理解释，特别是那些具有多重可改变风险因素和那些在未经监督或监测的运动训练风险较高的患者，即使在UA/NSTEMI之后，有证据支持。(Level of Evidence: B)

2. 非侵入性检测在UA/NSTEMI后CABG患者中是合理的。

3. 对于UA/NSTEMI患者与糖尿病患者，再血管化策略在单血管和多血管患者中是相同的。

CLASS IIa

1. 对于UA/NSTEMI和多血管的患者，CABG与使用内乳动脉可以对在UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 对于UA/NSTEMI和糖尿病患者，对糖尿病的单血管患者具有单血管和可诱导的疾病，有证据支持。(Level of Evidence: B)

3. 对于UA/NSTEMI和糖尿病患者，它是合理的。

CLASS IIa

1. 对于UA/NSTEMI和多血管的患者，CABG与使用内乳动脉可以对在UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

4. 为预防UA/NSTEMI和糖尿病患者中出现的疾病，应为UA/NSTEMI和糖尿病患者中出现的疾病。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

4. 对于UA/NSTEMI和糖尿病患者，应为UA/NSTEMI和糖尿病患者中出现的疾病。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。

CLASS IIa

1. 对于UA/NSTEMI和单血管的患者，CABG可以对UA/NSTEMI患者中治疗糖尿病的患者是有益的。(Level of Evidence: B)

2. 冠状动脉的介入治疗在UA/NSTEMI和糖尿病的单血管和多血管的患者中是合理的。

3. 在UA/NSTEMI和糖尿病患者中，应避免可能的再梗死。
E. CHRONIC KIDNEY DISEASE

CLASS I
1. Creatinine clearance should be estimated in UA/NSTEMI patients, and the doses of renally cleared drugs should be adjusted appropriately. (Level of Evidence: B)
2. In chronic kidney disease patients undergoing angiography, isosmolar contrast agents are indicated and are preferred. (Level of Evidence: C)

F. COCAINE AND METHAMPHETAMINE USERS

CLASS I
1. Administration of sublingual or intravenous NTG and intravenous or oral calcium antagonists is recommended for patients with ST-segment elevation or depression that accompanies ischemic chest discomfort after cocaine use. (Level of Evidence: C)
2. Immediate coronary angiography, if possible, should be performed in patients with ischemic chest discomfort after cocaine use whose ST segments remain elevated after NTG and calcium antagonists; PCI is recommended if occlusive thrombus is detected. (Level of Evidence: C)
3. Fibrinolytic therapy is useful in patients with ischemic chest discomfort after cocaine use who ST segments remain elevated despite NTG and calcium antagonists, if there are no contraindications, and if coronary angiography is not possible. (Level of Evidence: C)

CLASS IIa
1. Administration of NTG or oral calcium channel blockers can be beneficial for patients with normal ECGs or minimal ST-segment deviation suggestive of ischemia after cocaine use. (Level of Evidence: C)
2. Coronary angiography, if available, is probably recommended for patients with ischemic chest discomfort after cocaine use with ST-segment depression or isolated T-wave changes not known to be previously present and who are unresponsive to NTG and calcium antagonists. (Level of Evidence: C)
3. Management of UA/NSTEMI patients with methamphetamine use similar to that of patients with cocaine use is reasonable. (Level of Evidence: C)

CLASS IIb
Administration of combined alpha- and beta-blocking agents (e.g., labetalol) may be reasonable for patients after cocaine use with hypertension (systolic blood pressure greater than 150 mm Hg) or those with sinus tachycardia (pulse greater than 100 beats per min) provided that the patient has received a vasodilator, such as NTG or a calcium antagonist, within close temporal proximity (i.e., within the previous hour). (Level of Evidence: C)

CLASS III
Coronary angiography is not recommended in patients with chest pain after cocaine use without ST-segment or T-wave changes and with a negative stress test and cardiac biomarkers. (Level of Evidence: C)

G. VARIANT (PRINZMETAL’S) ANGINA

CLASS I
1. Diagnostic investigation is indicated in patients with a clinical picture suggestive of coronary spasm, with investigation for the presence of transient myocardial ischemia and ST-segment elevation during chest pain. (Level of Evidence: A)
2. Coronary angiography is recommended in patients with episodic chest pain accompanied by transient ST-segment elevation. (Level of Evidence: B)
3. Treatment with nitrates and calcium channel blockers is recommended in patients with variant angina whose coronary angiograms show no or nonobstructive coronary artery lesions. Risk factor modification is recommended, with patients with atherosclerotic lesions considered to be at higher risk. (Level of Evidence: B)

CLASS IIb
1. Percutaneous coronary intervention may be considered in patients with chest pain and transient ST-segment elevation and a significant coronary artery stenosis. (Level of Evidence: B)
2. Provocative testing may be considered in patients with no significant angiographic CAD and no documentation of transient ST-segment elevation when clinically relevant symptoms possibly explained by coronary artery spasm are present. (Level of Evidence: C)

CLASS III
Provocative testing is not recommended in patients with variant angina and high-grade obstructive stenosis on coronary angiography. (Level of Evidence: B)

H. CARDIOVASCULAR “SYNDROME X”

CLASS I
1. Medical therapy with nitrates, beta blockers, and calcium channel blockers, alone or in combination, is recommended in patients with cardiovascular syndrome X. (Level of Evidence: B)
2. Risk factor reduction is recommended in patients with cardiovascular syndrome X. (Level of Evidence: B)

CLASS IIb
1. Intracoronary ultrasound to assess the extent of atherosclerosis and rule out missed obstructive lesions may be considered in patients with syndrome X. (Level of Evidence: B)
2. If no ECGs during chest pain are available and coronary spasm cannot be ruled out, coronary angiography and provocative testing with acetylcholine, adenosine, or methacholine and 24-h ambulatory ECG may be considered. (Level of Evidence: C)
3. If coronary angiography is performed and does not reveal a cause of chest discomfort, and if syndrome X is suspected, invasive physiological assessment (i.e., coronary flow reserve measurement) may be considered. (Level of Evidence: C)
4. Imipramine or aminophylline may be considered in patients with syndrome X for continued pain despite implementation of Class I measures. (Level of Evidence: C)
5. Transcutaneous electrical nerve stimulation and spinal cord stimulation for continued pain despite the implementation of Class I measures may be considered for patients with syndrome X. (Level of Evidence: B)

CLASS III
Medical therapy with nitrates, beta blockers, and calcium channel blockers for patients with noncardiac chest pain is not recommended. (Level of Evidence: C)

II. Overview of the Acute Coronary Syndromes

A. Definition of Terms

Unstable angina/NSTEMI constitutes a clinical syndrome subset of ACS that is usually, but not always, caused by atherosclerotic CAD and is associated with an increased risk of cardiac death and subsequent MI. In the spectrum of ACS, UA/NSTEMI is defined by ECG ST-segment de-
pression or prominent T-wave inversion and/or positive biomarkers of necrosis (e.g., troponin) in the absence of ST-segment elevation and in an appropriate clinical setting (chest discomfort or anginal equivalent).

“Acute coronary syndrome” has evolved as a useful operational term to refer to any constellation of clinical symptoms that are compatible with acute myocardial ischemia. It encompasses MI (STEMI and NSTEMI) and UA. These guidelines focus on 2 components of ACS: UA and NSTEMI. The “Act in Time” initiative of the National Heart Attack Alert Program (7) summarizes the clinical information needed to make the diagnosis of probable ACS at the earliest phase of clinical evaluation and can be accessed at http://www.nhlbi.nih.gov/actintime/index.htm. The implication of this early provisional diagnosis is that patients should be placed in an environment with continuous ECG monitoring and defibrillation capability, where a 12-lead ECG can be obtained and interpreted expeditiously. The most urgent priority is to identify patients with STEMI who should be considered for immediate reperfusion therapy and managed according to the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (8) and to recognize other potentially catastrophic causes of patient symptoms, such as aortic dissection. In these guidelines, UA and NSTEMI are considered to be closely related conditions whose pathogenesis and clinical presentations are similar but of differing severity, that is, whether the ischemia is severe enough to cause myocardial injury with the release of a marker of myocardial injury, most commonly troponin I, troponin T, or CK-MB. The appearance of these biomarkers may be delayed by up to several hours after the onset of ischemic symptoms, after which the differentiation between UA (i.e., no biomarkers in circulation; usually transient, if any, ECG changes of ischemia) and NSTEMI (i.e., elevated biomarkers) can be made definitively.

B. Pathogenesis of UA/NSTEMI

These conditions are characterized by an imbalance between myocardial oxygen supply and demand. A relatively few nonexclusive causes are recognized (9). A reduction in oxygen supply is more commonly the principal mechanism than an increased requirement for oxygen.

- The most common cause of UA/NSTEMI is reduced myocardial perfusion due to coronary artery narrowing caused by a thrombus, usually nonocclusive, that develops on a disrupted atherosclerotic plaque. The release of myocardial markers can be caused by microembolization of platelet aggregates and plaque components. The most common underlying molecular and cellular pathophysiology of disrupted atherosclerotic plaque is arterial inflammation.
- A less common cause is dynamic obstruction (i.e., intense focal epicardial coronary artery spasm, spasm on top of plaque, or dynamic microvascular dysfunction/spasm).
- A third cause is severe narrowing alone (e.g., to progressive atherosclerosis or restenosis after a PCI).
- A fourth cause is coronary artery dissection (e.g., as a cause of ACS in peripartum women).
- The fifth mechanism is secondary UA, in which the precipitating condition is extrinsic to the coronary arterial bed, such as with fever, tachycardia, or thyrotoxicosis; anemia; hypoxemia; or hypotension. Often there is associated coronary atherosclerotic narrowing.

C. Presentations of UA and NSTEMI

There are 3 principal presentations of UA: 1) rest angina, 2) new-onset (less than 2 months) severe angina, and 3) increasing angina (in intensity, duration, and/or frequency) (10). Angina is graded according to the Canadian Cardiovascular Society classification (11). Non–ST-elevation MI generally presents as prolonged, more intense rest angina or angina equivalent.

D. Prevention of UA/NSTEMI

The major risk factors for development of CHD and UA/NSTEMI are well established. Modification of these risk factors can prevent the development of CHD (primary prevention) or reduce the risk of experiencing UA/NSTEMI in patients who have CHD (secondary prevention). The reader is referred to contemporary prevention guidelines for the evidence base and discussion supporting these guidelines (3,12,13). All practitioners should emphasize appropriate long-term preventive care.

E. Onset of UA/NSTEMI

1. Recognition of Symptoms by Patient

Recognition of symptoms of UA/NSTEMI must occur before evaluation and treatment can be pursued. Many people are unaware that symptoms besides chest discomfort, such as shortness of breath (14), diaphoresis (15), or extreme fatigue, can represent anginal equivalents (16,17). The average UA/NSTEMI patient does not seek medical care for approximately 2 h after symptom onset (17). Reasons for this delay have been studied and include a mismatch between expectation and actual symptoms (18–20) and an impression that symptoms are self-limited or are due to other chronic conditions (21).

2. Silent and Unrecognized Events

As many as one-half of all AMIs are clinically silent or unrecognized, and one third present with symptoms other than chest discomfort (22). Patients without chest discomfort are more likely to be older, to be women, to have diabetes mellitus, to have prior HF, and to delay going to the hospital. They also are less likely to be diagnosed correctly initially and to receive appropriate therapies. Unexplained dyspnea, even without angina, is a common and
serious symptom of atypical ischemia/infarction (14). Health care providers should maintain a high index of suspicion when evaluating groups at high risk for silent or unrecognized UA/MI.

III. Initial Evaluation and Management

A. Clinical Assessment

Morbidity and mortality from ACS can be reduced significantly if patients and bystanders recognize symptoms early, activate the EMS system, and shorten the time to definitive treatment. Educational materials are available on the “Act in Time” Web page (www.nhlbi.nih.gov/health/public/heart/acs/actin_time.html) (7). For symptoms of ACS, see Table 2.

When the patient makes contact with the medical care system, the health care provider must assess whether the symptoms are potentially a manifestation of an ACS. Health care providers should advise patients with possible ACS that an evaluation cannot be performed solely via the telephone, and they should especially target those with known CHD or CHD risk equivalents (24). They should also be sensitive to anginal risk equivalents, especially in older and diabetic patients (22). Patients with known CHD should be instructed to proceed rapidly to an ED when symptoms occur. When symptoms are moderate to severe or sustained and MI is suspected, they should be instructed to access the EMS system by calling 9-1-1 and to be transported to appropriate care facilities (8). All patients presenting to the ED with symptoms suggestive of ACS should be considered high-priority and should be evaluated with a predetermined protocol (Fig. 1) (27). Patients should be placed on a cardiac monitor, with emergency resuscitation and defibrillation equipment nearby. An ECG should be performed and interpreted as soon as possible, with a goal of within 10 min of ED arrival. If STEMI is present, a primary reperfusion strategy should be implemented (8).

The recommendation for self-medication has been to encourage earlier contacting of the EMS system, that is, after taking 1 dose of NTG for unrelieved symptoms suggestive of ACS (Fig. 2) (8). (While awaiting ambulance arrival, patients tolerating NTG can be instructed to take additional NTG every 5 min, up to 3 doses.) Patients may be advised to chew ASA (162 to 325 mg) while emergency personnel are en route, may receive ASA en route to the hospital, or may be given ASA on arrival at the hospital.

1. Patient Transportation and ED or Outpatient Facility Evaluation

Patients with chest discomfort at rest or other symptoms of ACS for more than 20 min, hemodynamic instability, or recent syncope/presyncope should be referred immediately to an ED. Patients with less severe symptoms and without high-risk features should be seen initially in an ED or an appropriate outpatient facility. High-risk patients should seek emergency transportation if available in less than 20 to 30 min.

The initial evaluation should answer 2 questions: what is the likelihood that the signs and symptoms represent ACS secondary to obstructive CAD, and what is the likelihood of an adverse clinical outcome? Traditional risk factors for CAD are less important than are symptoms, ECG findings, and cardiac biomarkers.

Table 2. Guidelines for the Identification of ACS Patients by ED Registration Clerks or Triage Nurses

<table>
<thead>
<tr>
<th>Registration/clerical staff</th>
<th>Patients with the following chief complaints require immediate assessment by the triage nurse and should be referred for further evaluation:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Chest pain, pressure, tightness, or heaviness; pain that radiates to neck, jaw, shoulders, back, or 1 or both arms</td>
</tr>
<tr>
<td></td>
<td>- Indigestion or &quot;heartburn&quot;; nausea and/or vomiting associated with chest discomfort</td>
</tr>
<tr>
<td></td>
<td>- Persistent shortness of breath</td>
</tr>
<tr>
<td></td>
<td>- Weakness, dizziness, lightheadedness, loss of consciousness</td>
</tr>
</tbody>
</table>

Triage nurse

Patients with the following symptoms and signs require immediate assessment by the triage nurse for the initiation of the ACS protocol:

- Chest pain or severe epigastric pain, nontraumatic in origin, with components typical of myocardial ischemia or MI:
  - Central/subternal compression or crushing chest pain
  - Pressure, tightness, heaviness, cramping, burning, aching sensation
  - Unexplained indigestion, belching, epigastric pain
  - Radiating pain in neck, jaw, shoulders, back, or 1 or both arms
- Associated dyspnea
- Associated nausea and/or vomiting
- Associated diaphoresis

If these symptoms are present, obtain stat ECG.

Medical history

The triage nurse should take a brief, targeted, initial history with an assessment of current or past history of:

- CABG, PCI, CAD, angina on effort, or MI
- NTG use to relieve chest discomfort
- Risk factors, including smoking, hyperlipidemia, hypertension, diabetes mellitus, family history, and cocaine or methamphetamine use
- Regular and recent medication use

The brief history must not delay entry into the ACS protocol.

Special considerations

Women may present more frequently than men with atypical chest pain and symptoms.

Diabetic patients may have atypical presentations due to autonomic dysfunction.

Elderly patients may have atypical symptoms such as generalized weakness, stroke, syncope, or a change in mental status.


ACS = acute coronary syndrome; CABG = coronary artery bypass graft surgery; CAD = coronary artery disease; ECG = electrocardiogram; ED = emergency department; MI = myocardial infarction; NTG = nitroglycerin; PCI = percutaneous coronary intervention.
B. Early Risk Stratification

1. Estimation of the Level of Risk

The initial medical history, physical examination, ECG, assessment of renal function, and cardiac biomarker measurements in patients with symptoms suggestive of ACS can be integrated into an estimation of the risk of death and nonfatal cardiac events (Table 3). An estimation of risk is useful in selection of the site of care and selection of initial medical and interventional therapies. The TIMI, GRACE, and PURSUIT risk scores, developed for short- and longer-term risk assessment, are discussed in Section III.B.3 below. Overall, risk is highest at the time of presentation and subsequently declines but remains elevated beyond the acute phase.

2. History

The 5 most important factors on the initial history, in order of importance, are 1) the nature of the anginal symptoms, 2) prior history of CAD, 3) sex (male), 4) older age, and 5) an increasing number of traditional risk factors (29,30). In patients without preexisting clinical CHD, older age is the most important factor.

Patients with UA/NSTEMI may have discomfort typical of chronic angina (31) except that the episodes are more severe, are prolonged, occur at rest, or are precipitated by less exertion. Patients often do not perceive anginal symptoms to be true “chest pain”; hence, “chest discomfort” is preferentially used in these guidelines. Some patients have no chest discomfort but present solely with jaw, neck, arm, shoulder, back, or epigastric discomfort or with unexplained dyspnea without discomfort (14,32,33). Features of discomfort not characteristic of UA include pleuritic pain (i.e., sharp pain brought on by respiration or cough); primary or sole location in the middle or lower abdominal region; pain localized to a fingertip; pain reproduced with movement or palpation; very brief episodes (e.g., a few seconds or less); and radiation into the lower extremities. Nevertheless, uncharacteristic features do not entirely exclude ACS (34), and the relief of chest discomfort by sublingual NTG is not reliably predictive of ACS (35), nor does the relief of discomfort by a “GI cocktail” reliably predict its absence (36).

A history of MI increases the risk of obstructive and multivessel CAD. Presentations also can differ by sex (see Section VII.A) and age (see Section VII.D). Traditional risk factors are only weakly predictive of the likelihood of acute ischemia (37), and they are less important than symptoms, ECG findings, and cardiac biomarkers. However, diabetes mellitus and extracardiac disease are major risk factors for poor outcomes in patients with ACS.
3. Tools to Estimate Risk at Presentation

The TIMI risk score tool, composed of 7 (1-point) risk indicators rated on presentation (Table 4), has been developed and validated for UA/NSTEMI patients (38,46) and is available at www.timi.org. It is useful to predict both 30-d and 1-year mortality. A second model is based on the PURSUIT trial (39). Risk models based on the GRACE database have been developed and validated for in-hospital and 6-month outcomes (40,47). The sum of 9 scores is applied to a reference monogram to determine risk of all-cause mortality (Fig. 3). The GRACE clinical application tool is available at www.outcomes-umassmed.org/grace. Among patients with UA/NSTEMI, there is progressively greater benefit with increasing risk score from more aggressive therapies, such as LMWH (41,42), platelet GP IIb/IIIa inhibition (43), and an invasive strategy with increasing risk score (44). Dynamic risk modeling promises more sophisticated predictive modeling in the future (45).

4. Electrocardiogram

The 12-lead ECG is central to the diagnostic and triage pathway for ACS (Fig. 1) and provides important prognostic information (48). Transient ST-segment changes (greater than or equal to 0.05 mV [i.e., 0.5 mm]) that develop during a symptomatic episode at rest strongly suggest acute ischemia due to severe CAD. Patients who present with ST-segment depression can have either UA or NSTEMI, the distinction being based on the later detection of biomarkers of myocardial necrosis. Inverted T waves, especially if marked (greater than or equal to 2 mm [0.2 mV]), also can indicate UA/NSTEMI (49). Q waves suggesting prior MI indicate a high likelihood of CAD. However, a normal ECG does not completely exclude ACS: 1% to 6% of such patients prove to have had an NSTEMI, and at least 4% will be found to have UA (50).

Approximately 4% of MI patients show ST elevation isolated to the posterior chest leads V7 through V9 (51). Posterior ST elevation is diagnostically important because it qualifies the patient for reperfusion therapy as a STEMI patient (8,52).

Serial or continuous ECGs increase diagnostic sensitivity, although the yield is greater with serial cardiac biomarker measurements (53–55). Electrocardiogram monitoring is also recommended, because ST elevation on 12-lead ECG is the principal criterion for reperfusion therapy.

5. Physical Examination

The major objectives of the physical examination are to identify potential precipitating causes of myocardial ischemia, such as uncontrolled hypertension, thyrotoxicosis, or gastrointestinal bleeding, and comorbid conditions that
could impact therapeutic risk and decision making, such as pulmonary disease and malignancies, as well as to assess the hemodynamic impact of the ischemic event. In every patient with suspected ACS, vital signs should be routinely measured (blood pressure, in both arms if dissection is suspected; heart rate; temperature), and such patients should undergo a focused but thorough cardiovascular examination. The physical examination can also lead to important alternative diagnoses, such as aortic dissection (unequal pulses) or acute pericarditis (friction rub). Cardiogenic shock manifested by hypotension and evidence of organ hypoperfusion can occur in patients with NSTEMI or STEMI and constitutes a medical emergency (56).


Three fourths of patients evaluated in the ED for suspected ACS will be found not to have acute ischemia (57). This includes patients with noncardiac pain (e.g., pulmonary embolism, musculoskeletal or esophageal discomfort) or cardiac pain not caused by myocardial ischemia (e.g., acute pericarditis). The remaining patients should be evaluated for secondary causes of UA, for example, aortic stenosis and hypertrophic cardiomyopathy; anemia due to gastrointestinal bleeding; hypoxemia due to worsening of chronic obstructive pulmonary disease; fever; hyperthyroidism;

---

**Table 3. Short-Term Risk of Death or Nonfatal MI in Patients With UA/NSTEMI**

<table>
<thead>
<tr>
<th>Feature</th>
<th>High Risk</th>
<th>Intermediate Risk</th>
<th>Low Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>History</strong></td>
<td>Accelerating tempo of ischemic symptoms in preceding 48 h</td>
<td>Prior MI, peripheral or cerebrovascular disease, or CABG; prior aspirin use</td>
<td>Increased angina frequency, severity, or duration</td>
</tr>
<tr>
<td><strong>Character of pain</strong></td>
<td>Prolonged ongoing (greater than 20 min) rest pain</td>
<td>Prolonged (greater than 20 min) rest angina, now resolved, with moderate or high likelihood of CAD</td>
<td>Angina provoked at a lower threshold</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rest angina (greater than 20 min) or relieved with rest or sublingual NTG</td>
<td>New onset angina with onset 2 weeks to 2 months prior to presentation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nocturnal angina</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>New-onset or progressive CCS class III or IV angina in the past 2 weeks without prolonged (greater than 20 min) rest pain but with intermediate or high likelihood of CAD (see Table 6)</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical findings</strong></td>
<td>Pulmonary edema, most likely due to ischemia</td>
<td>Age greater than 70 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>New or worsening MR murmur</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S₃ or new/worsening rales</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypotension, bradycardia, tachycardia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Age greater than 75 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ECG</strong></td>
<td>Angina at rest with transient ST-segment changes greater than 0.5 mm Bundle-branch block, new or presumed new</td>
<td>T-wave changes Pathological Q waves or resting ST-depression less than 1 mm in multiple lead groups (anterior, inferior, lateral)</td>
<td>Normal or unchanged ECG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sustained ventricular tachycardia</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiac markers</strong></td>
<td>Elevated cardiac TnT, TnI, or CK-MB (e.g., TnT or Tnl greater than 0.1 ng per ml)</td>
<td>Slightly elevated cardiac TnT, TnI, or CK-MB (e.g., TnT greater than 0.01 but less than 0.1 ng per ml)</td>
<td>Normal</td>
</tr>
</tbody>
</table>

---

**Table 4. TIMI Risk Score for Unstable Angina/Non–ST-Elevation MI**

<table>
<thead>
<tr>
<th>TIMI Risk Score</th>
<th>All-Cause Mortality, New or Recurrent MI, or Severe Recurrent Ischemia Requiring Urgent Revascularization Through 14 d After Randomization, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1</td>
<td>4.7</td>
</tr>
<tr>
<td>2</td>
<td>8.3</td>
</tr>
<tr>
<td>3</td>
<td>13.2</td>
</tr>
<tr>
<td>4</td>
<td>19.9</td>
</tr>
<tr>
<td>5</td>
<td>26.2</td>
</tr>
<tr>
<td>6–7</td>
<td>40.9</td>
</tr>
</tbody>
</table>

The TIMI risk score is determined by the sum of the presence of 7 variables at admission; 1 point is given for each of the following variables: age 65 y or older; at least 3 risk factors for CAD; prior coronary stenosis of 50% or more; ST-segment deviation on ECG presentation; at least 2 anginal events in prior 24 h; use of aspirin in prior 7 d; elevated serum cardiac biomarkers. Prior coronary stenosis of 50% or more remained relatively insensitive to missing information and remained a significant predictor of events. Reprinted with permission from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835–42 (46). Copyright © 2000 American Medical Association.

CABG = coronary artery bypass graft surgery; CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; CK-MB = creatine kinase, MB fraction; ECG = electrocardiogram; MI = myocardial infarction; MR = mitral regurgitation; NTG = nitroglycerin; TnI = troponin I; TnT = troponin T; UA/NSTEMI = unstable angina/non–ST-elevation myocardial infarction.
tachyarrhythmias; severe hypertension; and arteriovenous fistula placed for renal dialysis.

7. Cardiac Biomarkers of Necrosis and the Redefinition of AMI

Cardiac biomarkers have proliferated to address various facets of ACS pathophysiology. Favorable biomarker features of biomarkers of necrosis are high concentrations in the myocardium and absence in nonmyocardial tissue, release into the blood within a convenient diagnostic time window and in proportion to the extent of myocardial injury, and quantification with reproducible, inexpensive, rapid, and easily applied assays (58). The cardiac troponins
possess many of these features, have gained wide acceptance as the biomarkers of choice, and have inspired redefinitions of MI (59). Myocardial necrosis now is defined by an elevation of troponin above the 99th percentile of normal. Myocardial infarction, which is necrosis related to ischemia, is further defined by the addition of at least 1 of the following criteria: ischemic ST and T-wave changes, new left bundle-branch block, new Q waves, PCI-related marker elevation, or imaging showing a new loss of myocardium.

A. CREATINE KINASE-MB
Creatine kinase-MB, long a standard marker for the diagnosis of MI, is less sensitive and specific for MI than the cardiac troponins; however, it remains useful for the diagnosis of early infarct extension (reinfarction) and periprocedural MI because its short half-life better permits the detection of secondary increases in marker levels (60).

B. CARDIAC TROPONINS
The troponin subunits T and I are derived from heart-specific genes; hence, the term “cardiac troponins” (cTn) specifically refers to cardiac troponin T (cTnT) or I (cTnI). Because cTnT and cTnI generally are not detected in the blood of healthy persons, the cutoff values for elevated cTnT and cTnI levels may be set to slightly above the upper limits of the performance characteristics of the assay for a normal healthy population. Assays for cTnT and cTnI have evolved through several generations (61); hence, physicians need to know the characteristics of tests used in their hospitals.

C. MYOGLOBIN
Myoglobin, a low-molecular-weight heme protein found in both cardiac and skeletal muscle, is not cardiac specific, but it is released rapidly (as early as 2 h) after the onset of myocardial necrosis. Because it is not cardiac specific, it may be more useful to assist in rapidly “ruling out” rather than “ruling in” NSTEMI, which should be confirmed by troponin measurements (62).

D. CLINICAL USE
Although troponins can be detected in blood as early as 2 to 4 h after the onset of symptoms, elevation can be delayed for up to 8 to 12 h. This timing of elevation is similar to that of CK-MB but persists longer, for up to 5 to 14 days (Fig. 4). Approximately 30% to 40% of ACS patients without ST-segment elevation who would be diagnosed as having UA on the basis of the absence of CK-MB elevation have NSTEMI when assessed by troponin assays. The result is a change in case mix and overall survival by a troponin-based definition of NSTEMI (63). Troponin elevation also conveys prognostic information incremental to clinical characteristics, the ECG, and the predischarge exercise test (64–68) (Fig. 5). Although cTn accurately identifies myocardial necrosis, it does not inform as to the cause(s) of necrosis, which can be multiple (69). Therefore, in making the diagnosis of NSTEMI, cardiac troponins should be used in conjunction with other criteria.

Troponin elevation also permits the identification of high-risk patients who will benefit from aggressive therapies such as the LMWHs (vs. UFH) (41,42,71) and platelet GP IIb/IIIa inhibitors, alone (72,73) or in addition to clopidogrel (74), and in conjunction with overall risk assessment, a routine invasive strategy (75,76). When troponin and CK-MB are used together, those with both markers positive are at highest short-term risk, those with troponin elevation alone are at intermediate risk, and those with isolated CK-MB are at lowest risk, equivalent to those with normal marker levels (77). Equivalent diagnostic and prognostic information is provided by cTnI and cTnT except in patients with renal dysfunction (78), in whom cTnI is less specific but retains predictive ability (79).

Cardiac markers can be measured in the central chemistry laboratory or with point-of-care instruments in the ED (64). To date, bedside testing has not succeeded in becoming widely accepted or applied.

CLINICAL USE OF MARKER CHANGE SCORES
A newer method aims to identify or exclude MI within 6 h of symptoms by relying on changes in serum marker levels (delta values) over an abbreviated time interval (e.g., 2 h). This method focuses on increasing values while still in their
diagnosis should be referred for appropriate follow-up care and coronary imaging (Fig. 1, B1). Patients found to have an alternative diagnosis, chronic stable angina, possible ACS, and definite ACS, which is further divided into UA/NSTEMI and STEMI, based on the initial ECG (Fig. 1). Patients with a low likelihood of CAD should be evaluated for noncoronary presentations (Fig. 1, B1). Patients found to have an alternative diagnosis should be referred for appropriate follow-up care (Fig. 1, C1). Chronic stable angina diagnosed in this setting (Fig. 1, B2) should be managed according to the ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina (31). Patients with possible ACS (Fig. 1, B3 and D1) are candidates for additional observation (Fig. 1, E1). Those with definite ACS (Fig. 1, B4) are triaged based on the 12-lead ECG. Patients with ST-segment elevation (Fig. 1, C3) are evaluated for reperfusion therapy (Fig. 1, D3) and managed according to the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (8), whereas those without ST-segment elevation (Fig. 1, C2) are either managed by additional observation (Fig. 1, E1) or admitted to the hospital (Fig. 1, H3). Patients with low-risk ACS (negative initial testing) (Fig. 1, H1) may be discharged and treated as outpatients (Fig. 1, I1).

1. Chest Pain Units

To facilitate appropriate evaluation while avoiding both unnecessary hospital admissions and ED discharges, special ED “chest pain units” have been established (84,85). Here, patients at low risk of ACS undergo a predetermined observation period with serial cardiac biomarkers and ECGs, are reevaluated, and may then undergo functional cardiac testing or a noninvasive coronary imaging study (i.e., coronary CT angiography). Those with abnormal findings are admitted for inpatient management (Fig. 1, H3).

Extension of the use of chest pain units to intermediate-risk patients has been favorably tested (86). Such a strategy is facilitated by making available diagnostic (stress/imaging) testing 7 d per week. An appropriate inpatient telemetry unit may serve as an alternative to an ED-based chest pain unit when the latter is not available.

Patients with positive findings during ED/chest pain unit initial evaluation or follow-up observation (Fig. 1, D2, F2) should be admitted to the hospital (Fig. 1, H3) and managed as described in Section IV. Patients at low ACS risk (Fig. 1, F1) may be considered for a pre-discharge stress test or coronary CT angiography (Fig. 1, G1). Alternatively, the patient may be discharged, with appropriate precautionary medication and instructions, and return for testing within 72 h. In general, a physician should see patients as soon after discharge from the ED or chest pain unit as practical and appropriate, that is, usually within 72 h.

Two newer imaging modalities, cardiac magnetic resonance and multidetector CT for coronary calcification and coronary CT angiography, are undergoing clinical validation and application and hold promise as alternative or supplementary imaging modalities for the assessment of patients presenting with chest pain syndromes (87–89). Coronary CT angiography may be particularly appropriate for those with acute chest pain syndromes with low to intermediate pretest probability of CAD in the setting of nondiagnostic ECG and negative cardiac biomarkers (88).

---

**Figure 5. Troponin I Levels to Predict the Risk of Mortality in Acute Coronary Syndromes**

Mortality rates are at 42 d (without adjustment for baseline characteristics) in patients with acute coronary syndrome. The numbers at the bottom of each bar are the numbers of patients with cardiac troponin I levels in each range, and the numbers above the bars are percentages. *p* less than 0.001 for the increase in the mortality rate (and the risk ratio for mortality) with increasing levels of cardiac troponin I at enrollment. Reprinted with permission from Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342–9 (66). Copyright © 1996 Massachusetts Medical Society. All rights reserved.
Invasive Versus Conservative Strategy

<table>
<thead>
<tr>
<th>Preferred Strategy</th>
<th>Patient Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive</td>
<td>Recurrent angina or ischemia at rest or with low-level activities despite intensive medical therapy</td>
</tr>
<tr>
<td></td>
<td>Elevated cardiac biomarkers (TnT or Tnl)</td>
</tr>
<tr>
<td></td>
<td>New or presumably new ST-segment depression</td>
</tr>
<tr>
<td></td>
<td>Signs or symptoms of HF or new or worsening mitral regurgitation</td>
</tr>
<tr>
<td></td>
<td>High-risk findings from noninvasive testing</td>
</tr>
<tr>
<td></td>
<td>Hemodynamic instability</td>
</tr>
<tr>
<td></td>
<td>Sustained ventricular tachycardia</td>
</tr>
<tr>
<td></td>
<td>PCI within 6 months</td>
</tr>
<tr>
<td></td>
<td>Prior CABG</td>
</tr>
<tr>
<td></td>
<td>High risk score (e.g., TIMI, GRACE)</td>
</tr>
<tr>
<td></td>
<td>Reduced left ventricular function (LVEF less than 40%)</td>
</tr>
<tr>
<td>Conservative</td>
<td>Low risk score (e.g., TIMI, GRACE)</td>
</tr>
<tr>
<td></td>
<td>Patient or physician preference in the absence of high-risk features</td>
</tr>
</tbody>
</table>

CABG = coronary artery bypass graft surgery; GRACE = Global Registry of Acute Coronary Events; HF = heart failure; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction; Tnl = troponin I; TnT = troponin T.

### IV. Early Hospital Care

Patients with definite or probable UA/NSTEMI who are stable hemodynamically should be admitted to an inpatient unit for bed rest with continuous rhythm monitoring and careful observation for recurrent ischemia and managed with either an invasive or conservative strategy (Fig. 1, Table 5). High-risk patients, including those with continuing discomfort and/or hemodynamic instability, should be hospitalized in a coronary care unit and observed for at least 24 h without any major complications. (Shorter periods might be appropriate for patients who are successfully reperfused, have normal LV function, and have minimal or no necrosis.)

After admission, standard medical therapy is indicated. The optimal management of UA/NSTEMI has the twin goals of relief of ischemia and prevention of serious adverse outcomes. This is accomplished with anti-ischemic therapy, anticoagulant therapy, ongoing risk stratification, and appropriate use of invasive procedures. Unless contraindicated, treatment generally should include ASA, a beta blocker, anticoagulant therapy, a GP IIb/IIIa receptor antagonist, and a thienopyridine (i.e., clopidogrel); initiation may be deferred until a revascularization decision is made. A critical early decision is the choice of an angiographic (invasive) or an initially conservative strategy (Table 5). Assessment of LV function, which can influence management, is recommended.

**A. Anti-Ischemic and Analgesic Therapy**

**1. General Care**

Patients should be placed on bed rest initially but can be mobilized to a chair and use a bedside commode when symptom free. Subsequent activity should be liberalized when response to treatment occurs. Patients with or at risk for hypoxemia should receive supplemental oxygen. A short period of initial routine oxygen supplementation is reasonable during stabilization of the patient. Patients should undergo continuous ECG monitoring during their early hospital phases, because ventricular fibrillation is the major preventable cause of early death.

**2. Use of Anti-Ischemic Therapies**

**A. NITRATES**

The rationale for NTG use in UA/NSTEMI is extrapolated from STEMI and from pathophysiological principles and extensive clinical observations (90). Nitroglycerin is an endothelium-independent vasodilator with both peripheral and coronary vascular effects that result in reduction in myocardial oxygen demand and enhancement of myocardial oxygen delivery. Nitroglycerin promotes the dilation of large coronary arteries, as well as collateral flow and redistribution of coronary blood flow to ischemic regions.

Intravenous NTG can benefit patients who are unresponsive to sublingual NTG and beta blockers. Intravenous NTG is also useful in patients with HF or hypertension. Side effects include headache and hypotension.

Intravenous NTG may be initiated at a rate of 10 mcg per min and increased by 10 mcg per min every 3 to 5 min until relief of symptoms or blood pressure response is noted. A ceiling dose of 200 mcg per min is commonly used. Systolic blood pressure generally should not be reduced to less than 110 mm Hg in previously normotensive patients or to more than 25% below the starting mean arterial blood pressure if hypertension was present. Nitroglycerin should be avoided in patients with initial systolic blood pressure less than 90 mm Hg or 30 mm Hg or more below their baseline, or with marked bradycardia or tachycardia.

Topical or oral nitrates are acceptable alternatives for patients without ongoing refractory ischemic symptoms. After medical stabilization, intravenous NTG generally should be converted within 24 h to a nonparenteral alternative administered in a non–tolerance–producing regimen (lower and/or intermittent dosing) if ongoing therapy is required (91).

**B. MORPHINE SULFATE**

Morphine sulfate (1 to 5 mg intravenously [IV]) is reasonable for patients whose symptoms either are not relieved despite NTG or recur despite adequate anti-ischemic therapy. Hypotension, nausea, and respiratory depression are potential adverse effects of morphine. A large observational registry that included patients with UA/NSTEMI suggested a higher adjusted likelihood of death with morphine use (92). Although subject to uncontrolled selection biases, these results raise a safety concern and suggest the need for a randomized trial. Meanwhile, the recommendation for morphine use has been downgraded from a class I to a class IIa recommendation.
C. BETA-ADRENERGIC BLOCKERS

Beta blockers act by competitively blocking the effects of catecholamines on cell membrane beta receptors. The benefits of routine early intravenous use of beta blockers in earlier studies in AMI have been less impressive based on data in the reperfusion era (93,94). In the 45,852-patient Chinese COMMIT study (93% with STEMI, 7% with NSTEMI) (94), neither the composite of death, reinfarction, or cardiac arrest nor death alone was reduced for up to 28 d in the hospital. A modest reduction in reinfarction and ventricular fibrillation was counterbalanced by an increase in cardiogenic shock, primarily in those who were hemodynamically compromised. Thus, early aggressive beta blockade poses a net hazard in hemodynamically unstable patients and should be avoided. In an attempt to balance the evidence base overall for UA/NSTEMI patients, beta blockers are recommended to be initiated orally, in the absence of contraindications (e.g., HF), within the first 24 h. Greater caution is suggested in the early use of intravenous beta blockers, which should be targeted to specific indications and should be avoided with HF, hypotension, and hemodynamic instability. (In contrast, oral beta blockers are strongly recommended for secondary prevention before hospital discharge in those with compensated HF or LV systolic dysfunction) (95,96).

The rationale for use of beta blockers for secondary prevention after UA and NSTEMI derives from limited trial data and extrapolations from chronic angina, HF, and STEMI studies (95). Pooled results from relatively contemporary anticoagulant therapy trials in patients with ACS undergoing PCI and given beta-blocker therapy have shown reduced death rates at 30 d (0.6% vs. 2.0%) and 6 months (1.7% vs. 3.7%; both \( p < 0.001 \)) (96). High- or intermediate-risk patients undergoing cardiac or noncardiac surgery also have been shown to benefit (97).

D. CALCIUM CHANNEL BLOCKERS

Although members of the calcium channel blocker class of drugs are structurally diverse, the superiority of 1 agent over another in UA/NSTEMI has not been demonstrated, except for the increased risk posed by rapid-release nifedipine (98,99). The calcium channel blocker evidence base for benefit is greatest for verapamil and diltiazem (100,101). Beneficial effects in UA/NSTEMI are believed to be due to decreased myocardial oxygen demand and improved myocardial flow (90). Side effects include hypotension, worsening HF, bradycardia, and atrioventricular block.

Calcium channel blockers may be used to control ischemia-related symptoms in patients unresponsive to or intolerant of nitrates and beta blockers and in patients with variant angina. Rapid-release, short-acting dihydropyridines (e.g., nifedipine) must be avoided in the absence of concomitant beta blockade (98,99). Verapamil and diltiazem should be avoided in patients with pulmonary edema or severe LV dysfunction (100,101). Caution is indicated when a beta-blocker and calcium channel blocker are combined, because they act in synergy to depress LV function and sinus and atrioventricular node conduction.

E. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Angiotensin-converting enzyme inhibitors have been shown to reduce mortality rates in patients with AMI and in those who recently had an MI and have LV systolic dysfunction (102), in patients with diabetes mellitus with LV dysfunction (103), and in a broad spectrum of patients with high-risk chronic CAD, including patients with normal LV function (104). Angiotensin receptor blockers may be useful in post-MI and ischemic HF patients intolerant of ACE inhibitors (105,106).

The selective aldosterone receptor blocker eplerenone, used in patients with MI complicated by LV dysfunction and either HF or diabetes mellitus, has been shown to reduce morbidity and mortality (107). Spironolactone decreased morbidity and death in patients with severe HF, one-half of whom had an ischemic origin of the HF (108).

F. INTRA-AORTIC BALLOON COUNTERPULSATION

Intra-aortic balloon counterpulsation has been used for more than 30 years for refractory UA after MI, for cardiogenic shock, for hemodynamic support during catheterization and/or angioplasty, before high-risk surgery, and for mechanical complications of MI (109), although randomized data to support its benefit are limited.

G. ANALGESIC THERAPY

Because of the known increased risk of cardiovascular events among patients taking COX-2 inhibitors and NSAIDs (110–112), patients who are taking them at the time of UA/NSTEMI should discontinue them immediately (see Section 5.2.16 in the full text for additional discussion). A secondary analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (EXTRACT)-TIMI-25 study (113) demonstrated an increased risk of death, reinfarction, HF, or shock among patients who were taking NSAIDs within 7 d of enrollment. Longer-term management is considered in Section VI.C.

B. Antiplatelet/Anticoagulant Therapy in Patients With Likely or Definite UA/NSTEMI

Antiplatelet therapy is essential to modify the ACS disease process and its adverse consequences. A combination of ASA, an anticoagulant, and additional antiplatelet therapy represents the most effective therapy. The intensity of treatment is tailored to individual risk, and triple-anticoagulant treatment is used in patients with continuing ischemia or with other high-risk features and in patients oriented to an early invasive strategy (see Table 5 and Figs. 6, 7, and 8). Table 6 shows the recommended doses of the various agents. A problematic group of patients are those who present with UA/NSTEMI but who are therapeutically anticoagulated with warfarin. In such patients, clinical judgment is needed.
1. Antiplatelet Therapy (Aspirin, Ticlopidine, Clopidogrel)

A. ASPIRIN

Trials of ASA in UA/NSTEMI have consistently documented a benefit to its use compared with placebo (114–117). Platelets represent one of the principal participants in thrombus formation after plaque disruption. Aspirin acts promptly to inhibit COX-1 within platelets, which prevents the formation of thromboxane A2, diminishing the platelet aggregation promoted by this pathway. Indirect comparisons of doses ranging from less than 75 to 1,500 mg per day have shown similar reductions in the odds of vascular events; however, there is a dose-dependent increase in bleeding (118). Therefore, maintenance doses of 75 to 162 mg of ASA are recommended.

It is recommended that ASA be initiated as soon as the diagnosis of ACS is made or suspected unless contraindicated and that it be continued indefinitely. On the basis of prior randomized trial protocols and clinical experience, the initial dose of ASA should be between 162 and 325 mg. More rapid buccal absorption occurs with non–enteric-coated formulations than with enteric-coated formulations.
After stenting, a higher initial maintenance dose of ASA of 325 mg per day has been recommended for 1 month after bare-metal stent implantation and 3 to 6 months after drug-eluting stent implementation, which had been modified to an initial dose range of 162 to 325 mg per day based on the risk of excess bleeding with higher doses and an update of current evidence of outcomes after PCI (Table 6, Fig. 9).

Because of an interaction between ibuprofen and ASA, an alternative NSAID should be used, or ibuprofen should be taken at least 30 min after or at least 8 h before ASA (www.fda.gov/drug/infopage/ibuprofen/science_paper.html).

A reported interaction of ASA and ACE inhibitors does not appear to interfere importantly with clinical benefits (120).

B. ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS AND OTHER ANTIPLATELET AGENTS

Two thienopyridines—ticlopidine and clopidogrel—are adenosine diphosphate receptor (P2Y12) antagonists approved for antiplatelet therapy. The platelet effects of ticlopidine and clopidogrel are irreversible but take several days to achieve maximal effect in the absence of a loading dose. Ticlopidine has been used successfully for the secondary prevention of stroke and MI and for the prevention of...
stent closure and graft occlusion (121); however, the adverse potential of ticlopidine (i.e., neutropenia and, rarely, thrombotic thrombocytopenic purpura) (122) has limited its use. Clopidogrel has undergone extensive clinical testing and application. For secondary prevention, clopidogrel alone was at least as effective as or modestly more effective than ASA in the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) trial (123). Thus, clopidogrel is indicated in patients with UA/NSTEMI who are unable to tolerate ASA. In patients with a history of gastrointestinal bleeding while taking ASA, drugs to minimize the risk of recurrent bleeding (e.g., proton-pump inhibitors) should be prescribed when a thienopyridine is administered (124).

In the acute setting, an oral loading dose of clopidogrel is typically used to achieve more rapid platelet inhibition. A large evidence base exists for the approved loading dose of 300 mg. Small to moderate-sized trials have reported favorable outcomes with a 600- versus a 300-mg loading dose in patients undergoing PCI (125); however, larger-scale randomized trials are needed to rigorously establish the optimal loading dose.

The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial randomized 12,562 patients with UA and NSTEMI presenting within 24 h to placebo or clopidogrel (loading dose of 300 mg followed by 75 mg daily) and followed them for 3 to 12 months (118). All patients received ASA. Cardiovascular death, MI, or stroke occurred in 11.5% of placebo and 9.3% of clopidogrel patients (risk ratio [RR] = 0.80, \( p < 0.001 \)). Clopidogrel also reduced in-hospital severe ischemia and revascularization. A benefit was observed across subgroups and began within the first few hours. A small excess in bleeding was noted, which was increased in patients undergoing CABG surgery within 5 d of stopping clopidogrel.

The PCI-CURE study was an observational substudy of the 2,658 patients undergoing PCI within the CURE trial (126). Clopidogrel reduced the primary end point (a composite of cardiovascular death, MI, or urgent target-vessel revascularization within 30 d of PCI) by 30% (\( p = 0.03 \)) and reduced the incidence of cardiovascular death or MI by 31% (\( p = 0.002 \)). Therefore, clopidogrel is recommended in patients who undergo PCI.

The Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment (ISAR-REACT)-2 trial tested whether patients undergoing PCI who were preloaded with clopidogrel 600 mg at least 2 h before the procedure, as well as ASA, would derive additional benefit from GP IIb/IIIa receptor antagonist therapy (74). The study randomized 2,022 patients to abciximab or placebo. The primary end point was reached in 90 patients (8.9%) assigned to abciximab versus 120 patients (11.9%) assigned to placebo, a 25% reduction in risk with abciximab (RR 0.75, 95% confidence interval [CI] 0.58 to 0.97, \( p = 0.03 \)). However, this benefit was limited to patients...
<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Medical Treatment</th>
<th>Patient Received Initial Medical Treatment</th>
<th>Patient Did Not Receive Initial Medical Treatment</th>
<th>After PCI</th>
<th>At Hospital Discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Antiplatelet Therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>162 to 325 mg nonenteric formulation, orally or chewed</td>
<td>No additional treatment</td>
<td>162 to 325 mg nonenteric formulation orally or chewed</td>
<td>162 to 325 mg daily should be given† for at least 1 month after BMS implantation, 3 months after SES implantaion, and 6 months after PES implantaion, after which daily chronic aspirin should be continued indefinitely at a dose of 75 to 162 mg</td>
<td>162 to 325 mg daily should be given† for at least 1 month after BMS implantation, 3 months after SES implantaion, and 6 months after PES implantaion, after which daily chronic aspirin should be continued indefinitely at a dose of 75 to 162 mg</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>LD of 300 to 600 mg orally</td>
<td>A second LD of 300 mg orally may be given to supplement a prior LD of 300 mg</td>
<td>LD of 300 to 600 mg orally</td>
<td>For BMS: 75 mg daily for at least 1 month and ideally up to 1 year. For DES, 75 mg daily for at least 1 year (in patients who are not at high risk of bleeding) (See Fig. 9)</td>
<td>For BMS: 75 mg daily for at least 1 month and ideally up to 1 year. For DES, 75 mg daily for at least 1 year (in patients who are not at high risk of bleeding) (See Fig. 9)</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td>LD of 500 mg orally</td>
<td>No additional treatment</td>
<td>LD of 500 mg orally</td>
<td>No additional treatment</td>
<td>No additional treatment</td>
</tr>
<tr>
<td></td>
<td>MD of 250 mg orally twice daily</td>
<td></td>
<td>MD of 250 mg orally twice daily</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Anticoagulants**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Medical Treatment</th>
<th>Patient Received Initial Medical Treatment</th>
<th>Patient Did Not Receive Initial Medical Treatment</th>
<th>After PCI</th>
<th>At Hospital Discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bivalirudin</td>
<td>0.1 mg per kg bolus, 0.25 mg per kg per h infusion</td>
<td>0.5 mg per kg bolus, increase infusion to 1.75 mg per kg per h</td>
<td>0.75 mg per kg bolus, 1.75 mg per kg per h infusion</td>
<td>No additional treatment or continue infusion for up to 4 h</td>
<td>No additional treatment</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>120 IU per kg SC every 12 h (maximum 10,000 IU twice daily)†</td>
<td>IV GP Iib/Illa planned: target ACT 200 s using UFH</td>
<td>IV GP Iib/Illa planned: 60 to 70 U per kg§ of UFH</td>
<td>No additional treatment</td>
<td>No additional treatment</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>LD of 30 mg IV bolus may be given</td>
<td></td>
<td>MD — 1 mg per kg SC every 12 h; extend dosing interval to 1 mg per kg every 24 h if estimated creatinine clearance less than 30 mL per min</td>
<td></td>
<td>Last SC dose less than 8 h: no additional treatment</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg SC once daily. Avoid for creatinine clearance less than 30 mL per min</td>
<td></td>
<td>50 to 60 U per kg IV bolus of UFH is recommended by the OASIS 5 Investigators¶</td>
<td>50 to 60 U per kg IV bolus of UFH is recommended by the OASIS 5 Investigators¶</td>
<td>No additional treatment</td>
</tr>
</tbody>
</table>

Continued on next page
Table 6. Continued

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Medical Treatment</th>
<th>During PCI</th>
<th>After PCI</th>
<th>At Hospital Discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Unfractionated Heparin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LD of 60 U per kg (max 4,000 U) as IV bolus</td>
<td>IV GP Ibia planned: target ACT 200 s</td>
<td>IV GP Ibia planned: 60 to 70 U per kg§</td>
<td>No additional treatment</td>
</tr>
<tr>
<td></td>
<td>MD of IV infusion of 12 U per kg per h (max 1,000 U per h) to maintain aPTT at 1.5 to 2.0 times control (approximately 50 to 70 s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Abciximab</strong></td>
<td>Not applicable</td>
<td>Not applicable</td>
<td>LD of 0.25 mg per kg IV bolus MD of 0.125 mcg per kg per min (max 10 mcg per min)</td>
<td>Continue MD infusion for 12 h</td>
</tr>
<tr>
<td><strong>Eptifibatide</strong></td>
<td>LD of IV bolus of 180 mcg per kg MD of IV infusion of 2.0 mcg per kg per min; reduce infusion by 50% in patients with estimated creatinine clearance less than 50 mL per min</td>
<td>Continue infusion</td>
<td>LD of IV bolus of 180 mcg per kg followed 1.0 min later by second IV bolus of 180 mcg per kg MD of 2.0 mcg per kg per min; reduce infusion by 50% in patients with estimated creatinine clearance less than 50 mL per min</td>
<td>Continue MD infusion for 18 to 24 h</td>
</tr>
<tr>
<td><strong>Tirofiban</strong></td>
<td>LD of IV infusion of 0.4 mcg per kg per min for 30 min MD of IV infusion of 0.1 mcg per kg per min; reduce rate of infusion by 50% in patients with estimated creatinine clearance less than 30 mL per min</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Continue infusion</td>
<td></td>
<td>LD of IV infusion of 0.4 mcg per kg per min for 30 min MD of IV infusion of 0.1 mcg per kg per min; reduce rate of infusion by 50% in patients with estimated creatinine clearance less than 30 mL per min</td>
<td>Continue MD infusion for 18 to 24 h</td>
</tr>
</tbody>
</table>

Additional considerations include the possibility that a conservatively managed patient may develop a need for PCI, in which case an intravenous bolus of 50 to 60 U per kg is recommended if fondaparinux was given for initial medical treatment; the safety of this drug combination is not well established. For conservatively managed patients in whom enoxaparin was the initial medical treatment, as noted in the table, additional intravenous enoxaparin is an acceptable option. *This list is in alphabetical order and is not meant to indicate a particular therapy preference. †In patients in whom the physician is concerned about the risk of bleeding, a lower initial ASA dose after PCI of 75 to 162 mg/d is reasonable (Class IIa, LOE: C). ‡Dalteparin was evaluated for management of patients with UA/NSTEMI in an era before the widespread use of important therapies such as stents, clopidogrel, and GP IIb/IIIa inhibitors. Its relative efficacy and safety in the contemporary management era is not well established. §Some operators use less than 60 U per kg of UFH with GP IIb/IIIa blockade, although no clinical trial data exist to demonstrate the efficacy of doses below 60 U per kg in this setting. For patients managed by an initial conservative strategy, agents such as enoxaparin and fondaparinux offer the convenience advantage of SC administration compared with an intravenous infusion of UFH. They are also less likely to provoke heparin-induced thrombocytopenia than UFH. Available data suggest fondaparinux is associated with less bleeding than enoxaparin in conservatively managed patients using the regimens listed. ¶Personal communication, OASIS 5 Investigators, July 7, 2006. Note that this regimen has not been rigorously tested in prospective randomized trials.

ACT = activated clotting time; BMS = bare-metal stent; GP = glycoprotein; IU = international unit; IV = intravenous; LD = loading dose; MD = maintenance dose; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent; SC = subcutaneous; SES = sirolimus-eluting stent; U = units; UA/NSTEMI = unstable angina/non-ST-elevation myocardial infarction; UFH = unfractionated heparin.
with an elevated cTn level (13.1% vs. 18.3% event rate, RR 0.71, 95% CI 0.54 to 0.95, \( p < 0.02 \) \( p = 0.07 \) for interaction). Bleeding rates were similar in the 2 arms. Thus, it appears beneficial to add an intravenous GP IIb/IIIa inhibitor to thienopyridine treatment if an invasive strategy is planned in patients with high-risk features (e.g., elevated cTn level; Figs. 6, 7, and 8).

The optimal timing of administration (“upstream” vs. “in-lab”) of the loading dose of clopidogrel for those who are managed with an early invasive strategy cannot be determined with certainty from the PCI-CURE trial. Given the early separation of the curves, clopidogrel is recommended as initial, upstream therapy when there is a delay to coronary angiography (Figs. 6, 7, and 8).

Although clopidogrel has a role in patients with UA/NSTEMI managed both conservatively and invasively (127), the optimal duration of therapy is uncertain. Most of the incremental benefit of clopidogrel in CURE occurred within the first 1 to 3 months, but favorable results were observed over the entire trial period, which averaged 9 months, and for up to 1 year (118,128). Pathological (129) and clinical evidence (130,131) suggests the need for longer-term therapy, that is, at least 1 year, in patients who receive drug-eluting stents. Drug-eluting stents delay neointimal coverage of stent struts, increase late thrombotic events (by approximately 0.5%), and prevent restenosis. In contrast, clopidogrel was not beneficial in a large trial of high-risk primary prevention patients (132).

Because clopidogrel increases the risk of bleeding during major surgery, it has been recommended that it be withheld for at least 5 d in patients scheduled for elective CABG (133,134). Thus, many hospitals that use an early invasive approach for UA/NSTEMI delay starting clopidogrel until diagnostic angiography clarifies whether early CABG is indicated. However, when clopidogrel is given before catheterization, and urgent surgical intervention is indicated, some experience suggests that “early” bypass surgery may be undertaken by experienced surgeons at acceptable incremental bleeding risk (135). More data are needed to formulate definitive recommendations on this issue.

Sulfinpyrazone, dipyridamole, prostacyclin, and prostacyclin analogs have not been demonstrated to be of benefit in

---

Figure 9. Long-Term Anticoagulant Therapy at Hospital Discharge After UA/NSTEMI

*For aspirin (ASA) allergic patients, use clopidogrel alone (indefinitely), or try aspirin desensitization. †For clopidogrel-allergic patients, use ticlopidine 250 mg by mouth twice daily. ‡Continue ASA indefinitely and warfarin longer term as indicated for specific conditions such as atrial fibrillation; LV thrombus; or cerebral, venous, or pulmonary emboli. §When warfarin is added to aspirin plus clopidogrel, an INR of 2.0 to 2.5 is recommended. INR = international normalized ratio; LOE = level of evidence; LV = left ventricular; UA/NSTEMI = unstable angina/non–ST-elevation myocardial infarction.
UA or NSTEMI and are not recommended. The thromboxane synthase blockers and thromboxane A2 receptor antagonists have been evaluated in ACS and have not shown any advantage over ASA. A number of other antiplatelet drugs are currently available, and still others are under active investigation.

Considerable interpatient variability in inhibition of platelet aggregation to a specific dose of clopidogrel has been observed (136). Patients with diminished responsiveness appear to be at increased risk of ischemic events (137,138). Optimal strategies to avoid or overcome poor responsiveness remain to be established but might involve monitoring of individual responsiveness and dose adjustments (139,140).

2. Anticoagulants

An increasing number of anticoagulants (previously referred to as antithrombins) have become available for management of patients with UA/NSTEMI. Anticoagulant strategies recommended (class I or IIa) on the basis of the current data set are given in Figures 6, 7, and 8. Although each agent or regimen reviewed (UFH, enoxaparin, fondaparinux, and bivalirudin [invasive strategy only]) satisfies criteria for effectiveness, it is often difficult to conclude that one antithrombotic strategy is preferred over another, given differing study designs (blinded vs. unblinded; superiority vs. noninferiority) and questions of equipotency; differing patient populations (higher vs. lower risk); durations of therapy, and strategies (invasive vs. conservative); confounding by open-label and crossover use of anticoagulants; differing antiplatelet strategies; and differing clinical versus study protocols. The limitations of noninferiority trials also must be noted (141). It is suggested that each institution agree on an approved anticoagulant approach most consistent with local practice and preference.

A. UNFRACTIONATED HEPARIN

Unfractionated heparin (UFH) is a heterogeneous mixture of polysaccharide chains of molecular weights that range from 5,000 to 30,000 Daltons and that have varying anticoagulant activity (142). Unfractionated heparin accelerates the action of circulating antithrombin, which inactivates factor IIa, factor IXa, and factor Xa. Unfractionated heparin prevents thrombus propagation but does not lyse existing thrombi.

Meta-analysis of a relatively small, randomized database suggests a reduction of 33% to 56% (p = 0.06 to 0.03) in early ischemic events by the addition of UFH (143,144). Most of the benefit is short term, with reactivation of the thrombotic process ("rebound") after the discontinuation of UFH contributing to the loss of early gain (145).

Unfractionated heparin binds to a number of plasma proteins, blood cells, and endothelial cells, leading to the poor bioavailability, especially at low doses, and marked variability in anticoagulant response. As a consequence, the anticoagulant effect of heparin requires monitoring with the activated partial thromboplastin time (aPTT). A weight-adjusted dosing regimen provides more predictable anticoagulation than a fixed-dose regimen (146,147). An initial bolus of 60 U per kg (maximum 4,000 U) is followed by an initial infusion of 12 U per kg per hour (maximum 1,000 U per hour). Older age and female sex decrease UFH requirements. A therapeutic range equivalent to heparin levels of 0.3 to 0.7 U/mL, assessed by anti-factor Xa determinations, which correlates with aPTT values between 60 and 80 seconds, has been recommended (142). Nomograms should be established at each institution to achieve aPTT values in the target range of 1.5 to 2.5 times control aPTT values. Measurements should be made 6 h after any dosage change and whenever there are significant changes in clinical status and used to adjust UFH infusion until the aPTT exhibits a therapeutic level.

During UFH therapy, complete blood counts and platelet counts are recommended to monitor for anemia and heparin-induced thrombocytopenia, especially after prolonged (several days) infusions. The duration of UFH therapy in most UA/NSTEMI trials has been 2 to 5 d. The optimal duration of therapy is uncertain and likely varies by strategy.

B. LOW-MOLECULAR-WEIGHT HEPARIN

The LMWHs are obtained through chemical or enzymatic depolymerization of the polysaccharide chains of heparin to provide chains with different molecular-weight distributions (142,148). Approximately 25% to 50% of the pentasaccharide-containing chains of LMWH preparations contain more than 18 saccharide units, which inactivate both thrombin and factor Xa; LMWH chains of fewer than 18 saccharide units inactivate factor Xa but not thrombin. Therefore, LMWHs are relatively more potent in inhibiting factor Xa than inactivating thrombin. Advantages of LMWH over UFH include decreased binding to plasma proteins and endothelial cells and dose-independent clearance, with a longer half-life. This results in more predictable and sustained anticoagulation with once- or twice-a-day subcutaneous administration that usually does not require laboratory monitoring. Different preparations of LMWHs vary in mean molecular weights (ranging from 4,200 to 6,000 Daltons) and corresponding ratios of anti–Xa factor to anti–IIa factor (1.9 to 3.8) (148).

Unstable angina/NSTEMI trials of LMWH and ASA compared with ASA alone or with UFH have generally shown favorable results. Eight randomized trials have directly compared an LMWH with UFH (Table 7). Trials with dalteparin and nadroparin reported similar rates of death or nonfatal MI compared with UFH, whereas 5 of 6 trials of enoxaparin found point estimates for death or nonfatal MI that favored enoxaparin; the pooled OR was 0.91 (95% CI 0.83 to 0.99). This incremental benefit of enoxaparin appeared to be driven largely by a reduction in nonfatal MI. With an early invasive strategy, outcomes with
<table>
<thead>
<tr>
<th>Trial (Reference)</th>
<th>n</th>
<th>LMWH/Dose</th>
<th>UFH</th>
<th>End Point/ Drug Effect</th>
<th>Analysis</th>
<th>95% CI</th>
<th>p</th>
<th>Major Bleeding (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FRISC (150)</strong></td>
<td>1,506</td>
<td>(a) 6 d*: dalteparin 120 IU per kg‡ SC twice daily (maximum 10,000 IU) (b) During first 40 d: dalteparin 7,500 IU SC once per day</td>
<td>(a) 6 d: placebo (b) During first 40 d: placebo</td>
<td>(a) Death or new MI (6 d): LMWH 1.8%, Placebo 4.8% (b) Death or new MI (during first 40 d‡): LMWH 8%, placebo 10.7%</td>
<td>(a) RR 0.37 ARR 3% (b) RR 0.75 ARR 2.7%</td>
<td>(a) 0.20 to 0.68 (b) 0.54 to 1.03</td>
<td>(a) 0.001 (b) 0.07</td>
<td>(a) LMWH 0.8%, placebo 0.5%; ARR −0.3% (p = NR) (b) During first 40 d: LMWH 0.3%, placebo 0.3%; ARR 0% (p = NR)</td>
</tr>
<tr>
<td><strong>ESSENCE (41)</strong></td>
<td>3,171</td>
<td>Enoxaparin 1 mg per kg SC twice daily (minimum 48 h, maximum 8 d)</td>
<td>UFH IV bolus (usually 5,000 units and continued IV infusion)</td>
<td>(a) Death, MI, or recurrent angina at 14 d: LMWH 16.6%, UFH 19.8% (b) OR at 30 d = 0.80 ARR 3.2%</td>
<td>(a) 0.67 to 0.96 (b) 0.68 to 0.96</td>
<td>(a) 0.019 (b) 0.016</td>
<td>At 30 d: LMWH 6.5%, UFH 7%; ARR 0.5% (p = 0.57)</td>
<td></td>
</tr>
<tr>
<td><strong>FRIC (151)</strong></td>
<td>1,482</td>
<td>(a) Days 1 to 6: dalteparin 120 IU per kg SC twice daily (b) Days 6 to 45§: dalteparin 7,500 IU SC once per day</td>
<td>(a) Days 1 to 6: UFH 5,000 units IV bolus and IV infusion of 1,000 units per h for 48 h (b) Days 6 to 45: placebo SC once daily</td>
<td>(a) Death, MI, or recurrence of angina (Days 1 to 6): LMWH 9.3%, UFH 7.6% (b) Death, MI, or recurrence of angina (Days 6 to 45): 12.3% in both the LMWH and UFH groups</td>
<td>(a) OR at 14 d = 0.80 ARR 3.2% (b) OR at 30 d = 0.81 ARR 3.5%</td>
<td>(a) 0.67 to 0.96 (b) 0.68 to 0.96</td>
<td>(a) RR 1.18 ARR −1.7% (b) RR 2.01 ARR 0%</td>
<td>(a) 0.84 to 1.66 (b) 0.74 to 1.38</td>
</tr>
<tr>
<td><strong>FRAX.I.S. (152)</strong></td>
<td>3,468</td>
<td>(a) Nadroparin 6 d: nadroparin 86 anti-Xa IU per kg IV bolus, followed by nadroparin 86 anti-Xa IU per kg SC twice daily for 6 d (b) Nadroparin 14 d: nadroparin 86 anti-Xa IU per kg IV bolus, followed by nadroparin 86 anti-Xa IU per kg SC twice daily for 14 d</td>
<td>Cardiac death, MI, refractory angina, recurrence of UA at Day 14: LMWH 17.8%, UFH 14 d 20.0% UFH 18.1%</td>
<td>(a) ARR 0.3% (b) ARR −1.9%</td>
<td>(a) 0.85 to 3.4 (b) −5.1 to 1.3</td>
<td>(a) 0.057 (b) 0.24</td>
<td>At 6 d: UFH 1.6%, LMWH 1.5%, ARR 0.1% At 14 d: UFH 1.6%, LMWH 3.5%, ARR −1.9% (p = 0.0035)</td>
<td></td>
</tr>
</tbody>
</table>

Continued on next page
Table 7. Continued

<table>
<thead>
<tr>
<th>Trial (Reference)</th>
<th>n</th>
<th>LMWH/Dose</th>
<th>UFH</th>
<th>End Point/Drug Effect</th>
<th>Analysis</th>
<th>95% CI</th>
<th>p</th>
<th>Major Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIMI 11B (42)</td>
<td>3,910</td>
<td>(a) Inpatient: enoxaparin 30 mg IV bolus immediately followed by 1 mg per kg SC every 12 h (b) Outpatient: enoxaparin 40 mg SC twice per day (patients weighing less than 65 kg) or 60 mg SC twice per day (patients weighing at least 65 kg)</td>
<td>(a) Inpatient: UFH 70 units per kg bolus and infusion at 15 units per h titrated to aPTT (treatment maintained for a minimum of 3 and maximum of 8 d at physician’s discretion) (b) Outpatient: placebo SC twice per day</td>
<td>Death, MI, urgent revascularization at 48 h; LMWH 5.5% UFH 7.3%</td>
<td>(a) OR 0.75 ARR 1.8%</td>
<td>(a) 0.58 to 0.97 (b)</td>
<td>(a) 0.026 (b) 0.048 (c) 0.029 (d) 0.048</td>
<td>At 48 h: LMWH 0.8%, UFH 0.7%, ARR −0.1% (p = 0.14)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACUTE II (153)</td>
<td>525</td>
<td>Enoxaparin 1 mg per kg SC every 12 h</td>
<td>UFH 5,000 units IV bolus and maintenance infusion at 1,000 units per h IV adjusted to aPTT</td>
<td>(a) Death or MI at 30 d (a) LMWH 2.5%, UFH 1.9% (b) LMWH 6.7%, UFH 7.1%</td>
<td>(a) RR −1.3 ARR −0.6% (b) RR 0.94 ARR 0.4%</td>
<td>(a) 0.06 to 3.93 (b) 0.45 to 2.56</td>
<td>(a) 0.77 (b) 0.86</td>
<td>LMWH 0.3%, UFH 1%, ARR 0.7% (p = 0.57)</td>
</tr>
<tr>
<td>INTERACT (154)</td>
<td>746</td>
<td>Enoxaparin 1 mg per kg SC every 12 h</td>
<td>UFH 70 units per kg IV bolus followed by continuous infusion at 15 units per kg per h</td>
<td>Death or MI at 30 d: LMWH 5.0%, UFH 9.0%</td>
<td>RR 0.55 ARR 4%</td>
<td>0.30 to 0.96</td>
<td>0.031</td>
<td>At 96 h: LMWH 1.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A to Z** (155)</td>
<td>3,987</td>
<td>Enoxaparin 1 mg per kg SC every 12 h</td>
<td>UFH 4,000 units IV bolus followed by 900 units per h IV infusion for patients weighing at least 70 kg UFH 60 units per kg (maximum 4,000 units) IV bolus followed by 12 units per kg per h IV infusion for patients weighing less than 70 kg</td>
<td>All-cause death, MI, or refractory ischemia within 7 d of tirofiban initiation: LMWH 8.4%, UFH 9.4%</td>
<td>HR 0.88 ARR 1%</td>
<td>0.71 to 1.08</td>
<td>NR</td>
<td>LMWH 0.9%, UFH 0.4%; ARR −0.5% (p = 0.05)</td>
</tr>
</tbody>
</table>

Continued on next page
Table 7. Continued

<table>
<thead>
<tr>
<th>Trial (Reference)</th>
<th>n</th>
<th>LMWH/Dose</th>
<th>UFH</th>
<th>End Point/Drug Effect</th>
<th>Analysis</th>
<th>95% CI</th>
<th>p</th>
<th>Major Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYNERGY†† (156)</td>
<td>9,978</td>
<td>Enoxaparin 1 mg per kg SC every 12 h</td>
<td>UFH 60 units per kg IV bolus (maximum of 5,000 units) and followed by IV infusion of 12 units per kg per h (maximum of 1,000 units per h initially)</td>
<td>Death or nonfatal MI during first 30 d after randomization</td>
<td>LMWH 14.0%, UFH 14.5%, HR 0.96</td>
<td>ARR 0.5%</td>
<td>0.86 to 1.06</td>
<td>0.40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For specific interventions and additional medications during the study, see individual study references. Major bleeding was classified as follows in the various trials: A to Z: decrease in hemoglobin of more than 5 mg per dl, or intracranial or pericardial bleeding. ESSENCE: Major hemorrhage was defined as bleeding resulting in death, transfusion of at least 2 U of blood, a fall in hemoglobin of 30 g per liter or more, or a retroperitoneal, intracranial, or intracardiac hemorrhage. TIMI 11B: Overt bled resulting in death; a bleed in a retroperitoneal, intracranial, or intracardiac location; a hemoglobin drop of greater than or equal to 3 g per dl; or the requirement of transfusion of at least 2 U of blood. SYNERGY: TIMI and GUSTO criteria. ACUTE II: Severity was recorded on the basis of the TIMI trial bleeding criteria. TIMI major bleeding involved a hemoglobin drop greater than 5 g per dl (with or without an identified site, not associated with coronary artery bypass grafting) or intracranial hemorrhage or cardiac tamponade. INTERACT: Major bleeding included bleeding resulting in death, or retroperitoneal hemorrhage, or bleeding at a specific site accompanied by a drop in hemoglobin greater than or equal to 3 g per dl. FRIC: A bleeding event was classified as major if it led to a fall in the hemoglobin level of at least 20 g per liter, required transfusion, was intracranial, or caused death or cessation of the study treatment. *Primary study end point was first 6 d; †Initial dose of 150 IU per kg SC twice daily decreased to 120 IU per kg SC twice daily due to increased bleeding during first 6 d (4 patients or 6% major bleeding episodes and 9 patients or 1.4% minor episodes among 63 actively treated patients); ‡Follow-up incomplete in 13 patients (8 dalteparin; 5 placebo) at their request; §Primary study outcome was Days 6 to 45. [All patients in ACUTE II received a tirofiban loading dose of 0.4 mcg per kg per min over 30 min, followed by a maintenance infusion at 0.1 mcg per kg per min; ††All patients in INTERACT received eptifibatide 180 mcg per kg bolus followed by a 2.0 mcg per kg per min infusion for 48 h. **All patients enrolled in the A to Z Trial received aspirin and tirofiban; †††Patients also received glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel; patients eligible for enrollment even if LMWH or UFH given before enrollment, adjustments made to enoxaparin and UFH during percutaneous coronary intervention."

UFH and LMWH (enoxaparin) were similar (156) (Fig. 10).

The Enoxaparin Versus Tinzaparin (EVET) trial directly compared 2 LMWHs, enoxaparin and tinzaparin, in 436 patients with UA/NSTEMI. Exenaparin was associated with a lower rate of death/MI/recurrent angina at 7 and 30 d than tinzaparin (149). Bleeding rates were similar.

Four trials evaluated the potential benefit of prolonged administration of LMWH after hospital discharge, with little or no benefit beyond the acute phase (see Table 7) (157). In addition to providing ease of administration and eliminating the need for monitoring, LMWHs stimulate platelets less than UFH (158) and less frequently cause heparin-induced thrombocytopenia (159). They are associated with more frequent minor but not major bleeding. A post hoc analysis from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial (Fig. 10) (156) suggested that some of the excess bleeding seen with enoxaparin could be explained by crossover to UFH at the time of PCI. It thus appears reasonable to maintain consistent anticoagulant therapy from the pre-PCI phase throughout the procedure itself. For patients in whom CABG is planned, it is recommended that LMWH be discontinued and UFH used during the operation.

C. DIRECT THROMBIN INHIBITORS

Hirudin, the prototype direct thrombin inhibitor, has been studied extensively but with mixed results, including excess bleeding with higher doses (160,161). Bivalirudin is a synthetic analog of hirudin that binds reversibly to thrombin and inhibits clot-bound thrombin. Bivalirudin was investigated in 13,819 patients with UA/NSTEMI in the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial (162). In a 2 × 2 factorial design, a heparin (UFH or enoxaparin), with or without upstream GP IIb/IIIa inhibition, was compared to bivalirudin, with or without upstream GP IIb/IIIa inhibition; a third arm with bivalirudin alone and provisional GP IIb/IIIa inhibition was also included. The study was randomized but open-label. Bivalirudin compared with heparin (both with GP IIb/IIIa inhibitors) gave noninferior 30-d rates of composite ischemia (7.7% vs. 7.3%), major bleeding (5.3% vs. 5.7%), and net clinical outcomes (11.8% vs. 11.7%; Fig. 11). Bivalirudin alone was comparable to heparin plus GP IIb/IIIa inhibition for the subgroup of patients who received a thienopyridine before angiography or PCI (composite ischemic end-point rate 7.0% vs. 7.3%), but it was inferior in patients who did not (ischemic event rate 9.1% vs. 7.1%, RR 1.29, 95% CI 1.03 to 1.63; p for interaction = 0.054) (Fig. 12). Bleeding rates were lower with bivalirudin alone. In sum-
mary, UA/NSTEMI patients should be treated with concomitant GP IIb/IIIa inhibition or a thienopyridine, administered before angiography, to optimize outcomes if a bivalirudin-based anticoagulant strategy is used.

D. FACTOR XA INHIBITORS

Factor Xa inhibitors act proximally in the coagulation cascade to inhibit the multiplier effects of the downstream reactions, thereby suppressing thrombin generation. Advantages of the pentasaccharide factor Xa inhibitor fondaparinux over UFH include decreased binding to plasma proteins and endothelial cells and dose-independent clearance with a longer half-life, which results in more predictable and sustained anticoagulation and allows fixed-dose, once-daily subcutaneous administration. As with the LMWHs, fondaparinux does not require laboratory monitoring. Fondaparinux is renally cleared. The factor Xa inhibitors do

Figure 10. SYNERGY Primary Outcomes at 30 D

CI = confidence interval; MI = myocardial infarction; SYNERGY = Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors; UFH = unfractionated heparin.

Figure 11. ACUITY Clinical Outcomes at 30 D

*p for noninferiority; ACUITY = Acute Catheterization and Urgent Intervention Triage strategy; CI = confidence interval; GP = glycoprotein; UFH = unfractionated heparin.
not have any action against thrombin that is already formed, a possible explanation for the increased rate of catheter-associated thrombosis with fondaparinux.

The Organization to Assess Strategies for Ischaemic Syndromes (OASIS)-5 investigators evaluated the use of fondaparinux in 20,078 patients with UA/NSTEMI (163). Patients were randomized (double-blind, double-dummy design) to a control strategy of enoxaparin 1.0 mg per kg subcutaneous twice daily (reduced to 1.0 mg per kg once daily for patients with an estimated creatinine clearance less than 30 mL per min) or to fondaparinux 2.5 mg SC once daily. Unfractionated heparin initially was not used with PCI, but because of an increased incidence of catheter-associated thrombus, the protocol was amended to permit the use of open-label UFH at the investigator’s discretion. The OASIS-5 primary composite outcome (death, MI, or refractory ischemia at 9 d) was similar in the 2 groups (579 with fondaparinux [5.8%] vs. 573 with enoxaparin [5.7%]; hazard ratio [HR] 1.01; 95% CI 0.90 to 1.13), which satisfied prespecified noninferiority criteria (Fig. 13). Rates of major bleeding at 9 d were lower with fondaparinux (2.2% vs. 4.1%, p less than 0.001), which yielded a lower efficacy plus safety composite (Fig. 13). Primary composite events trended lower in the fondaparinux group at 30 d and 6 months; 6-month rates of death (5.8% vs. 6.5%) and death, MI, and stroke (11.3% vs. 12.5%) were also lower at 6 months with fondaparinux.

At present, on the basis of limited experience in OASIS-5 and concerns raised by OASIS-6 (164), UFH (50 to 60 U per kg IV) is recommended with a fondaparinux strategy during angiography/PCI. Fondaparinux appears to represent a preferred anticoagulant strategy in those at higher risk of bleeding managed with a noninvasive strategy.

E. LONG-TERM ANTICOAGULATION
The long-term administration of warfarin or other coumarins after UA/NSTEMI or STEMI has been evaluated in several small and a few moderate-size trials with variable results (165). Moderate-intensity warfarin with low-dose ASA appears to be modestly more effective than ASA alone when applied to post-MI patients treated primarily with a noninterventional approach, but it is associated with a higher risk of bleeding (166,167). The relevance of routine long-term anticoagulation with warfarin to contemporary practice is unclear given the current routine use of clopidogrel and the much more frequent use of an invasive strategy.

In contrast, occasional UA/NSTEMI patients present with a specific indication for oral anticoagulant therapy with warfarin (i.e., atrial fibrillation, mechanical prosthetic valve, or LV thrombus) in addition to ASA plus clopidogrel. The evidence base for such “triple-anticoagulant therapy” remains small. When triple-combination therapy is selected for clear indications, on the basis of clinical judgment that the benefit will outweigh the incremental risk of bleeding, therapy should be given for the minimum time and doses necessary to achieve protection.

3. Platelet GP IIb/IIIa Receptor Antagonists
When platelets are activated by a number of mechanisms, their GP IIb/IIIa cell membrane receptors undergo a
conformation change that increases receptor affinity for fibrinogen (168). The binding of fibrinogen molecules to receptors on adjacent platelets results in platelet aggregation. The platelet GP IIb/IIIa receptor antagonists act by occupying the receptors, preventing fibrinogen from binding and thereby preventing platelet aggregation. Experimental and clinical studies have suggested that occupancy of 80% or more of the receptor population and inhibition of platelet aggregation to adenosine diphosphate (5 to 20 micromoles per liter) by 80% or more results in potent anticoagulant effects (169).

The 3 approved GP IIb/IIIa antagonists differ in pharmacokinetic and pharmacodynamic properties (170). Abciximab is a Fab fragment of a humanized murine antibody that has a short plasma half-life but strong affinity for the receptor. Platelet aggregation gradually returns to normal 24 to 48 h after discontinuation. Eptifibatide is a cyclic heptapeptide that contains the KGD (Lys-Gly-Asp) sequence; tirofiban is a nonpeptide mimetic of the RGD (Arg-Gly-Asp) sequence of fibrinogen. They bind with high specificity to the GP IIb/IIIa receptor, but platelet aggregation returns to normal 4 to 8 h after discontinuation of these 2 drugs, consistent with their relatively short half-lives of 2 to 3 h (171).

The efficacy of GP IIb/IIIa antagonists for the prevention of PCI-related complications has been documented in several trials, many composed primarily of patients with UA (Table 8). Abciximab has been studied primarily in PCI trials, in which it consistently reduced rates of MI and the need for urgent revascularization. In subgroups of patients who had ACS, abciximab reduced the 30-d risk of ischemic complications after PCI by 60% to 80%. Two trials specifically studied patients with ACS. In the c7E3 Fab Anti-platelet Therapy in Unstable Refractory Angina (CAPTURE) trial (172), abciximab reduced the rate of death, MI, or urgent revascularization within 30 d from 15.9% to 11.3% (RR 0.71, \( p = 0.012 \)). Hence, abciximab is approved for the treatment of UA/NSTEMI as an adjunct to PCI or when PCI is planned within 24 h. In contrast, the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IV-ACS trial (173) enrolled 7,800 patients with UA/NSTEMI in whom early (less than 48 h) revascularization was not intended and found no benefit or adverse trends in rates of death or MI. Although the explanation for these results is not clear, abciximab should not be used in the management of patients with UA/NSTEMI in whom an early invasive management strategy is not planned.

Tirofiban was studied in the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) (182) and Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) (181) trials (Table 8). The PRISM trial compared tirofiban with heparin in 3,232 patients with UA/NSTEMI. The primary composite outcome (death, MI, or refractory ischemia at the end of a 48-h infusion) was reduced from 5.6% to 3.8% (RR 0.67, \( p = 0.01 \)). At 30 days, the frequency of the composite outcome was similar in the 2 groups, but the rate of death or MI trended lower with tirofiban (7.1% vs. 5.8%), and mortality was reduced (3.6% vs. 2.3%, \( p = 0.02 \)). Benefit primarily occurred in patients with elevated troponin. PRISM-PLUS randomized 1,915 UA/NSTEMI patients to tirofiban alone, UFH alone, or the combination for 48 to 108 h (181). The tirofiban-alone arm was dropped during the trial because of an adverse early
Table 8. UA/NSTEMI Outcome of Death or Myocardial Infarction in Clinical Trials of GP IIb/IIIa Antagonists Involving More Than 1,000 Patients

<table>
<thead>
<tr>
<th>Trial (Year)</th>
<th>Study Population</th>
<th>Drugs</th>
<th>Placebo</th>
<th>GP IIb/IIIa</th>
<th>Results</th>
<th>ARR, %</th>
<th>RR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCI trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPIC (1994) (174)</td>
<td>High-risk PTCA</td>
<td>Abciximab</td>
<td>72/696 10.3</td>
<td>49/708 6.9*</td>
<td>3.4 0.68</td>
<td>0.47 to 0.95</td>
<td>0.022</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPILOG (1997) (175)</td>
<td>All PTCA</td>
<td>Abciximab</td>
<td>85/939 9.1</td>
<td>35/935 3.7*</td>
<td>5.4 0.41</td>
<td>0.28 to 0.61</td>
<td>Less than 0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAPTURE (1997) (172)</td>
<td>UA</td>
<td>Abciximab</td>
<td>57/635 9.0</td>
<td>30/630 4.8</td>
<td>4.2 0.53</td>
<td>0.35 to 0.81</td>
<td>0.003</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMPACT II (1997) (176)</td>
<td>All PTCA</td>
<td>Epifibatide</td>
<td>112/1328 8.4</td>
<td>93/1349 6.9</td>
<td>1.5 0.83</td>
<td>0.63 to 1.06</td>
<td>0.134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RESTORE (1997) (177)</td>
<td>UA</td>
<td>Tirofiban</td>
<td>69/1070 6.4</td>
<td>54/1071 5.0</td>
<td>1.4 0.78</td>
<td>0.55 to 1.10</td>
<td>0.162</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPISTENT (1998) (178)</td>
<td>Elective stenting</td>
<td>Abciximab</td>
<td>112/1328 8.4</td>
<td>93/1349 6.9</td>
<td>1.5 0.83</td>
<td>0.63 to 1.06</td>
<td>0.134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESPRIT (2000) (179)</td>
<td>Elective stenting</td>
<td>Epifibatide</td>
<td>104/1024 10.2</td>
<td>66/1040 6.3</td>
<td>3.9 0.62</td>
<td>0.46 to 0.84</td>
<td>0.0016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISAR-REACT (2004) (180)</td>
<td>Elective stenting with clopidogrel pretreatment</td>
<td>Abciximab</td>
<td>42/1080 3.9</td>
<td>43/1079 4.0</td>
<td>0.1 1.02</td>
<td>0.68 to 1.55</td>
<td>0.91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACS trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRISM-PLUS (1998) (181)</td>
<td>UA/NQWMI</td>
<td>Tirofiban</td>
<td>95/797 11.9</td>
<td>67/733* 9.1*</td>
<td>2.8 0.70</td>
<td>0.51 to 0.96</td>
<td>0.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRISM (1998) (182)</td>
<td>UA/NQWMI</td>
<td>Tirofiban</td>
<td>115/1616 7.1</td>
<td>94/1616 5.8†</td>
<td>1.3 0.82</td>
<td>0.61 to 1.05</td>
<td>0.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PURSUIT (1998) (183)</td>
<td>Epifibatide</td>
<td>744/4739 15.7</td>
<td>67/4722 14.3</td>
<td>0.09 0.07 to 0.12</td>
<td>Less than 0.0001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAGON A (1998) (184)</td>
<td>UA/NQWMI</td>
<td>Lamifiban</td>
<td>89/758 11.7</td>
<td>80/755 10.6†</td>
<td>1.1 0.90</td>
<td>0.68 to 1.20</td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GUSTO IV ACS (2001) (173)</td>
<td>UA/NQWMI</td>
<td>Abciximab</td>
<td>209/2598 8.0</td>
<td>450/5202‡ 8.7</td>
<td>0.7 1.08</td>
<td>0.92 to 1.26</td>
<td>0.36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PARAGON B (2002) (185)</td>
<td>UA/NQWMI</td>
<td>Lamifiban</td>
<td>296/2597 11.4</td>
<td>278/2628 10.6</td>
<td>0.8 0.94</td>
<td>0.77 to 1.09</td>
<td>0.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISAR-REACT (2006) (74)</td>
<td>UA/NSTEMI§</td>
<td>Abciximab</td>
<td>116/1010 11.5</td>
<td>87/1012 8.6</td>
<td>2.9 0.75</td>
<td>1.57 to 9.02</td>
<td>0.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All PCI trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ACS trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All PCI and ACS trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Best treatment group selected for analysis. †Platelet GP IIb/IIIa antagonist without heparin. ‡Pooled results for 24- and 48-h infusion arms. §Used an invasive (PCI) strategy; all patients received clopidogrel.

ACS = acute coronary syndrome; CAPTURE = c7E3 Fab Antibody Therapy in Unstable Refractory Angina; CI = confidence interval; EPIC = Evaluation of c7E3 for the Prevention of Ischemic Complications; EPLOG = Evaluation of c7E3 for the Prevention of Ischemic Complications; IMPACT II = Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis II; ISAR-REACT = Intracoronary Stenting and Antiplatelet Therapy in Unstable Angina; NSTEMI = non–ST-elevation myocardial infarction; PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network; PCI = percutaneous transluminal coronary angioplasty; PRISM = Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Unstable 16 Angina: Receptor Suppression Using Integrilin Therapy; RESTORE = Randomized Efficacy Study of Tirofiban for Outcomes and ReStenosis; RR = risk ratio; UA = unstable angina; UA/NSTEMI = unstable angina/non-ST-elevation myocardial infarction.
mortality trend. The combination of tirofiban and UFH compared with UFH alone reduced the primary composite end point of death, MI, or refractory ischemia at 7 d (from 17.9% to 12.9% RR 0.68, p = 0.004), as well as at 30 days (by 22%, p = 0.03) and at 6 months (19%, p = 0.02). Death or nonfatal MI was reduced at 7 d (43%, p = 0.006), at 30 d (30%, p = 0.03), and at 6 months (22%, p = 0.06). Incremental benefit was observed both before and after PCI. Analysis of coronary angiograms, obtained after 48 h, showed reduced thrombus burden and improved coronary flow (186). Tirofiban, in combination with heparin, is approved for the treatment of patients with ACS, including patients managed medically and those undergoing PCI.

Eptifibatide, added to standard management until hospital discharge or for 72 h, was studied in the PURSUIT trial, which enrolled 10,948 UA/NSTEMI patients (183). The primary outcome of death or nonfatal MI at 30 days was reduced from 15.7% to 14.2% with eptifibatide (RR 0.91, p = 0.042). Event rate reduction (31%) was substantially greater in those undergoing PCI within 72 h (16.7% to 11.6%). Benefits were maintained at 6-month follow-up. Eptifibatide is approved for the treatment of patients with ACS (UA/NSTEMI) who are treated medically or with PCI.

In summary, the CAPTURE, PRISM-PLUS, and PURSUIT trials each showed a significant reduction in the rate of death or MI during the phase of medical management and an augmented benefit after PCI. A meta-analysis of the 6 large, placebo-controlled GP IIb/IIIa antagonist trials (including GUSTO IV) involving 31,402 patients with UA/NSTEMI not routinely scheduled to undergo coronary revascularization suggested a modest overall benefit in reducing the risk of death or MI by 30 d (11.8% vs. 10.8%, OR 0.91 and 95% CI 0.84 to 0.98, respectively; p = 0.015) at a modest increase (from 1.4% to 2.4%) in major bleeding events (187). Treatment effect was greater among higher-risk patients with troponin elevation and ST-segment depression. These and other data have elevated troponin level to a major factor in decision making for the use of these agents in UA/NSTEMI. Although not specified in these trials, PCI or CABG was performed in 19% of patients within 5 d and in 38% within 30 d. These subgroups noted a greater risk reduction (OR 0.79, 95% CI 0.68 to 0.91 and OR 0.89, 95% CI 0.80 to 0.98, respectively) than in those not undergoing intervention (OR 0.95, 95% CI 0.86 to 1.05). These findings in the context of other PCI trial data suggest that GP IIb/IIIa inhibitors are of substantial benefit in patients with UA/NSTEMI who undergo PCI, are of modest benefit in patients who are not routinely scheduled to undergo revascularization (but who may do so), and are of questionable benefit in patients who do not undergo revascularization.

Glycoprotein IIb/IIIa antagonists increase the risk of bleeding, most commonly mucocutaneous or vascular access site bleeding. No trials have shown an excess of intracranial bleeding. Aspirin has been used with the intravenous GP IIb/IIIa receptor blockers in all trials, and adjunctive UFH appears beneficial (181,183). Hence, clinical recommendations call for the concomitant use of heparin with GP IIb/IIIa inhibitors. Lower heparin doses diminish the bleeding risk associated with GP IIb/IIIa blockade in the setting of PCI and likely the medical phase of management as well. Thrombocytopenia is an uncommon (less than 0.5%) complication of these agents that is reversible but is associated with increased bleeding risk.

Several trials have demonstrated that GP IIb/IIIa inhibitors can be used with LMWH in ACS patients (155,156). The A to Z Trial (Aggrastat to Zocor; 3,987 patients) found nonsignificant trends toward fewer ischemic end points but more frequent bleeding with enoxaparin than with UFH (155). In the larger SYNERGY trial, 10,027 patients with high-risk ACS were randomized to UFH or enoxaparin. Glycoprotein IIb/IIIa antagonists were administered to 57% of patients, and 92% underwent coronary angiography. Rates of the primary end point of death or MI by 30 d were similar (14.0% vs. 14.5%) (Fig. 10), and the therapies offered similar protection against ischemic events during PCI, although enoxaparin was associated with a 1.5% increase in bleeding events (156).

A challenge for the current guidelines is the integration of the GP IIb/IIIa antagonist studies from the 1990s with more recent studies using preangiography clopidogrel loading and newer anticoagulants. The current evidence base and expert opinion suggest that for UA/NSTEMI patients in whom an initial invasive strategy is selected, either an intravenous GP IIb/IIIa inhibitor or clopidogrel should be added to ASA and anticoagulant therapy before diagnostic angiography (upstream) for lower-risk, troponin-negative patients, and that both should be given before angiography for high-risk, troponin-positive patients (Class I recommendations). For UA/NSTEMI patients in whom an initial conservative (i.e., noninvasive) strategy is selected, the evidence for benefit is less; for this strategy, the addition of eptifibatide or tirofiban to anticoagulant and oral antiplatelet therapy may be reasonable for high-risk UA/NSTEMI patients (Class IIb recommendation). The randomized trial database has shown no benefit of fibrinolysis versus standard therapy in UA/NSTEMI patients (191). Fibrinolytic therapy is not recommended for the management of ACS patients without ST-segment elevation, a posterior-wall MI, or a presumably new left bundle-branch block.

C. Initial Conservative Versus Initial Invasive Strategies

1. General Principles and Care Objectives

Two treatment pathways have emerged for treating UA/NSTEMI patients: the early “invasive strategy” and an initial “conservative strategy” (192,192a). Patients treated with an invasive strategy generally will undergo coronary angiography within 4 to 24 h of admission. The invasive strategy can be subdivided into 2 groups. The
first group consists of patients requiring urgent angiography/ revascularization urgently because of ongoing ischemic symptoms or hemodynamic or rhythm instability. With these patients, GP IIb/IIIa antagonists or clopidogrel may be delayed at the physician’s discretion until the time of angiography (Figs. 6, 7, and 8). The second, larger group comprises others with UA/NSTEMI who are designated by patient/physician discretion or after risk assessment to benefit from “early” but nonurgent angiography/intervention. For these patients, “upstream” therapy with GP IIb/IIIa antagonists and/or clopidogrel being associated with greater incremental benefit of aggressive antiplatelet therapy. In contrast, the “conservative strategy” (or “selective invasive management”) calls for invasive evaluation only with symptomatic failure of medical therapy or other objective evidence of recurrent or latent ischemia.

The primary objective in selecting a treatment strategy in UA/NSTEMI is to yield the best long-term clinical outcome. Estimating the risk for an adverse outcome is paramount for determining which strategy is best applied to individual patients. General characteristics favoring one or the other strategy are presented in Table 5. Although general guidelines can be offered, individual judgment is required.

2. Rationale for the Conservative Strategy

The conservative strategy seeks to avoid the routine early use of invasive procedures unless patients experience refractory or recurrent ischemic symptoms or develop hemodynamic instability. With this strategy, an early echocardiogram should be considered to identify significant LV dysfunction. In addition, an exercise or pharmacological stress test is recommended before or shortly after discharge to identify patients with latent ischemia who could benefit from revascularization. The use of aggressive anticoagulant and antiplatelet agents has reduced the incidence of adverse outcomes in patients managed conservatively.

3. Rationale for the Invasive Strategy

The routine use of angiography within 24 h of hospital admission provides an invasive approach to risk stratification. It can identify the 10% to 20% of patients with no significant coronary stenoses as well as the approximately 20% with 3-vessel disease with LV dysfunction or left main CAD who derive a substantial survival benefit from CABG (Section V). For the other approximately 60% to 70%, PCI of the culprit lesion can reduce subsequent hospitalizations and the need for multiple antianginal drugs. Contemporary anticoagulant and antiplatelet therapies have lessened the early hazard of PCI. Excluding those in need of urgent intervention, 2 alternatives for the invasive approach have emerged: early (“immediate”) or deferred angiography (i.e., before or after a 12- to 48-h window). Support for immediate angiography comes from the Intracoronary Stenting with Antithrombotic Regimen Cooling-off Study (ISAR-COOL) trial (193). In that trial, all 410 UA/NSTEMI patients were treated with intensive medical therapy, including ASA, heparin, clopidogrel (600-mg loading dose), and the intravenous GP IIb/IIIa receptor inhibitor tirofiban, and were randomized to immediate angiography (median time 2.4 h) or delayed angiography after a prolonged “cooling off” period (median 86 h) before catheterization. Patients randomized to immediate angiography had fewer deaths or MIs at 30 d (5.9% vs. 11.6%, \( p = 0.04 \)). Importantly, this difference was attributed to events that occurred before catheterization. Additional data comparing these 2 invasive strategies are needed.

4. Comparison of Invasive and Conservative Strategies

Prior meta-analyses have concluded that routine invasive therapy is better than a conservative or selectively invasive approach (194). In contrast, the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) trial (192) favored a strategy of selective invasive therapy. ICTUS randomized 1,200 UA/NSTEMI patients to routine invasive or selective invasive management. At the end of 1 year, there was no significant difference in the composite ischemic end point. Results were unchanged during 3-year follow-up (192a). ICTUS required troponin positivity. Thus, troponin alone might not be an adequate single criterion for strategy selection. Proposed explanations for the lack of incremental benefit with an invasive strategy include the high rate of revascularization in the selective invasive therapy arm (47%), more aggressive medical therapy (statins, clopidogrel) in both arms, routine use of clopidogrel in the conservative arm, and limited power owing to the relatively low rate of hard end points (195). Given the results of ICTUS, these guidelines recognize that an initially conservative (selective invasive) strategy may be considered as a treatment option in stabilized UA/NSTEMI patients. Additional comparative trials of a selective versus a routine invasive strategy are encouraged using aggressive contemporary medical therapies in both arms.

In the RITA-3 trial (Third Randomized Intervention Treatment of Angina), 1,810 UA/NSTEMI patients were randomized to interventional versus conservative treatment. At 1 year, death and MI rates were similar, but at 5 years, a significant reduction in death or MI emerged in the early invasive treatment arm (196). Benefits were seen mainly in high-risk patients, which supports appropriate risk stratification. Long-term outcomes of the FRagmin and fast revascularization during InStability in Coronary artery disease (FRISC II) trial have also been published (197). At 5 years, the invasive strategy was favored for the primary end point of death or nonfatal MI (HR 0.81, \( p = 0.009 \)). Benefit was confined to men, nonsmokers, and patients with 2 or more risk factors.

A contemporary meta-analysis of 7 randomized trials of management strategies in UA/NSTEMI, including ICTUS, supports the long-term benefit of an early invasive strategy (Fig. 14) (198). Among 8,375 patients, the inci-
Figure 14. Relative Risk of Outcomes With Early Invasive Versus Conservative Therapy in UA/NSTEMI

A: Relative risk of all-cause mortality for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. B: Relative risk of recurrent nonfatal myocardial infarction for early invasive therapy compared with conservative therapy at a mean follow-up of 2 years. C: Relative risk of recurrent unstable angina resulting in rehospitalization for early invasive therapy compared with conservative therapy at a mean follow-up of 13 months. Modified from The Journal of the American College of Cardiology, 48, Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials, 1319–25, Copyright 2006, with permission from Elsevier (198). CI = confidence interval; FRISC-II = FRagmin and fast Revascularization during InStability in Coronary artery disease; ICTUS = Invasive versus Conservative Treatment in Unstable coronary Syndromes; ISAR-COOL = Intracoronary Stenting with Antithrombotic Regimen COOLing-off study; RITA-3 = Third Randomized Intervention Treatment of Angina trial; RR = risk ratio; TIMI-18 = Thrombolysis In Myocardial Infarction-18; TRUCS = Treatment of Refractory Unstable angina in geographically isolated areas without Cardiac Surgery; VINO = Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: Open multicenter randomized trial.
idence of all-cause mortality at 2 years was 4.9% in the early invasive group compared with 6.5% in the conservative groups (RR 0.75, 95% CI 0.63 to 0.90, p = 0.001). Nonfatal MI (7.6% vs. 9.1%, respectively, RR 0.83, 95% CI 0.72 to 0.96, p = 0.012) and hospitalization (RR 0.69, 95% CI 0.65 to 0.74, p less than 0.0001) also were reduced. See the full-text guidelines for discussion of individual trials.

A. SUBGROUPS

caveats about the application of invasive and conservative strategies in several subgroups of interest, including women (Section VII.A), diabetics (Section VII.B), older patients (Section VII.D), and those with chronic kidney disease (Section VII.E), are addressed in Section VII. Patients with PCI within the previous 6 months and those with prior CABG represent subgroups for which coronary angiography without preceding functional testing is generally indicated.

Management decisions must account for extensive comorbidities, such as 1) advanced or metastatic malignancy with a limited life expectancy, 2) intracranial malignancy that contraindicates the use of systemic anticoagulation or causes severe cognitive or physical limitations, 3) end-stage cirrhosis, and 4) CAD that is known from previous angiography not to be amenable to revascularization.

5. Risk Stratification Before Discharge

A. GENERAL PRINCIPLES AND CARE OBJECTIVES

Important presedischARGE prognostication is derived from careful initial assessment, the patient’s hospital course, and response to anti-ischemic and anticoagulant therapy. Formal risk assessment tools, such as GRACE and TIMI, can be useful not only for in-hospital and short-term assessments but also for longer term (6-month) assessment of risk (Table 4, Fig. 3). Coronary angiography and revascularization represent powerful modifiers of risk and tools for prognostication. Cardiac biomarkers (i.e., troponins and BNP) add to the assessment of postdischarge and in-hospital risk. An assessment of LV function by any of several methods is generally recommended to guide therapy and assess prognosis. Noninvasive stress testing before or shortly after discharge also provides very useful supplemental information to clinically based risk assessment (Table 9).

The goals of noninvasive testing are to 1) determine the presence or absence of ischemia in patients with a low or intermediate likelihood of CAD and 2) estimate prognosis. A detailed discussion of noninvasive stress testing in CAD is presented in the ACC/AHA Guidelines for Exercise Testing, the ACC/AHA Guidelines for the Clinical Use of Cardiac Radionuclide Imaging, and the ACC/AHA Guidelines for the Clinical Application of Echocardiography (Table 9) (31,199–201). Noninvasive criteria for estimating risk as high, intermediate, or low are summarized in Table 9.

Stress echocardiography and nuclear ventriculography represent important alternatives. Myocardial perfusion imaging with pharmacological stress is particularly useful in patients who are unable to exercise. Cardiac magnetic resonance is a newer imaging modality that can effectively and simultaneously assess cardiac function, perfusion (i.e., with adenosine stress), and viability (202).

B. NONINVASIVE TEST SELECTION

There are no conclusive data comparing various noninvasive tests. Furthermore, prognostic information is largely extrapolated from studies in stable angina/chronic CAD populations. Hence, test selection may be based primarily on individual patient characteristics, physician judgment, and test expertise and availability (204). Low- and intermediate-risk patients may undergo symptom-limited stress testing if they have been clinically stable for 12 to 24 h. Earlier stress testing (i.e., within 3 to 7 d after UA/NSTEMI) is superior to later testing (i.e., at 1 month) (205) in that it identifies patients at risk for adverse events within the first month.

C. SELECTION FOR CORONARY ANGIOGRAPHY

Coronary angiography provides detailed structural information as the basis for assessing prognosis and directing management. When combined with LV angiography, it also

---

**Table 9. Noninvasive Risk Stratification**

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>High risk (greater than 3% annual mortality rate)</td>
<td>Severe resting LV dysfunction (LVEF less than 0.35)</td>
</tr>
<tr>
<td></td>
<td>High-risk treadmill score (score ≤ 11 or less)</td>
</tr>
<tr>
<td></td>
<td>Severe exercise LV dysfunction (exercise LVEF less than 0.35)</td>
</tr>
<tr>
<td></td>
<td>Stress-induced large perfusion defect (particularly if anterior)</td>
</tr>
<tr>
<td></td>
<td>Stress-induced multiple perfusion defects of moderate size</td>
</tr>
<tr>
<td></td>
<td>Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>Echocardiographic wall-motion abnormality (involving more than 2 segments) developing at low dose of dobutamine (10 mg per kg per min or less) or at a low heart rate (less than 120 beats per min)</td>
</tr>
<tr>
<td></td>
<td>Stress echocardiographic evidence of extensive ischemia</td>
</tr>
<tr>
<td>Intermediate risk (1% to 3% annual mortality rate)</td>
<td>Mild/moderate resting LV dysfunction (LVEF = 0.35 to 0.49)</td>
</tr>
<tr>
<td></td>
<td>Intermediate-risk treadmill score (≤ 11 to 5)</td>
</tr>
<tr>
<td></td>
<td>Stress-induced moderate perfusion defect without LV dilation or increased lung intake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>Limited stress echocardiographic ischemia with a wall-motion abnormality only at higher doses of dobutamine involving less than or equal to 2 segments</td>
</tr>
<tr>
<td>Low risk (less than 1% annual mortality rate)</td>
<td>Low-risk treadmill score (score 5 or greater)</td>
</tr>
<tr>
<td></td>
<td>Normal or small myocardial perfusion defect at rest or with stress*</td>
</tr>
<tr>
<td></td>
<td>Normal stress echocardiographic wall motion or no change of limited resting wall-motion abnormalities during stress*</td>
</tr>
</tbody>
</table>

*Although the published data are limited, patients with these findings will probably not be at low risk in the presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF less than 0.35). Reproduced from Table 23 in Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina). 2002. Available at: http://www.acc.org/qualityandscience/clinical/statements.htm (203).

LV = left ventricular; LVEF = left ventricular ejection fraction.
provides an assessment of global and regional LV function. Indications for coronary angiography are interwoven with indications for possible therapeutic plans such as PCI or CABG. In contemporary practice, many intermediate- and high-risk patients receive coronary angiography as part of an invasive management strategy. In addition, coronary angiography is usually indicated in other UA/NSTEMI patients who have either recurrent symptoms or ischemia despite adequate medical therapy or who develop high-risk features clinically (Tables 5 and 9) (205a).

V. Coronary Revascularization

A. General Principles and Care Objectives

As discussed in Section IV, coronary angiography is useful for defining the coronary artery anatomy in patients with UA/NSTEMI and for identifying subsets of high-risk patients who can benefit from early revascularization. Coronary revascularization (PCI or CABG) is performed to improve prognosis, relieve symptoms, prevent ischemic complications, and improve functional capacity. The indications for coronary revascularization in patients with UA/NSTEMI are similar to those for patients with chronic stable angina and are presented in greater detail in the ACC/AHA Guidelines for the Management of Patients With Chronic Stable Angina (31) and in the ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery (206) and the 2005 ACC/AHA/SCAI Guidelines Update for Percutaneous Coronary Intervention (5). These indications are tempered by individual patient characteristics. Selection criteria for coronary revascularization in patients with UA/NSTEMI are, in general, similar to those for patients with stable angina (122). Revascularization appears to be of most benefit when performed early in the hospital course, particularly in those with high-risk characteristics. See Figure 15 for details of the decision tree.

In recent years, stenting, other technological advances, and the use of improved antiplatelet and anticoagulant agents have improved the safety and durability of PCI in UA/NSTEMI. Stenting has reduced the risks of both acute vessel closure and late restenosis. Drug-eluting stents have reduced the risk of restenosis but modestly increase the risk of late coronary thrombotic events (129–131).

Published success rates of PCI in patients with UA/NSTEMI are high overall. Outcomes have approached those

---

Figure 15. Revascularization Strategy in UA/NSTEMI

*There is conflicting information about these patients. Most consider CABG to be preferable to PCI. CABG = coronary artery bypass graft; LAD = left anterior descending coronary artery; PCI = percutaneous coronary intervention UA/NSTEMI = unstable angina/non-ST-elevation myocardial infarction.
of elective surgery with the use of stents and potent antiplatelet therapy (207–209). The use of drug-eluting stents for UA/NSTEMI has increased dramatically in recent years, with favorable rates of early death and recurrent infarction (210).

1. Platelet Inhibitors and PCI

Glycoprotein IIb/IIIa receptor antagonists and thienopyridines represent important therapeutic advances in patients with UA/NSTEMI, particularly in the setting of PCI, as reviewed in Section IV.B. Key trials of these agents in the settings of PCI and UA/NSTEMI are summarized in Table 8. Only 1 comparative trial (TARGET: Do Tirofiban And ReoPro Give similar Efficacy Trial) directly compared these agents (tirofiban vs. abciximab) in patients undergoing PCI with intended stenting. An advantage of abciximab in preventing early ischemic events was observed among the subgroup presenting with UA/NSTEMI (211). An insufficient loading dose of tirofiban to achieve an optimal early (periprocedural) antiplatelet effect has been proposed as a possible explanation for this difference (212).

Whether GP IIb/IIIa inhibition is still useful in UA/NSTEMI patients undergoing PCI who have received a high loading dose (600 mg) of clopidogrel was raised by a study in an elective setting (ISAR-REACT) (213). To address this issue, ISAR-REACT 2 enrolled patients with UA/NSTEMI undergoing PCI, loaded them with clopidogrel 600 mg at least 2 h before the procedure, and then randomized them to receive either abciximab or placebo at the time of PCI (74). As discussed earlier, the primary end point of death, nonfatal reinfarction, or urgent target-vessel revascularization within 30 d was reduced by 25% in the abciximab group, an advantage limited entirely to patients with an elevated troponin level. These findings have been incorporated into the overall UA/NSTEMI treatment algorithm shown in Figures 6, 7, and 8.

Comparisons of PCI and CABG are summarized in the next section.

B. Surgical Revascularization

Dramatic changes in surgical technique and in medical and percutaneous therapies have occurred over the past 2 decades, limiting the implications of older trial results for contemporary practice. The Bypass Angioplasty Revascularization Investigation (BARI) trial, the largest randomized comparison of CABG and percutaneous transluminal coronary angioplasty (PTCA) in multivessel CAD (214, 215), observed a survival benefit with CABG that was confined to patients with diabetes mellitus. The Coronary Angioplasty versus Bypass Revascularization Investigation (CABRI) also showed a survival benefit for CABG in patients with diabetes and multivessel CAD (216). An Emory University study also was confirmatory (217). However, a CABG-related advantage was not reproduced in the BARI registry (218), which suggests that physicians might be able to recognize characteristics of CAD in diabetic patients that permits the safe selection of either revascularization therapy.

Hannan et al. (219) compared 3-year risk-adjusted survival rates in 29,646 CABG patients and 29,930 PTCA patients undergoing revascularization in the state of New York in 1993. Anatomic extent of disease was the only variable that interacted with revascularization therapy to influence survival. Patients with 1-vessel disease not involving the LAD had higher survival rates with PTCA, whereas patients with proximal LAD stenosis and 3-vessel disease had higher survival rates with CABG. A follow-up study using the same registry compared 37,212 patients who underwent CABG with 22,102 patients who underwent PCI using stents (220). The unanticipated finding was that the risk-adjusted long-term mortality of patients in all 5 anatomic subsets assessed was lower with CABG.

The most recent randomized comparisons of PCI and CABG surgery can be summarized as follows: The Angina With Extremely Serious Operative Mortality Evaluation (AWESOME) trial found comparable survival with CABG and PCI, which included stenting or atherectomy (221). Similarly, the ARTS trial (Arterial Revascularization Therapy Study), which compared coronary stenting with CABG (222) and which included but was not limited to patients with UA, found identical 3-year survival rates free of stroke and MI (222). A meta-analysis of 4 trials of CABG versus PCI with bare-metal stenting for multivessel disease between 1995 and 2000 also reported no difference in the primary composite end point of death, MI, and stroke or death alone between the CABG and the stent groups. None of these trials adequately reflect current interventional cardiology practice, which includes a broad use of drug-eluting stents, double- or triple-antiplatelet therapy, and newer anticoagulants. Surgical management also has evolved, and risk-adjusted mortality for CABG has declined progressively (223).

Nevertheless, when data from available trials and cohort studies are combined, these data suggest that it is reasonable to consider CABG to be a preferred revascularization strategy for most patients with 3-vessel disease, especially if it involves the proximal LAD, and for patients with multivessel disease and treated diabetes mellitus or LV dysfunction (Fig. 15). However, it would be unwise to deny contemporary PCI to a patient with diabetes mellitus and less severe CAD on the basis of the current information (224,225).

VI. Late Hospital Care, Hospital Discharge, and Post-Hospital Discharge Care

A. General Principles and Care Objectives

Two broad goals during the hospital discharge phase are 1) to prepare the patient for normal activities to the extent possible and 2) to use the acute event as an opportunity to reevaluate care, focusing on lifestyle and aggressive risk factor modification. Patients who have undergone successful PCI with an uncomplicated course are usually discharged...
the next day. Patients who undergo uncomplicated CABG generally are discharged 4 to 7 d later. Low-risk patients may be discharged soon after noninvasive testing or coronary angiography. Management of high-risk, unstable patients often requires more prolonged and vigilant inpatient care.

Inpatient oral anti-ischemic, antiplatelet, and other secondary preventive medications used in the nonintensive phase generally should be continued after discharge. A multidisciplinary team is ideal to prepare the patient for discharge.

1. Long-Term Medical Therapy

Patients with UA/NSTEMI require secondary prevention at discharge. The acute phase of UA/NSTEMI is usually over within 1 to 3 months, after which most patients assume a course of chronic CAD. Therefore, chronic secondary prevention measures are similar to those for other CAD patients (3,8,12,13,31) (see Section VI.C below). Recommendations for lipid lowering are fully discussed elsewhere (3,12,13).

B. Postdischarge Risk Assessment and Follow-Up

Patient-specific risk within 1 year can be predicted on the basis of clinical information and the ECG. The PURSUIT, TIMI, and GRACE risk models, introduced in Section III.B, are also useful for postdischarge risk assessment (see Fig. 3).

At discharge, detailed discharge instructions for post-UA/NSTEMI patients should include education on medications, diet, exercise, and smoking cessation (if appropriate); referral to a cardiac rehabilitation/secondary prevention program (when appropriate); and the scheduling of a timely follow-up appointment. Low-risk medically treated patients and revascularized patients should return in 2 to 6 weeks, and higher-risk patients should return within 14 d. When stable, typically by 1 to 3 months after discharge, patients may be followed up as for stable CAD.

Minimizing the risk of recurrent cardiovascular events requires optimizing patient compliance with prescribed therapies and recommended lifestyle modifications.

C. Risk Factor Modification

A health care team with expertise in aggressively managing CAD risk factors should work with patients and their families, including patients who have undergone revascularization (226), to educate them in detail regarding specific targets for LDL-C and HDL-C (3,12,13), blood pressure (6), diabetes mellitus, diet and weight management (12), physical activity (12), tobacco cessation (12), and other appropriate lifestyle modifications (226,228). There is a wealth of evidence that cholesterol-lowering therapy reduces vascular events in patients with CAD and hypercholesterolemia (229) or mild cholesterol elevation after MI (230,231). Indeed, there is mounting evidence that statin therapy is beneficial regardless of baseline LDL-C levels (232–234). More aggressive lipid lowering further lowers cardiovascular event rates and is safe, although the incremental impact on mortality over moderate lipid-lowering remains to be clearly established (235).

Data on the utility of ACE inhibitors in stable CAD in the absence of HF or LV dysfunction have been conflicting. A meta-analysis of 3 major trials (HOPE [Heart Outcomes Prevention Evaluation], EUROPA [EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease], and PEACE [Prevention of Events with Angiotensin Converting Enzyme Inhibition]) supports a benefit across the risk spectrum studied (236); however, the absolute benefit is proportional to disease-related risk, with those at lowest risk benefitting least (236,237). All patients with elevated systolic or diastolic blood pressures should be educated and motivated to achieve systolic and diastolic blood pressures in the normal range (i.e., less than 140/90 mm Hg; 130/80 mm Hg if the patient has diabetes or chronic kidney disease) (6,12).

For patients who smoke, tobacco cessation has substantial potential to improve survival (238). Physician counseling, referral to a smoking cessation program, and the use of pharmacological agents (239–242) are recommended (239).

Overweight patients should be instructed in a weight loss regimen, with emphasis on the importance of regular exercise and a lifelong prudent diet to maintain ideal body mass index.

Glycemic control is discussed in Section VII.B.

The use of NSAIDS and COX-2–selective inhibitors should be minimized in post-UA/NSTEMI patients because of an increase in cardiovascular risk (112,243,244). Cardiovascular risk associated with NSAID use may be lowest with naproxen, which has antiplatelet activity (111,243). An AHA scientific statement on the use of NSAIDS has recommended a stepped-care approach to musculoskeletal pain control to minimize risk (245).

Folic acid/B-vitamin supplementation given to reduce homocysteine levels did not reduce the risk of CAD events in 2 major trials (246,247), and its routine use for secondary prevention is not recommended. Antioxidant vitamins (C, E, beta carotene) also have not demonstrated benefit in secondary prevention and are not recommended (13).

See Section I.C.5.B for lipid lowering and other risk factor modification recommendations.

D. Physical Activity

Regular physical activity is important to improving functional capacity and well-being, losing weight and maintaining weight loss, and reducing other risk factors such as insulin resistance (248,249). Exercise training generally can begin within 1 to 2 weeks after revascularized UA/NSTEMI (249). Unsupervised exercise may target a heart rate range of 60% to 75% of maximum predicted; supervised training (see next section) may target a somewhat higher heart rate (70% to 85% of maximum) (249). Additional restrictions apply when residual ischemia is
preinfarction angina (258). Cardiac rehabilitation programs can contribute to return to work (260). Contemporary information on the impact of current aggressive intervention treatment of UA/NSTEMI, with shortened hospital length of stay and early rehabilitation, on return to work and disability is needed. In PAMI (Primary Angioplasty in Myocardial Infarction)-II, a study of primary PTCA in low-risk patients with MI, patients were encouraged to return to work at 2 weeks (261). Although the actual timing of return to work was not reported, no adverse events occurred as a result of this strategy.

G. Other Activities

Daily walking can be encouraged immediately in all patients. In stable patients without complications, sexual activity with the usual partner can be resumed within 1 week to 10 d. For stable patients, driving can begin 1 week after discharge if otherwise in compliance with state laws. After complicated MI, driving should be delayed until 2 to 3 weeks after symptoms have resolved. Air travel within the first 2 weeks of MI should be undertaken only if a patient has no angina, dyspnea, or hypoxemia at rest or fear of flying, flies with a companion, carries NTG, and avoids rushing and increased physical demands of travel. Low-risk patients with UA/NSTEMI who are revascularized and otherwise stable may accelerate their return to work, driving, flying, and other normal activities (often, within a few days).

H. Patient Records and Other Information Systems

Effective medical record systems, including electronic systems, that document the course and plan of care should be established or enhanced. Tools such as the ACC’s “Guidelines Applied in Practice” and the AHA’s “Get With the Guidelines” can improve quality of care and patient safety. Reliable health care information relevant to UA/NSTEMI patients is available, and patient access to it should be encouraged (http://www.heartauthority.com; http://www.nhlbi.nih.gov/health/dci/index.html; http://www.nlm.nih.gov/medlineplus/tutorial.html; http://www.fda.gov/hearthealth/index.html).

VII. Special Groups

A. Women

1. Profile of UA/NSTEMI in Women

Women present at an older age but account for a considerable proportion of UA/NSTEMI. Women are more likely to have hypertension, diabetes mellitus, and HF with preserved systolic function; to manifest UA rather than NSTEMI; to have atypical symptoms (e.g., primarily dyspnea); and to have causes unrelated to CAD (22,32,262–265,266) Women have similar rates of ST depression but less often have elevated biomarkers (267). Nevertheless, the prognostic value of elevated biomarkers is similar in women and men (268). Coronary angiography reveals less extensive CAD in women and a higher proportion (as high as 37%) with nonobstructive CAD (262,269). This profile makes it challenging to confirm the diagnosis of UA/NSTEMI and is a likely cause of underutilization or overtreatment of therapies in women (267). Unlike STEMI, female sex is not a risk factor for adverse outcomes for UA/NSTEMI when adjusted for baseline characteristics (22,203,267,270–277).

2. Stress Testing

Indications for noninvasive testing in women are the same as in men (203,270). Exercise ECG testing is less predictive in women, however, primarily because of the lower pretest probability of CAD (271–273). Perfusion studies with sestamibi have good sensitivity and specificity in women.
(275). The Duke Treadmill Score performs well in women for the exclusion of CAD (276).

3. Management

A. Pharmacological Therapy

Women derive the same treatment benefit as men from ASA, clopidogrel, anticoagulants, beta blockers, ACE inhibitors, and statins, but they are given ASA and other anticoagulant less frequently (278). A meta-analysis of GP IIb/IIIa antagonists in UA/NSTEMI reported an apparent lack of efficacy and possible harm in women (187); however, women with elevated troponin levels received the same beneficial effect as men. Higher rates of dosing errors and subsequent bleeding with antiplatelet and anticoagulant therapy have been reported for women than for men (279). Creatinine clearance (Cockroft-Gault formula) and weight-based adjustments of medications, where recommended, can reduce this risk.

B. Coronary Artery Revascularization

Angiographic success and late outcomes after PCI for women, including those presenting with UA/NSTEMI, have improved and are generally similar to men, although in some series, early complications occurred more frequently in women (264,280,281). Similarly, more recent studies show a favorable outlook for women with ACS undergoing CABG (262,282,282a).

C. Initial Invasive Versus Initial Conservative Strategy

Clinical trials of UA/NSTEMI have consistently demonstrated a benefit with an invasive strategy for men (see Section IV.C), but results in women have been conflicting. A meta-analysis of trials in the era of stents and GP IIb/IIIa antagonists has failed to show a survival benefit of a direct invasive strategy in women at 6 to 12 months (OR for women 1.07, 95% CI 0.82 to 1.41; OR for men 0.68, 95% CI 0.57 to 0.81) (283). In TACTICS (Treat Angina with Aggrastat and determination Cost of Therapy with Invasive or Conservative Strategy) TIMI-18, there was a reduction in the composite risk of death, nonfatal MI, or rehospitalization for UA in women with intermediate (3 to 4) or high (5 to 7) TIMI risk scores undergoing an early invasive strategy that was similar to that in men (284). In contrast, women with a low TIMI risk score had an increased risk of events (OR 1.59, 95% CI 0.69 to 3.67) with the invasive versus the conservative strategy, whereas low-risk men had similar outcomes with the 2 strategies. However, the number of events was small (n = 26 events), and the probability value for interaction did not achieve significance (p = 0.09). Similarly, women with an elevated troponin T benefited from an invasive strategy (adjusted OR 0.47, 95% CI 0.26 to 0.83), whereas the primary end point was significantly more frequent in women (but not men) treated invasively with a negative troponin (OR 1.46, 95% CI 0.78 to 2.72) (284). The FRISC II (197) and RITA-3 (196,269,285) randomized trials reported improved outcomes with an invasive strategy only in men, but a high percentage of women were low risk, and an assessment of outcomes by risk or troponin status has not been reported.

In summary, women with UA/NSTEMI and high-risk features, including elevated cardiac biomarkers, appear to benefit from an invasive strategy with adjunctive GP IIb/IIIa antagonist use, although more data are needed. There is no benefit of a direct invasive strategy for low-risk women, and the weight of evidence suggests that there may be excess risk in this group, for which a conservative strategy is recommended.

B. Diabetes Mellitus

1. Profile and Initial Management of Diabetic and Hyperglycemic Patients With UA/NSTEMI

Coronary artery disease accounts for 75% of deaths in patients with diabetes, and approximately 20% to 25% of patients with UA/NSTEMI have diabetes mellitus (215,286). Diabetic patients with UA/NSTEMI have more severe CAD (286–288), more ulcerated plaques and intracoronary thrombi (289), more vascular comorbidities, and are more often post-CABG patients (290). Diabetic autonomic dysfunction raises the threshold for the perception of angina, which confounds the diagnosis of UA/NSTEMI (291). Importantly, diabetes mellitus is an independent predictor of death, MI, or readmission with UA (292).

Glucose level on admission to the hospital is a significant predictor of 1-year mortality (293); however, the optimal approach to managing hyperglycemia remains uncertain (294–296). Pending additional trials that include ACS patients, a reasonable approach may be to target a blood glucose goal of less than 150 mg per dL during the first 3 d in the intensive care unit/critical care unit in very ill patients (e.g., those with ventilators or on parenteral feeding) (297). Thereafter, or in less ill patients, a more intensive insulin regimen could be instituted, with a goal of normoglycemia (80 to 110 mg per dL).

2. Coronary Revascularization

An advantage for CABG over PTCA was found in treated patients with diabetes mellitus in the randomized BARI (286), CABRI (216), and Emory University trials (217), as discussed in Section V.C. Specifically, mortality was lower in patients who received internal thoracic artery grafts. However, a CABG-related advantage was not reproduced in the BARI registry population (218), which suggests that physicians might be able to recognize characteristics of CAD in diabetic patients that permit the safe selection of either revascularization therapy. Similarly, in the Duke University registry study, although outcome was worse in diabetic patients, there was no differential effect of PCI versus CABG (298).

Stents have improved the outcome of patients with diabetes mellitus who undergo PCI. In a study with histor-
tical controls, the outcome after coronary stenting was superior to that after PTCA, and the restenosis rate was reduced (63% vs. 36%), diabetes vs. no diabetes, with balloon PTCA at 6 months \( p = 0.0002 \) compared with 25% and 27% with stents \( p = NS \) (299). Nevertheless, “BARI-like” comparisons of long-term survival after PCI with frequent stenting versus CAGB have reported better risk-adjusted long-term survival in diabetic subgroups with 3-vessel disease treated with CAGB (300).

Glycoprotein IIb/IIIa antagonists improve the outcome of PCI in patients with diabetes mellitus. In the Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa receptor blockade (EPICLOG), abciximab resulted in a greater decline in death/MI over 6 months after PCI in patients with diabetes mellitus (HR 0.36, 95% CI 0.21 to 0.61) than in those without diabetes (HR 0.60, 95% CI 0.44 to 0.829) (301). A similar differential benefit in diabetic patients has been reported for tirofiban (225). In the Evaluation of IIb/IIIa Platelet Inhibitor for STENTing (EPISTENT) trial, which studied 2,399 patients, 21% with diabetes and 20% with UA (178), abciximab reduced the 30-d event rate (death, MI, or urgent revascularization) in diabetic patients from 12.1% (stent plus placebo) to 5.6% (stent plus abciximab; \( p = 0.040 \)). At 6 months, revascularization of target arteries was reduced by more than 50% (16.6% vs. 8.1%, \( p = 0.02 \)). Death or MI was reduced to a similar degree in diabetic and nondiabetic patients (303), and benefits were maintained at 1 year (304).

Data on outcomes in diabetic patients with the contemporary use of drug-eluting stents, GP IIb/IIIa inhibitors, and long-term clopidogrel are limited. However, given the diffuse nature of diabetic CAD, the relative benefits of CAGB over PCI may persist for diabetic patients, even in the era of drug-eluting stents.

**C. Post-CABG Patients**

Overall, up to 20% of patients presenting with UA/NSTEMI have previously undergone CAGB (290). Conversely, approximately 20% of post-CABG patients develop UA/NSTEMI during an interval of 7.5 years (305). Post-CABG patients who present with UA/NSTEMI are at higher risk than those who have not undergone surgery.

1. **Pathological Findings**

Pathologically, post-CABG patients have a particular tendency for atherosclerotic and thrombotic lesions to develop in SVGs, as well as native-vessel progression, which can lead to UA/NSTEMI (306). Angiographically, SVGs more frequently have friable plaques, complex lesions, thrombi, and total occlusions than native vessels (307). Approximately 50% of SVGs develop obstructive lesions within 5 years and more than 90% at greater than 10 years (307), and there is a high rate of early graft failure in current practice (occlusion in up to one third at 1 year). Thus, SVG disease is a serious and unstable process.

2. **Clinical Findings and Approach**

Post-CABG patients are more frequently male, older, and diabetic; have more extensive CAD; and have more prior MIs and LV dysfunction than non-CABG patients presenting with UA/NSTEMI. Resting ECG abnormalities often limit the utility of ECG stress testing, but myocardial stress perfusion imaging or dobutamine echocardiography can help to identify and define areas of ischemia. Given complex disease with many anatomic possibilities that cause ischemia, there should be a low threshold for angiography in post-CABG patients with UA/NSTEMI.

Revascularization with either PCI or reoperation may be considered in post-CABG patients with UA/NSTEMI on the basis of individual characteristics. Stents are generally preferred to balloon angioplasty of SVGs (308). When possible, PCI of a native vessel is preferred to PCI of an SVG. Embolization of friable atherosclerotic can increase the risk of PCI-related complications (309). Despite relatively similar early outcomes, post-CABG patients experience up to twice the incidence of adverse events (death, MI, or recurrent UA) during the first year, which is attributable, at least in part, to a lower rate of complete revascularization (305,310).

**D. Older Adults**

The terms “elderly” or “older adults” are often used to refer to those aged 75 years and older. Older adults account for more than one-third of UA/NSTEMI patients (311) and present with special challenges. First, they more often present with atypical symptoms, including dyspnea and confusion (312). Second, they are more likely to have altered cardiovascular physiology, including hypertension or hypotension, cardiac hypertrophy, and HF and LV dysfunction, especially diastolic dysfunction (313), and they more frequently have other cardiac comorbidities. Third, older patients tend to be treated with a greater number of medications, have reduced renal function, and are at greater risk for adverse drug interactions. Hence, older age is associated with both higher disease severity and greater treatment risk (311).

1. **Pharmacological Management**

Overall, older subgroups in clinical trials have relative or absolute risk reductions that are relatively similar to those of younger patients for many commonly used treatments for UA/NSTEMI. Despite this, older patients less often receive an early invasive strategy and key pharmacotherapies, including anticoagulants, beta blockers, clopidogrel, and GP IIb/IIIa inhibitors (44,311,314). With this said, proper drug selection and dose adjustment are needed to account for altered drug metabolism, distribution, and elimination, as well as exaggerated drug effects. In a community-based registry, 38% of UA/NSTEMI patients aged 75 years or older received an excessive dose of UFH, 17% received excessive LMWH, and 65%
received an excessive dose of a GP IIb/IIIa antagonist (311); 15% of major bleeding could be attributed to excess dosing (279). Mortality and length of stay were greater with excessive dosing. Altered pharmacodynamic responses to drugs also result from lower cardiac output, plasma volume, and vasomotor tone and responsiveness.

2. Functional Studies

Older persons often have difficulty performing exercise testing and have a higher prevalence of preexisting ECG abnormalities. In such patients, pharmacological stress testing with cardiac imaging can be useful.

3. Contemporary Revascularization Strategies in Older Patients

Experience has shown that coronary stenting can be performed in older patients with high procedural success and acceptably low complication rates (315). Similarly, an invasive strategy in UA/NSTEMI can benefit older patients with UA/NSTEMI. In the TACTICS TIMI-18 trial (316), the early invasive strategy conferred an absolute reduction in total ischemic events of 10.8 percentage points and a relative risk reduction of 50% (10.8% vs. 21.6%; p = 0.016) in patients older than 75 years. Benefits came with an increased risk of major bleeding events (16.6% vs. 6.5%; p = 0.009). Thus, selection of older patients for an early invasive strategy remains challenging and requires clinical judgment and individual application; however, age alone should not preclude the use of a PCI-based strategy.

Operative morbidity and mortality rates also increase for CABG with advanced age, but outcomes have progressively improved and are favorable compared with medical therapy; quality of life improves as well (317). A contemporary review of 662,033 patients enrolled in the Society of Thoracic Surgeons National Cardiac Database (318) found a CABG operative mortality rate of 2.8% for patients 50 to 79 years of age, 7.1% for patients 80 to 89 years of age, and 11.8% for patients aged 90 years or greater. Risk was lower in the absence of certain factors (renal failure, emergency surgery, and noncoronary vascular disease). Thus, with appropriate selection, CABG surgery can be an appropriate revascularization strategy, even in the oldest patient subgroups.

E. Chronic Kidney Disease

Chronic kidney disease is a potent risk factor for cardiovascular disease and qualifies as a coronary risk equivalent (319). Chronic kidney disease is also a risk factor for adverse outcomes after MI, including NSTEMI (47,320,321). Of concern, however, is the underrepresentation of patients with renal disease in randomized controlled trials (322). Limited evidence and current opinion suggest that when appropriately monitored, cardiovascular medications and interventional strategies can be safely applied to these patients (320). However, bleeding risk is higher because of platelet dysfunction and dosing errors (279). Renin-angiotensin-aldosterone inhibitors can impose a greater risk of hyperkalemia and worsening renal function. Angiography carries an increased risk of contrast-induced nephropathy, and PCI is associated with a higher rate of early and late complications (322). Thus, chronic kidney disease carries a far worse prognosis, but unlike in several other high-risk subsets, the value of aggressive therapeutic interventions is less certain and should be further studied.

In patients with chronic kidney disease or chronic kidney disease and diabetes mellitus who are undergoing angiography, isosmolar contrast material has been shown to lessen the rise in creatinine: It reduced the risk of contrast-induced nephropathy in both a randomized clinical trial (RECOVER [Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography]) comparing iodixanol with ioxaglate (323) and a meta-analysis of 2,727 patients from 16 randomized clinical trials (324).

An assessment of renal function is critical to proper medical therapy of UA/NSTEMI. Many cardiovascular drugs used in UA/NSTEMI patients are renally cleared; their doses should be adjusted for estimated creatinine clearance. Clinical studies and labeling that defines adjustments for several of these drugs have been based on the Cockcroft-Gault formula for estimating creatinine clearance, which should be used to generate dose adjustments.

F. Cocaine and Methamphetamine Users

The widespread use of cocaine and, more recently, methamphetamines and their known association with UA/NSTEMI makes it mandatory to consider these drugs as a potential cause of UA/NSTEMI, because pathophysiology and therapy for these drugs are distinctive.

1. Pathophysiology and Presentation

The potential of cocaine to induce coronary spasm has been demonstrated both in vitro (325) and in vivo (326–328). Treatment with calcium antagonists inhibits or reverses cocaine-induced vasconstriction (328,329). Cocaine also increases platelet responsiveness and reduces anticoagulant factors, which predisposes the individual to coronary thrombosis (326,330).

Cocaine users can develop chest discomfort that is indistinguishable from UA/NSTEMI secondary to coronary atherosclerosis. Thus, UA/NSTEMI patients should be questioned about the use of cocaine and methamphetamines (331).

2. Treatment

Initial management of cocaine-induced ACS should include sublingual NTG and a calcium antagonist (e.g., diltiazem 20 mg IV) (326,332). If ST-segment elevation is present and the patient is unresponsive to initial treatment, immediate coronary angiography is preferred over fibrinolytic therapy. After cocaine use, increased motor activity causing CK and CK-MB
elevations can occur in the absence of MI (333); hence, troponin levels should be used to assess myocardial injury. The use of beta blockers for cocaine-induced ischemia is controversial (334). If used, labetalol, an alpha and beta blocker, has been advocated, because it has been shown not to induce coronary artery vasospasm (335). However, NTG and calcium antagonists are preferred (332,334). Cocaine users with possible/probable UA/NSTEMI should be observed and managed medically for 9 to 24 h. Thereafter, if the ECG and biomarkers are normal and the patient is stable, the patient can be discharged (336).

3. Methamphetamine Use and UA/NSTEMI

Although methamphetamine abuse has increased dramatically, the evidence base for UA/NSTEMI after methamphetamine use and its treatment is limited to a few publications of case reports and small series (337–339). These suggest a clinical presentation that resembles cocaine-associated ACS. Therapy similar to that for cocaine-induced UA/NSTEMI is reasonable pending information more specific to methamphetamine use.

G. Variant (Prinzmetal’s) Angina

Variant angina (Prinzmetal’s angina, periodic angina) is an unusual form of UA that usually occurs spontaneously, is classically characterized by transient ST-segment elevation, and spontaneously resolves or resolves with NTG use, usually without progression to MI.

1. Clinical Picture, Pathogenesis, and Diagnosis

Anginal discomfort usually occurs at rest, simulating UA/NSTEMI. Attacks can be precipitated by emotional stress, hyperventilation, exercise, or exposure to cold and occur more frequently in the early morning. Patients with variant angina are generally younger and, except for smoking, have fewer coronary risk factors (340,341). Occasionally, prolonged vasospasm can result in MI, ativoventricular block, ventricular tachycardia, or sudden death (342,343).

The cause of variant angina is epicardial coronary artery spasm, most commonly focal but potentially at more than 1 site (344). ST-segment elevation implies transmural ischemia associated with complete or near-complete coronary occlusion. These sites can be angiographically normal (presumably with endothelial dysfunction or inapparent plaques) (345) or may show nonobstructive or obstructive CAD (346). The key to diagnosis is the documentation of transient ST-segment elevation during chest discomfort. Both noninvasive tests (ambulatory ECG recording, morning treadmill exercise) and coronary angiography (which can include pharmacological provocation) can be useful in diagnosis.

2. Treatment and Prognosis

Variant angina is usually responsive to NTG, long-acting nitrates, and calcium antagonists (347–349), which are considered first-line therapies. (Beta blockers have theoretical adverse potential, and their clinical effect is controversial.) Smoking should be discontinued. Patients with very active disease can require a combination of nitrates and 2 calcium antagonists of different classes (i.e., a dihydropyridine with verapamil or diltiazem). Alpha-receptor blockers may be tried in resistant patients (350). Coronary spasm (with or without provocation) that occurs during coronary angiography should be treated with 0.3 mg of NTG infused directly into the coronary artery involved. Prognosis with medical therapy is usually good in the presence of a normal or near-normal coronary arteriogram (351) but is worse in the presence of CAD (352).

H. Cardiovascular “Syndrome X”

1. Definition and Clinical Picture

Cardiovascular “syndrome X” refers to with a syndrome of angina or angina-like discomfort with exercise, ST-segment depression on exercise testing or other objective signs of ischemia (353), and normal or nonobstructed coronary arteries on arteriography (354). Syndrome X is more common in women than in men (354–357). Chest discomfort can be typical or atypical (356), may occur with activity or at rest, and may or may not respond to NTG (358). Prolonged episodes can simulate UA/NSTEMI. The cause of syndrome X is not well understood but has been postulated to involve microvascular dysfunction and/or abnormal pain perception (359,360). Recent data from the Women’s Ischemia Syndrome Evaluation (WISE) (361,362) suggest that long-term prognosis might not be as benign as previously thought: Women with no or minimal obstructive disease had a 9.4% occurrence of MI or death by 4 years.

2. Treatment

Persistence of symptoms is common, and many patients do not return to work (358). The demonstration of normal coronary arteries on angiography can be reassuring. Beta blockers and calcium antagonists can reduce the number of episodes of chest discomfort (363,364). Nitrates are effective in one-half of patients. Imipramine 50 mg daily can benefit patients with chronic pain syndromes, including syndrome X (365). Estrogen in postmenopausal women can reduce the frequency of chest pain episodes (366) but can increase cardiovascular risk. Statin therapy and exercise training can improve exercise capacity, endothelial function, and symptoms (367,368). Cognitive behavioral therapy can be beneficial (369). Other causes of chest discomfort, especially esophageal dysmotility, should be ruled out. Coronary risk factor reduction is appropriate, especially if even minimal CAD is present. Transcutaneous electrical nerve stimulation and spinal cord stimulation have been used for pain control in highly symptomatic, refractory cases (370).
APPENDIX 1. RELATIONSHIPS WITH INDUSTRY—ACC/AHA COMMITTEE TO UPDATE THE 2002 GUIDELINES FOR
THE MANAGEMENT OF PATIENTS WITH UNSTABLE ANGINA/NON–ST-ELEVATION MYOCARDIAL INFARCTION

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Research Grant</th>
<th>Speaker’s Bureau</th>
<th>Stock Ownership</th>
<th>Consultant,/Advisory Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cynthia D. Adams</td>
<td>None</td>
<td>GlaxoSmithKline</td>
<td>None</td>
<td>CHF Technologies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guidant</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medtronic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffery L. Anderson</td>
<td>AstraZeneca, Bristol-Myers Squibb</td>
<td>Merck</td>
<td>Bristol-Myers Squibb, Merck, Sanofi, ThromboVision</td>
<td></td>
</tr>
<tr>
<td>Elliott M. Antman</td>
<td>Accumetrics, Amgen, AstraZeneca, Bayer Healthcare LLC, Biosite, Boehringer Mannheim, Beckman Coulter, Bristol-Myers Squibb, Centocor, CV Therapeutics, Dade, Dendrion, Eli Lilly, Genentech, GlaxoSmithKline, Inotek Pharmaceuticals Corp., Integrated Therapeutics Corp., Merck, Millennium, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics GmbH, Sanofi-Aventis Research Institute, Sanofi-Synthelabo Recherche, Schering-Plough, Sunovis Molecular, The National Institutes of Health</td>
<td>None</td>
<td>None</td>
<td>Eli Lilly, Sanofi-Aventis</td>
</tr>
<tr>
<td>Charles R. Bridges</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Committee Member</td>
<td>Research Grant</td>
<td>Speaker’s Bureau</td>
<td>Stock Ownership</td>
<td>Consultant/Advisory Member</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Robert M. Califf</td>
<td>Abbott Laboratories</td>
<td>Bristol-Myers Squibb</td>
<td>NITROX</td>
<td>Conceptis</td>
</tr>
<tr>
<td></td>
<td>Abbott Vascular Devices</td>
<td>Conceptis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acorn Cardiovascular</td>
<td>Guilford Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Actelion</td>
<td>Novartis Pharmaceutical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acusphere, Inc</td>
<td>Pfizer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advanced CV Systems</td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advanced Stent Tech</td>
<td>Schering-Plough</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Agilent Technologies</td>
<td>The Medicines Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ajinomoto</td>
<td>Yamanouchi</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alexion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Allergan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alsius</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amgen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amylin Pharmaceuticals Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anadys</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ANGES MG, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arglionx Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ark Therapeutics, Ltd.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aventis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aviron Flu Mist</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer AG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer Corp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Berlex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biocompatibles, Ltd.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biogen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bioheart</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biomarin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biosense Webster, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biosite</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biotronik</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biotechnology General Corp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boehringer Ingleheim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Boston Scientific</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bracco Diagnostics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CanAm Bioresearch, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiac Science, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cardiodynamics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CardioKinetics, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Caro Research</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Committee Member</td>
<td>Research Grant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert M. Califf (continued)</td>
<td>Celsion Corp.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Centocor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chase Medical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chugai Biopharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coley Pharma Group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conor Medsystems, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corautus Genetics, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cordis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corgentech</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Covalent Group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Critical Therapeutics, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CryoVascular Systems, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CTS Durham</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cubist Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CV Therapeutics, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dade Behring</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dalichi</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dupont</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dyax</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Echosens, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eclipse Surgical Technologies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Edwards Lifesciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enzon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ernst and Young</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Esai</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ev3, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evolve, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Circle Medical, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>First Horizon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flow Cardia, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fox Hollow Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fujisawa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genentech</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Electric Healthcare</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>General Electric Medical Systems</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genome Canada</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genzyme Corporation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilead</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guidant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guilford Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemosol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hewlett Packard</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Human Genome Sciences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Humana</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IDB Medical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Idun Pharmaceuticals, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Indenix Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INFOMD, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>InfrareDx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Inhibitex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INO Therapeutics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Integris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>InterMune Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISIS Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IOMED</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Johnson &amp; Johnson</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jomed, Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>KAI Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kerberos Proximal Inc.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>King Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kuhera</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lilly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lumen Biomedical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MedAcoustics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medco Health Solutions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Committee Member</td>
<td>Research Grant</td>
<td>Speaker’s Bureau</td>
<td>Stock Ownership</td>
<td>Consultant/Advisory Member</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------</td>
<td>------------------</td>
<td>----------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Robert M. Califf</td>
<td><strong>Medicare</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(continued)</td>
<td><strong>MediFlex, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Medimmune</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Medtronic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Medtronic Vascular, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Merck</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>MicroMed Tech, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Millenium Pharmaceutical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mitsubishi</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mycosol, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Myogen</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NABI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NitroMed</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>NovaCardia, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Novartis AG Group</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Novartis Pharmaceutical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Organon International</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ortho Biotech</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Osiris Therapeutics, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Otsuka America Pharmaceutical, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pathway Medical Tech</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pfizer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pharmacia/Upjohn</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pharmanetics, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pharsight</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Procter &amp; Gamble</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Prometheus</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Recem Managed Systems</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Regado Biosciences, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Roche Diagnostic Corp.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Roche Holdings, Ltd.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Roche Labs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Salix Pharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sanofi Pasteur</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sanofi-Aventis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sanofi-Synthelabo</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Schering-Plough</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Scios</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Searle</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sicel Technologies</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Siemens</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SmithKlineBeecham</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Spectranetics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Summit</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sunetis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synaptic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Synthetic Blood International</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Terumo Corp</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>The Medicines Company</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Theravance</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TherOx, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Titan Pharmaceuticals, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Valentis Pharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Valentis, Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Velomed</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Veridex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Vertex Pharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>VIAVSYS Healthcare Inc.</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Vicuron Pharmaceutical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Wyeth-Ayerst</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>XOMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Xsira Pharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>XTL Biopharmaceuticals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Xylum</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Yamanouchi</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Committee Member</td>
<td>Research Grant</td>
<td>Speaker’s Bureau</td>
<td>Stock Ownership</td>
<td>Consultant/Advisory Member</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
<td>------------------</td>
<td>----------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Donald E. Casey, Jr.</td>
<td>None</td>
<td>None</td>
<td>• Johnson &amp; Johnson</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Merck</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Pfizer</td>
<td></td>
</tr>
<tr>
<td>William E. Chavey II</td>
<td>None</td>
<td>NitroMed</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Francis M. Fesmire</td>
<td></td>
<td>Millenium</td>
<td>None</td>
<td>• CRUSADE</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Daidle</td>
<td></td>
</tr>
<tr>
<td>Judith S. Hochman</td>
<td></td>
<td></td>
<td>Network for Continuing Medical Education (supported by Bristol-Myers Squibb/Sanofi)</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Eli Lilly</td>
<td>• Dataspex</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Millennium</td>
<td>• Eli Lilly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Procter &amp; Gamble</td>
<td>• GlaxoSmithKline</td>
</tr>
<tr>
<td>Thomas N. Levin</td>
<td>None</td>
<td></td>
<td>• Bristol-Myers Squibb/Sanofi</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Foxhollow</td>
<td>• Johnson &amp; Johnson</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Schering-Plough</td>
<td>• Medtronic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pfizer</td>
</tr>
<tr>
<td>A. Michael Lincoff</td>
<td>• Alexion Pharm*</td>
<td>• The Medicines Company*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>• Amer Bioscience*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• AstraZeneca*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Atherogenics*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Biosite*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Centocor*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Converge Medical*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Cordis*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dr. Reddy’s Laboratory*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Eli Lilly*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• GlaxoSmithKline*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glaxo Wellcome*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Guilford*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Medtronic*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Novartis*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pfizer*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Pharmacia Upjohn*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Philips*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Orphan Therapeutic*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sankyo*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sanofi*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Scios*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Takeda America*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The Medicines Company*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Vasogenix*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eric D. Peterson</td>
<td>• Bristol-Myers Squibb/Sanofi</td>
<td>• Millennium Pharmaceuticals</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>• Millennium Pharmaceuticals</td>
<td>Schering-Plough</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pierre Theroux</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>• AstraZeneca</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Sanofi-Aventis</td>
<td></td>
<td>• Boston Scientific</td>
<td>• Proctor &amp; Gamble</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Cardiovascular Therapeutics</td>
<td>• Sanofi-Aventis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Therapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Medtronic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Merck</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Procter &amp; Gamble</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Sanofi-Aventis</td>
<td></td>
</tr>
<tr>
<td>Committee Member</td>
<td>Research Grant</td>
<td>Speaker’s Bureau</td>
<td>Stock Ownership</td>
<td>Consultant/ Advisory Member</td>
</tr>
<tr>
<td>------------------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>----------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Nanette Kass Wenger</td>
<td>• Pfizer</td>
<td>• Bristol-Myers Squibb</td>
<td>None</td>
<td>• Abbott</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CV Therapeutics</td>
<td></td>
<td>• AstraZeneca AB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Eli Lilly</td>
<td></td>
<td>• Bristol Myers Squibb</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Merck</td>
<td></td>
<td>• CV Therapeutics*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• NitroMed</td>
<td></td>
<td>• GlaxoSmithKline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Novartis</td>
<td></td>
<td>• NitroMed Heart Failure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer</td>
<td></td>
<td>Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Sanofi-Aventis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Schering-Plough</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>R. Scott Wright</td>
<td>• Centocor*</td>
<td>None</td>
<td>None</td>
<td>• Merck/Schering-Plough</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Novartis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Pfizer</td>
</tr>
</tbody>
</table>

This table represents the actual or potential relationships with industry that were reported as of February 13, 2007. This table was updated in conjunction with all meetings and conference calls of the writing committee. *Indicates significant (greater than $10,000) relationship.

APPENDIX 2. RELATIONSHIPS WITH INDUSTRY—EXTERNAL PEER REVIEW FOR THE ACC/AHA COMMITTEE TO UPDATE THE 2002 GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH UNSTABLE ANGINA/NON–ST-ELEVATION MYOCARDIAL INFARCTION

<table>
<thead>
<tr>
<th>Peer Reviewer*</th>
<th>Representation</th>
<th>Consulting Fees/ Honoraria</th>
<th>Speaker’s Bureau</th>
<th>Ownership/ Partnership/ Principal</th>
<th>Research Grants</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eugene Braunwald</td>
<td>• Official</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>AccuMetrics, Inc.†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bayer Healthcare</td>
<td></td>
<td></td>
<td>AstraZeneca†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Daidichi Sankyo</td>
<td></td>
<td></td>
<td>Bayer Healthcare†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Merck and Co.</td>
<td></td>
<td></td>
<td>Beckman Coulter†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Momenta</td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer</td>
<td></td>
<td></td>
<td>CV Therapeutics†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sanofi-Aventis</td>
<td></td>
<td></td>
<td>Eli Lilly†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Schering-Plough</td>
<td></td>
<td></td>
<td>Inotek Pharmaceuticals†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Scios†</td>
<td></td>
<td></td>
<td>Johnson &amp; Johnson†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Merck and Co.†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>National Institutes of Health†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Novartis†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nuucid†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Roche Diagnostics†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi-Aventis†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schering-Plough†</td>
<td></td>
</tr>
<tr>
<td>Bernard Gersh</td>
<td>• Official–AHA</td>
<td>• Abbott</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Asanorycyle Inc</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• AstraZeneca</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Boston Scientific</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cardiovascular Therapeutics†</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

Downloaded from http://circ.ahajournals.org/ by guest on August 16, 2017
<table>
<thead>
<tr>
<th>Peer Reviewer*</th>
<th>Representation</th>
<th>Consulting Fees/ Honoraria</th>
<th>Speaker’s Bureau</th>
<th>Ownership/ Partnership/ Principal</th>
<th>Research Grants</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Granger</td>
<td>• Official–AHA</td>
<td>• AstraZeneca†</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• GlaxoSmithKline†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Medicores Co.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sanofi-Aventis†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>David Holmes</td>
<td>• Official–ACC Board of Trustees</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Kristen Newby</td>
<td>• Official–AHA</td>
<td>• Biosite</td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• CV Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Eli Lilly</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Inverness Medical</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Procter &amp; Gamble</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rick Nishimura</td>
<td>• Official–ACC Lead Task Force Reviewer</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Eugene Sherman</td>
<td>• Official–ACC Board of Governors</td>
<td>None</td>
<td></td>
<td>• Abbott</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• GlaxoSmithKline</td>
<td></td>
<td>• Novartis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sanofi-Aventis</td>
<td></td>
<td>• Takeba</td>
<td></td>
<td></td>
</tr>
<tr>
<td>William Brady</td>
<td>• Organizational–American College of Emergency Physicians</td>
<td>• Heartscape</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Medicolegal Review</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deborah Diercks</td>
<td>• Organizational–American College of Emergency Physicians</td>
<td>• Astellas</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Inovise Technology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Medicines Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Sanofi-Aventis†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lakshimi Halasyamani</td>
<td>• Organizational–American College of Physicians‡</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Robert Higgins</td>
<td>• Organizational–Society of Thoracic Surgeons‡</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Morton Kern</td>
<td>• Organizational–Society for Cardiovascular Angiography and Interventions and ACC/AHA/SCAI PCI Guidelines Writing Committee‡</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Marjorie King</td>
<td>• Organizational–American Association of Cardiovascular and Pulmonary Rehabilitation‡</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peer Reviewer*</td>
<td>Representation</td>
<td>Consulting Fees/Honoraria</td>
<td>Speaker’s Bureau</td>
<td>Ownership/Partnership/Principal</td>
<td>Research Grants</td>
<td>Salary</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>--------------------------</td>
<td>-----------------</td>
<td>-------------------------------</td>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>Michael Lim</td>
<td>● Organizational–Society for Cardiovascular Angiography and Interventions‡</td>
<td>None</td>
<td>● Bristol-Myers Squibb</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Walter Merrill</td>
<td>● Organizational–Society of Thoracic Surgeons‡</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Charles Pollack</td>
<td>● Organizational–Society for Academic Emergency Medicine‡</td>
<td>● Bristol-Myers Squibb</td>
<td>● Sanofi-Aventis</td>
<td>● GlaxoSmithKline†</td>
<td>● Spouse employed by The Medicines Company†</td>
<td>None</td>
</tr>
<tr>
<td>Mazen Abu-Fadel</td>
<td>● Content–ACCF Cardiac Catheterization and Intervention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Paul Armstrong</td>
<td>● Content–ACC/AHA STEMI Guidelines Writing Committee</td>
<td>● Abbott Laboratories</td>
<td>None</td>
<td>● Boehringer Ingelheim†</td>
<td>● Medicure†</td>
<td>None</td>
</tr>
<tr>
<td>Eric Bates</td>
<td>● Content–ACC/AHA STEMI Guidelines Writing Committee</td>
<td>● AstraZeneca</td>
<td>None</td>
<td>● Eli Lilly</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Alexander Battler</td>
<td>● Content–ACC/AHA Acute Coronary Syndromes Data Standards Writing Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Vera Bittner</td>
<td>● Content–ACCF Prevention of Cardiovascular Disease Committee</td>
<td>● CV Therapeutics</td>
<td>None</td>
<td>● Atherogenics†</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Peer Reviewer*</td>
<td>Representation</td>
<td>Consulting Fees/ Honoraria</td>
<td>Speaker’s Bureau</td>
<td>Ownership/ Partnership/ Principal</td>
<td>Research Grants</td>
<td>Salary</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------------------------</td>
<td>----------------</td>
<td>--------</td>
</tr>
<tr>
<td>Christopher Cannon</td>
<td>+ Content–ACC/AHA Acute Coronary Syndromes Data Standards Writing Committee</td>
<td>• AstraZeneca† • BGB New York • Bristol-Myers Squibb† • DIME • GlaxoSmithKline† • Merck† • NGME • Pfizer† • Sanofi-Aventis† • Schering-Plough†</td>
<td>• Accumetrics† • AstraZeneca† • Bristol-Myers Squibb† • Merck† • Pfizer†</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Bernard Chaitman</td>
<td>+ Content–ACC/AHA Acute Coronary Syndromes Data Standards Writing Committee</td>
<td>• Merck† • CV Therapeutics†</td>
<td>• Pfizer†</td>
<td>None</td>
<td>CV Therapeutics†</td>
<td>None</td>
</tr>
<tr>
<td>Jose Diez</td>
<td>+ Content–ACCF Cardiac Catheterization and Intervention Committee</td>
<td>• Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Stephen Ellis</td>
<td>+ Content–ACC/AHA Acute Coronary Syndromes Data Standards Writing Committee</td>
<td>• Abbott • Boston Scientific • Cordis • Viacor</td>
<td>None</td>
<td>None</td>
<td>Centocor</td>
<td>None</td>
</tr>
<tr>
<td>James Ferguson</td>
<td>+ Content–ACCF Cardiac Catheterization and Intervention Committee</td>
<td>• Bristol-Myers Squibb • Eisai† • GlaxoSmithKline • Prism • Sanofi-Aventis† • Schering-Plough • Takeda • The Medicus Co. • Therox</td>
<td>• Bristol-Myers Squibb • Eisai† • Sanofi-Aventis† • Schering-Plough</td>
<td>None</td>
<td>Eisai</td>
<td>None</td>
</tr>
</tbody>
</table>

* Peer Reviewer representation includes consulting fees, honoraria, speaking bureau, ownership/partnership, principal research grants, and salary.
<table>
<thead>
<tr>
<th>Peer Reviewer*</th>
<th>Representation</th>
<th>Consulting Fees/ Honoraria</th>
<th>Speaker’s Bureau</th>
<th>Ownership/ Partnership/ Principal</th>
<th>Research Grants</th>
<th>Salary</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregg Fonarow</td>
<td>• Content–ACCF Prevention of Cardiovascular Disease Committee</td>
<td>• AstraZeneca</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>• Guidant</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bristol-Myers</td>
<td>• Bristol-Myers</td>
<td></td>
<td>• Medtronic†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Squibb/Sanoũ†</td>
<td>• Squibb/Sanoũ†</td>
<td></td>
<td>• Pfizer†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• GlaxoSmithKline†</td>
<td>• GlaxoSmithKline†</td>
<td></td>
<td>• St. Judes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Guidant</td>
<td>• Medtronic†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Merck/Schering-Plough†</td>
<td>• Merck/Schering-Plough†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer†</td>
<td>• Pfizer†</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• St. Judes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Harrington</td>
<td>• Content–ACC/AHA Acute Coronary Syndromes Data Standards Writing Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca†</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Squibb†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lilly†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>JMC†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Merck†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi-Aventis†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Schering-Plough†</td>
<td></td>
</tr>
<tr>
<td>Edward Havranek</td>
<td>• Content–ACC/AHA Task Force on Data Standards</td>
<td>CV Therapeutics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>McKesson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harlan Krumholz</td>
<td>• Content–ACC/AHA STEMI Guidelines Writing Committee, ACC/AHA Acute Coronary</td>
<td>CV Therapeutics</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Syndromes Data Standards Writing Committee</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>United Healthcare†</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janet Long</td>
<td>• Content–ACCF Prevention of Cardiovascular Disease Committee</td>
<td>None</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Noel Bairey Merz</td>
<td>• Content–Individual Reviewer</td>
<td>• AstraZeneca</td>
<td>None</td>
<td>• Eli Lilly†</td>
<td>Merck</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bayer†</td>
<td></td>
<td></td>
<td>Pfizer†</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• KOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Merck</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Debabrata Mukherjee</td>
<td>• Content–ACCF Cardiac Catheterization and Intervention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Charles Mullany</td>
<td>• Content–ACC/AHA STEMI Guidelines Writing Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Avicure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Avant Immunotherapeutics</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Baxter</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Carbomedics/Sorin Group</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CryoLife</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Jarvik Heart</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medtronic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>St. Jude Medical</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thoratec Corporation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>TransTech Pharma</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>W.L. Gore and Associates</td>
<td></td>
</tr>
</tbody>
</table>
This table represents the relationships of peer reviewers with industry that were disclosed at the time of peer review of this guideline. It does not necessarily reflect relationships with industry at the time of publication. *Names are listed in alphabetical order with each category of review. †Indicates a significant relationship (valued at $10,000 or more). ‡Participation in the peer review process does not imply endorsement of this document.

ACC = American College of Cardiology; ACCF = American College of Cardiology Foundation; AHA = American Heart Association; ESC = European Society of Cardiology; NHLBI = National Heart, Lung, and Blood Institute; SCAI = Society for Cardiovascular Angiography and Interventions.

### REFERENCES


137. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAX.I.S. (FRAxparin in Ischaemic Syndrome). Eur Heart J 1999;20:1553–62.


188. Deleted in proof.

189. Deleted in proof.

190. Deleted in proof.


196. Deleted in proof.


227. Deleted in proof.
242. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release...
bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47–55.


286. Fava S, Azzopardi J, Agius-Muscat H. Outcome of unstable angina
283. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional
282. Mikhail GW. Coronary revascularisation in women. Heart 2006;92
281. Bavry AA, Kumbhani DJ, Quiroz R, Ramchandani SR, Kenchaiah S,
280. Coronary angioplasty in diabetic patients: the National Heart, Lung,
279. Islam and increased risk of death after myocardial infarction in patients
278. Coronary angioplasty in diabetic patients: the National Heart, Lung,
277. Anderson et al ACC/AHA UA/NSTEMI Guideline Revision 875
276. Similar results of percutaneous transluminal coronary angioplasty for
275. Similar results of percutaneous transluminal coronary angioplasty for
274. Malinak GW. Coronary revascularisation in women. Heart 2006;92
273. Bavy AA, Kumbhani DJ, Qoriz R, Ramchandani SR, Kenchaiah S,
272. Antman EM. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non–ST–
271. Significant improvement in short-term mortality in women under-
270. Westby FK, Mittleman MA, Healy RW, Muller JE, Shrubrooks SJ. Similar results of percutaneous transluminal coronary angioplasty for
258. Deleted in proof.
250. Alexander KP, Roe MT, Chen AT, et al. Evolution in cardiovas-

Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114:1083–7.


_Circulation_. 2007;116:803-877; originally published online August 6, 2007;
doi: 10.1161/CIRCULATIONAHA.107.185752

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/116/7/803.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/